Substituted tetrahydrofurans as sodium channel modulators

By developing compounds or pharmaceutical compositions targeting NaV1.8 channels, the problems of insufficient selectivity and adverse events of existing NaV inhibitors are solved, and efficient treatment of neuropathic pain is achieved, and a safer pain management plan is provided.

CN114945566BActive Publication Date: 2024-11-12VERTEX PHARMACEUTICALS INC
View PDF 62 Cites 0 Cited by

Patent Information

Application Number
CN202080092215.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-12-06
Filing Date
2020-12-04
Publication Date
2024-11-12
Estimated Expiration
2040-12-04

AI Technical Summary

Technical Problem

Existing NaV inhibitors have adverse therapeutic windows and lack of selectivity, making it difficult to effectively target the NaV1.8 channel, resulting in adverse events caused by non-selective blockers and lack of efficient treatment for neuropathic pain.

Method used

Develop a compound or pharmaceutical composition for the treatment of a variety of painful and neurological diseases, including chronic pain, neuropathic pain, etc. by inhibiting voltage-gated sodium channels, especially NaV1.8 channels.

Benefits of technology

This compound or pharmaceutical composition can effectively inhibit the NaV1.8 channel and reduce pain. Due to its high selectivity, it reduces adverse events caused by non-selective blockers, providing a safer and more efficient pain management solution.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_9
    Figure SMS_9
  • Figure SMS_12
    Figure SMS_12
Patent Text Reader

Abstract

Provided are compounds useful as sodium channel inhibitors and pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts thereof, and methods of using the compounds, pharmaceutically acceptable salts and pharmaceutical compositions to treat various conditions, including pain.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-references to related applications

[0002] This application claims the benefit of U.S. Provisional Application No. 62 / 944,869, filed December 6, 2019, which is incorporated herein by reference in its entirety. Background Technology

[0003] Pain is a protective mechanism that enables healthy animals to avoid tissue damage and prevent further damage to damaged tissues. However, in many cases, pain persists beyond its utility, or the patient would benefit from pain suppression. Neuropathic pain is a form of chronic pain caused by damage to sensory nerves (Dieleman, JP et al., Incidence rates and treatment of neuropathic pain conditions in the general population. Pain, 2008, 137(3): 681-8). Neuropathic pain can be divided into two categories: pain caused by systemic metabolic damage to nerves and pain caused by discrete nerve damage. Metabolic neuropathy includes postherpetic neuropathy, diabetic neuropathy, and drug-induced neuropathy. Indications for discrete nerve damage include post-amputation pain, postoperative nerve injury pain, and nerve entrapment injuries, such as neuropathic back pain.

[0004] Voltage-gated sodium channel (Na V This involves pain signal transduction. V Sodium channels are biological mediators of electronic signal transduction because they mediate the rapid rise in action potentials in various excitable cell types, such as neurons, skeletal muscle cells, and cardiomyocytes. Evidence for the role of these channels in normal physiology, pathological states caused by mutations in sodium channel genes, preclinical studies in animal models, and the clinical pharmacology of known sodium channel modulators all suggest that sodium... V The main role of pain sensation (Rush, AM and TRCummins, Painful Research: Identification of a Small-Molecule Inhibitor that Selectively Targets Na VSodium channels and nociception: recent concepts and therapeutic opportunities. Curr. Opin. Pharmacol. 8(1), pp. 50-56 (2008)). Na V It mediates the rapid rise of action potentials in various excitable cell types (e.g., neurons, skeletal muscle cells, cardiomyocytes), and is therefore involved in the initiation of signal transduction in those cells (Hille, Bertil, Ion Channels of Excitable Membranes, 3rd ed. (Sinauer Associates, Inc., Sundland, MA, 2001)). Due to Na... V Its role in the initiation and propagation of neuronal signals, reducing Na V Current antagonists can prevent or reduce nerve signal transmission, and Na+ has been used to... V Channels are considered potential targets for reducing pain under observed hyperexcitability conditions (Chahine, M., Chatelier, A., Babich, O., and Krupp, JJ, Voltage-gated sodium channels in neurological disorders. CNS Neurol. Disord. Drug Targets 7(2), pp. 144-58 (2008)). Several clinically applicable analgesics have been identified as sodium channels. V Inhibitors of the Na+ channel. Local anesthetics (such as lidocaine) work by inhibiting Na+ channels. VThe study proposes that other compounds proven effective in reducing pain (such as carbamazepine, lamotrigine, and tricyclic antidepressants) work by inhibiting sodium channels (Soderpalm, B., Anticonvulsants: parameters of their mechanisms of action. Eur. J. Pain 6 Supplement A, pp. 3-9 (2002); Wang, GK, Mitchell, J. and Wang, SY, Block of persistent late Na + currents by antidepressant sertraline andparoxetine. J. Membr. Biol. 222(2), pp. 79-90 (2008)).

[0005] Na V This forms a subfamily of the voltage-gated ion channel superfamily and includes a subfamily called Na. V 1,1-Na V Nine isoforms of 1.9. These nine isoforms have different organizational orientations. Na V 1.4 is the main sodium channel in skeletal muscle and Na V 1.5 is the main sodium channel in cardiomyocytes. V 1.7, 1.8, and 1.9 are mainly located in the peripheral nervous system, while Na... V 1.1, 1.2, 1.3, and 1.6 are neuronal channels found in the central and peripheral nervous systems. The nine isoforms have similar functional properties, but their voltage dependence and kinetic details differ (Catterall, WA, Goldin, AL, and Waxman, SG, International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol. Rev. 57(4), p. 397 (2005)).

[0006] After its discovery, Na VChannel 1.8 was identified as a potential target for analgesia (Akop ian, AN, L. Sivilotti and JN Wood, A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons. Nature, 1996, 379(6562): 257-62). Subsequently, it has been shown that Na... V 1.8 To enable a sodium current carrier that maintains the firing of action potentials in dorsal root ganglion (DRG) neurons (Blair, NT and BPBean, Roles of tetrodotoxin (TTX)-sensitive Na+ current, TTX-reactive Na+). + current, and Ca 2+ current in the action potentials of nociceptive sensoryneurons. J. Neurosci., 2002.22(23): pp. 10277-90). Na V 1.8 Involves spontaneous generation in damaged neurons, such as spontaneous firing that contributes to neuropathic pain (Roza, C. et al., The tetrodotoxin-resistant Na...). + channel Na V 1.8 is essential for the expression of spontaneous activity indama ged sensory axons of mice. J. Physiol., 2003.550 (Pt 3): Page 921-6; Jarvis, MF et al., A-803467, a potent and selective Na V 1.8 sodi um channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc.Natl.Acad.Sci.US A, 2007.104(20): Page 8520-5; Joshi, SK et al., Involvement of the TTX-resistant sodium chann el Na V1.8 in inflammatory and neuropathic, but not post-operative, pain states. Pain, 2006. 123(1-2): pp. 75-82; Lai, J. et al., Inhibition of neuropathic pain by decreased expression of the tetrodotoxin-resistant sodium channel, Na V 1.8. Pain, 2002. 95(1-2): pp. 143-52; Dong, X.W. et al., Small interfering RNA-mediated selective knockdown of Na V1.8 tetrodotoxin-resistant sodium channel reverses mechanical allodynia in neuropathicrats. Neuroscience, 2007.146(2): pages 812-21; Huang, HL et al., Proteomic profiling of neuromas reveals alterations in protein composition and local proteinsynthesis in hyp er-excitable nerves. Mol. Pain, 2008.4: Page 33; Black, JA et al., Multiple sodium channel isoforms and mitogen-activated protein kin ases arepresent in painful human neuromas. Ann. Neurol., 2008.64(6): Page 644-53; Coward, K. et al., Immunolocalization of SNS / PN3and NaN / SNS2 sodium channels in human painstates.Pain, 2000.85(1-2): pages 41-50; Yiangou, Y. et al., SNS / PN3 and SNS2 / NaN sodium channel-like immunoreactivity in human adult and neonate in jured sensorynerves. FEBS Lett., 2000.467(2-3): pages 249-52; Ruangsri, S. et al., Relationship of axonal voltage-gated sodium channel 1.8 (Na V 1.8) mRNA accumulation to sciatic nerve injury-induced painful neuropathy in rats. J. Biol. Chem. 286(46): 39836-47. Expression of Na V The 1.8-inch small DRG neurons include pain receptors involved in pain signal transduction. Na V1.8 Large-amplitude action potentials mediated by small neurons in the dorsal root ganglion (Blair, NT, and BPBean, Roles of tetrodotoxin (TTX)-sensitive Na) + current, TT X-resistant Na + current, and Ca 2+ current in the action potentials of nociceptive sensory neurons. J. Neurosci., 2002.22(23): pp. 10277-90). Na V 1.8 is essential for rapid repetitive action potentials in pain receptors and for spontaneous activity in damaged neurons (Choi, JS and SGWaxman, Physiological interactions between Na+). V 1.7 andNa V 1.8 sodium channels: a computer si mulation study.J.Neurophysiol.106(6): pp. 3173-84; Renganathan, M., TRCummins and SGWaxman, Contribution of Na( V )1.8sodium channels to action potential electrogenesis in DRGneurons.J.Neurophysiol., 2001.86(2): pp. 629-40; Roza, C. et al., The tetrodo toxin-resistant Na + channel Na V 1.8 is essential for the expression of spontaneous activity in damaged sensory axons of mice. (J. Physiol., 2003, 550(Pt 3): 921-6). In depolarized or damaged DRG neurons, Na... V1.8 appears to be a driver of hyperexcitability (Rush, AM et al., Asingle sodium channel mutation produces hyper-or hypoexcitability indifferent types of neurons. Proc. Natl. Acad. Sci. USA, 2006. 103(21): 8245-50). In some animal models of pain, sodium in the DRG has been shown to be a driver of hyperexcitability (DRG). V 1.8 Increased mRNA expression (Sun, W. et al., Reduced conversion failure of the main axon of polymodal nociceptive C-fibers contributes to painful diabetic neuropathy in rats. Brain, 135(Pt 2): 359-75; Strickland, IT et al., Changes in the expression of Na+). V 1.7,Na V 1.8 and Na V 1.9in a distinct population of dorsal root ganglia innervating the ratknee joint in a model of chronic inflammatory joint pain. Eur.J.Pain, 2008.12(5): pp. 564-72; Qiu, F. et al., Increased expression of tetrodotoxin-resistantsodium channels Na V 1.8 and Na V 1.9 within dorsal root ganglia in a rat model of bone cancer pain. Neurosci. Lett., 512(2): pp. 61-6).

[0007] Some known Na V The main drawback of inhibitors is their poor therapeutic window, which is likely a consequence of their lack of isotype selectivity. Due to Na... V 1.8 Primarily limited to neurons that sense pain, therefore selective Na+ V 1.8 Blockers are unlikely to induce nonselective Na+V Adverse events are common with inhibitors. Therefore, further research and development of other Na+ inhibitors is still needed. V Channel modulator, preferably for Na V 1.8 Highly effective and highly selective Na V Channel regulator. Summary of the Invention

[0008] In one aspect, the present invention relates to the compounds described herein or pharmaceutically acceptable salts thereof.

[0009] In another aspect, the present invention relates to a pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers or mediators.

[0010] In another aspect, the present invention relates to a method for inhibiting voltage-gated sodium channels in a subject by administering a compound, a pharmaceutically acceptable salt, or a pharmaceutical composition to the subject.

[0011] In another aspect, the present invention relates to a method for treating or reducing the severity of various diseases, conditions, or disorders in a subject by administering a compound, a pharmaceutically acceptable salt, or a pharmaceutical composition to the subject, said diseases, conditions, or disorders including (but not limited to) chronic pain, intestinal pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, postoperative pain (e.g., Pain from bunionectomy, herniorrhaphy, or abdominoplasty, visceral pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence, pathological cough, and arrhythmias. Attached Figure Description

[0012] Figure 1 The XRPD spectral characteristics of compound 7, form A, were depicted.

[0013] Figure 2 The TGA thermogram characteristics of compound 7, form A, were depicted.

[0014] Figure 3 The DSC thermogram characteristics of compound 7, form A, were depicted.

[0015] Figure 4 The XRPD spectral characteristics of compound 7, form B, were depicted.

[0016] Figure 5 The solid state of compound 7, form B, is described. 13 C NMR spectral characteristics.

[0017] Figure 6 The solid state of compound 7, form B, is described. 19 F NMR spectral characteristics.

[0018] Figure 7 The TGA thermogram characteristics of compound 7, form B, were depicted.

[0019] Figure 8 The DSC thermogram features of compound 7, form B, were depicted.

[0020] Figure 9 The IR spectral characteristics of compound 7, form B, were described.

[0021] Figure 10 The thermal ellipsoid features of compound 7, form B, were depicted.

[0022] Figure 11 The thermal ellipsoid features of compound 9, form A, were depicted.

[0023] Figure 12 The XRPD spectral characteristics of compound 11, form A, were depicted.

[0024] Figure 13 The XRPD spectral characteristics of compound 11, form B, were depicted.

[0025] Figure 14 The thermal ellipsoid features of compound 11, form A, were depicted.

[0026] Figure 15 The XRPD spectral characteristics of compound 19, form A, were depicted.

[0027] Figure 16 The solid state of compound 19, form A, is described. 13 C NMR spectral characteristics.

[0028] Figure 17 The solid state of compound 19, form A, is described. 19 F NMR spectral characteristics.

[0029] Figure 18 The thermal ellipsoid features of compound 19, form A, were depicted.

[0030] Figure 19 The XRPD spectral characteristics of compound 22, form A, were depicted.

[0031] Figure 20 The solid state of compound 22, form A, is described. 13 C NMR spectral characteristics.

[0032] Figure 21 The solid state of compound 22, form A, is described.19 F NMR spectral characteristics.

[0033] Figure 22 The XRPD spectral characteristics of compound 23, form A, were depicted.

[0034] Figure 23 The solid state of compound 23, form A, is described. 13 C NMR spectral characteristics.

[0035] Figure 24 The solid state of compound 23, form A, is described. 19 F NMR spectral characteristics.

[0036] Figure 25 The thermal ellipsoid features of compound 23, form A, were depicted.

[0037] Figure 26 The XRPD spectral characteristics of compound 25, form A, were depicted. Detailed Implementation

[0038] In one aspect, the present invention relates to compounds of formula (I).

[0039]

[0040] Or its pharmaceutically acceptable salt, wherein:

[0041] X 2a It is N, N + -O - or CR 2a ;

[0042] X 4a It is N, N + -O - or CR 4a ;

[0043] X 5a It is N, N + -O - or CR 5a ;

[0044] X 6a It is N, N + -O - or CR 6a ;

[0045] Each R is independently H or a C1-C6 alkyl group;

[0046] R 2a R 4a R 5a and R 6aEach is independently H, a halogen, a C1-C6 alkyl group, or a C1-C6 haloalkyl group;

[0047] R 4b1 and R 4b2 Each is independently H, C1-C6 alkyl, C3-C6 cycloalkyl, or C1-C6 haloalkyl;

[0048] R 5b1 and R 5b2 Each is independently H, C1-C6 alkyl, C3-C6 cycloalkyl, or C1-C6 haloalkyl;

[0049] X 3c Is it N or CR? 3c ;

[0050] X 4c Is it N or CR? 4c ;

[0051] X 5c Is it N or CR? 5c ;

[0052] X 6c Is it N or CR? 6c ;

[0053] R 2c It is H, OH, halogen, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or -L 1 -L 2 -(C3-C6 cycloalkyl), wherein the cycloalkyl group is optionally substituted with 1-2 halogen groups;

[0054] L 1 It is a key or an O;

[0055] L 2 It is a bond or a C1-C6 alkylene group;

[0056] R 3c It is H, a halogen, a C1-C6 alkyl group, or a C1-C6 haloalkyl group;

[0057] R 4c It is H, a halogen, a C1-C6 alkyl group, or a C1-C6 haloalkyl group;

[0058] R 5c It is H, a halogen, a C1-C6 alkyl, or a C1-C6 haloalkyl; and

[0059] R 6c It is H, a halogen, a C1-C6 alkyl group, or a C1-C6 haloalkyl group;

[0060] The constraint is X2a X 4a X 5a and X 6a No more than two of them are N or N + -O - ;and

[0061] The constraint is X 3c X 4c X 5c and X 6c No more than one of them is N.

[0062] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 2a It is CR 2a ;X 5a It is CR 5a ;X 6a It is CR 6a ;R 4b1 and R 4b2 Each is independently H, C1-C6 alkyl, or C1-C6 haloalkyl; R 5b1 and R 5b2 Each is independently H, C1-C6 alkyl, or C1-C6 haloalkyl; X 3c It is CR 3c ;X 4c It is CR 4c ;X 5c It is CR 5c ;X 6c It is CR 6c And R 2c It is H, OH, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C1-C6 haloalkoxy.

[0063] For the purposes of this invention, chemical elements are identified according to the Periodic Table of the Elements, CAS edition, Handbook of Chemistry and Physics, 75th edition. Furthermore, the general principles of organic chemistry are described in “Organic Chemistry”, Thomas Sorrell, University Science Books, Sausalito: 1999 and “March's Advanced Organic Chemistry”, 5th edition, edited by Smith, MB and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are incorporated herein by reference.

[0064] As used herein, the term "compound of the present invention" refers to compounds of formulas (I), (IA), (IA-1), (IB), (IB-1), (IC), and (IC-1) as described herein, and all embodiments thereof, as well as compounds identified in Tables A, B, and C.

[0065] As described herein, the compounds of the present invention comprise a plurality of variable groups (e.g., R, X). 4a R 5b (etc.). As those skilled in the art will recognize, the combinations of groups contemplated in this invention are combinations that result in the formation of stable or chemically viable compounds. In this context, the term "stable" means a compound that remains substantially unchanged when subjected to conditions that allow for its production, testing, and preferably its recovery, purification, and use for one or more purposes disclosed herein. In some embodiments, a stable or chemically viable compound is one that remains substantially unchanged when kept at a temperature of 40°C or lower for at least one week in the absence of moisture or other chemically reactive conditions.

[0066] The understanding of the chemical structures described herein is intended for those skilled in the art to understand. For example, with respect to formulas (I), (IA), (IB), and (IC), those skilled in the art should understand that X 5a and X 6a Connected by double bonds and X 4c and X 5c The groups are connected by single bonds, but the bonds between these groups can be masked by atomic markings in the chemical structure. Furthermore, those skilled in the art will understand that substituents depicted as "CF3" or "F3C" in the chemical structure refer to trifluoromethyl substituents, regardless of their appearance in the chemical structure.

[0067] As used herein, the term "halogen" refers to F, Cl, Br, or I.

[0068] As used herein, the term "alkyl" refers to a straight-chain or branched hydrocarbon chain group consisting only of carbon and hydrogen atoms, without any degree of unsaturation, and having a specified number of carbon atoms, connected to the rest of the molecule by single bonds. For example, "C1-C6 alkyl" refers to alkyl groups having one to six carbon atoms.

[0069] As used herein, the term "haloalkyl" refers to an alkyl group having a specified number of carbon atoms, wherein one or more hydrogen atoms of the alkyl group are replaced by halogen groups. For example, "C1-C6 haloalkyl" is an alkyl group having one to six carbon atoms, wherein one or more hydrogen atoms of the alkyl group are replaced by halogen groups.

[0070] As used herein, the term "alkenyl" refers to a straight-chain or branched hydrocarbon chain group consisting only of carbon and hydrogen atoms, containing one or more carbon-carbon double bonds and having a specified number of carbon atoms, which are connected to the rest of the molecule by single bonds. For example, "C2-C6 alkenyl" is an alkenyl group having two to six carbon atoms.

[0071] As used herein, the term "cycloalkyl" refers to a stable, non-aromatic, monocyclic or bicyclic (fused, bridged, or spirocyclic) saturated hydrocarbon group consisting only of carbon and hydrogen atoms, having a specified number of carbon ring atoms connected to the rest of the molecule by single bonds. For example, "C3-C8 cycloalkyl" refers to a cycloalkyl group having three to eight carbon atoms.

[0072] As used herein, the term "alkylene" refers to a divalent, straight-chain or branched hydrocarbon chain group consisting only of carbon and hydrogen atoms, without any degree of unsaturation, and having a specified number of carbon atoms connected to the rest of the molecule by two single bonds. For example, "C1-C6 alkylene" refers to alkylene groups having one to six carbon atoms.

[0073] As used herein, the term “optionally substituted” refers to a group that is unsubstituted or substituted by a substituent subsequently identified. For example, a group “optionally substituted by 1-2 halogens” is unsubstituted, substituted by 1 halogen, or substituted by 2 halogens.

[0074] Unless otherwise specified, the compounds of this invention (whether identified by chemical name or chemical structure) include all stereoisomers (e.g., enantiomers and diastereomers), double bond isomers (e.g., (Z) and (E)), conformational isomers, and tautomers of the compounds identified by the chemical names and chemical structures provided herein. Furthermore, single stereoisomers, double bond isomers, conformational isomers, and tautomers, as well as mixtures of stereoisomers, double bond isomers, conformational isomers, and tautomers, are all within the scope of this invention.

[0075] As used herein, in any chemical structure or formula, the bold or hash straight bonds attached to the stereoisomer centers of the compound (respectively...) ), such as

[0076] middle,

[0077] This indicates the relative stereochemistry of a stereoisomer center with respect to other stereoisomer centers connected by bold or hash straight bonds.

[0078] As used herein, in any chemical structure or formula, the bold or scattered wedge-shaped bonds (respectively) attached to the stereoisomer centers of the compound ), such as in

[0079] middle,

[0080] The absolute stereochemistry of the stereoisomer center, and the relative stereochemistry of the stereoisomer center relative to other stereoisomer centers connected by bold or scattered wedge bonds.

[0081] As used herein, when used in conjunction with chiral compounds, the prefix "rac-" indicates a racemic mixture of the compound. In compounds with the "rac-" prefix, the (R)- and (S)- indicators in the chemical name reflect the relative stereochemistry of the compound.

[0082] As used herein, when used in conjunction with chiral compounds, the prefix "rel-" refers to a single enantiomer with an unknown absolute configuration. In compounds with the "rel-" prefix, the (R)- and (S)- indicators in the chemical name reflect the relative stereochemistry of the compound, but not necessarily its absolute stereochemistry.

[0083] As used herein, when referring to the compounds of the present invention, the term "compound" means a collection of molecules having the same chemical structure except that isotopic variations may exist in the constituent atoms of the molecules. The term "compound" includes such a collection of molecules regardless of the purity of a given sample containing said collection of molecules. Therefore, the term "compound" includes a collection of such molecules in pure form, in the form of a mixture with one or more other substances (e.g., a solution, suspension, colloid, or pharmaceutical composition, or dosage form), or in the form of hydrates, solvates, or cocrystals.

[0084] Unless otherwise stated, any atom not specifically designated as a particular isotope in any compound of the invention is intended to represent any stable isotope of the specified element. In the embodiments, when an atom is not specifically designated as a particular isotope in any compound of the invention, no work has been done to enrich the atom with the specific isotope, and therefore those skilled in the art will understand that such atoms may be present with a natural abundance isotopic composition approximately that of the specified element.

[0085] As used herein, when referring to isotopes, the term "stable" means an isotope whose spontaneous radioactive decay is unknown. Stable isotopes include (but are not limited to) isotopes whose decay patterns are not identified in the VS Shirley and CM Lederer, Isotopes Project, Nuclear Science Division, Lawrence Berkeley Laboratory, Table of Nuclides (January 1980).

[0086] As used herein, in the specification and claims, "H" refers to hydrogen and includes any stable isotope of hydrogen, i.e. 1 H and D. In embodiments where the atom is designated as "H", no work was done to enrich the specific isotope of hydrogen, and therefore those skilled in the art will understand that such hydrogen atoms are likely present at approximately the natural abundance concentration of hydrogen.

[0087] As used in this article, " 1 "H" refers to protium. When an atom in a compound of the present invention or a pharmaceutically acceptable salt thereof is designated as protium, protium is present at the designated location at at least the natural abundance concentration of protium.

[0088] As used in this article, “D”, “d” and “ 2 "H" refers to deuterium.

[0089] In some embodiments, the compounds of the present invention or pharmaceutically acceptable salts thereof comprise each constituent atom in approximately the natural abundance isotopic composition of the specified elements.

[0090] In some embodiments, the compounds of the present invention and their pharmaceutically acceptable salts comprise one or more atomic masses or mass numbers having a different atomic mass or mass number from the most abundant isotope of the specified element (“isotope-labeled” compounds and salts). Examples of commercially available stable isotopes suitable for use in the present invention include (but are not limited to) isotopes of hydrogen, carbon, nitrogen, oxygen, and phosphorus, respectively, for example... 2 H, 13 C 15 N、 18 O、 17 O and 31 P.

[0091] Isotope-labeled compounds and salts can be used in a variety of advantageous ways, including as pharmaceuticals. In some embodiments, the isotope-labeled compounds and salts are deuterium (…). 2 Marked with H). Deuterium ( 2 H)-labeled compounds and salts are therapeutically useful and have advantages over non-H) 2 The potential therapeutic advantages of H-labeled compounds. Generally, due to the kinetic isotope effect described below, deuterium (H-labeled compounds) exhibits greater therapeutic benefits compared to unlabeled compounds and salts. 2 H)-labeled compounds and salts may exhibit higher metabolic stability. Higher metabolic stability directly translates to longer in vivo half-lives or lower dosage, which in most cases represents a preferred embodiment of the invention. Isotope-labeled compounds and salts can generally be prepared by performing the procedures disclosed in the synthetic schemes, examples, and related descriptions, replacing non-isotope-labeled reactants with readily available isotope-labeled reactants.

[0092] deuterium( 2 H)-labeled compounds and salts can have their oxidative metabolic rates manipulated through primary kinetic isotope effects. Primary kinetic isotope effects are changes in the rate of a chemical reaction resulting from isotopic nuclear exchange, which in turn is caused by changes in the ground-state energy of the covalent bonds involved in the reaction. Exchange of heavier isotopes typically leads to a decrease in the ground-state energy of the chemical bonds and thus a reduction in the rate-limiting bond breaking. If bond breaking occurs in or near a saddle point region along the coordinates of a multi-product reaction, the product distribution ratio can be substantially altered. For example, if deuterium is bonded to a carbon atom at a non-exchangeable position, then k H / k D The rate difference of 2-7 is typical. For further discussion, see S.L. Harbeson and R.D. Tung, Deuterium In Drug Discovery and Development, Ann. Rep. Med. Chem. 2011, 46, 403-417, which are incorporated herein by reference in their entirety.

[0093] The concentration of an isotope (e.g., deuterium) incorporated at a given position in an isotopically labeled compound of the present invention or a pharmaceutically acceptable salt thereof can be defined by an isotope enrichment factor. As used herein, the term "isotope enrichment factor" means the ratio between the abundance of the isotope at a given position in an isotopically labeled compound (or salt) and the natural abundance of said isotope.

[0094] When the atom in the compounds of the present invention or their pharmaceutically acceptable salts is designated as deuterium, the isotope enrichment factor of such compounds (or salts) for such atom is at least 3000 (about 45% deuterium doping). In some embodiments, the isotope enrichment factor is at least 3500 (about 52.5% deuterium doping), at least 4000 (about 60% deuterium doping), at least 4500 (about 67.5% deuterium doping), at least 5000 (about 75% deuterium doping), at least 5500 (about 82.5% deuterium doping), at least 6000 (about 90% deuterium doping), at least 6333.3 (about 95% deuterium doping), at least 6466.7 (about 97% deuterium doping), at least 6600 (about 99% deuterium doping), or at least 6633.3 (about 99.5% deuterium doping).

[0095] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein each R is H. In other embodiments, each R is independently H or CH3. In other embodiments, N(R)2 is NHCH3.

[0096] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X2a It is N. In other implementations, X 2a It is CR 2a In some implementations, R 2a It is H, D, a halogroup, or a C1-C6 alkyl group. In other embodiments, R 2a It is H, D, F, or CH3. In some implementations, X 2a It is N, CH, CD, C-(C1-C6 alkyl), or C-halogen. In other embodiments, X 2a It is N, CH, CD, C-CH3 or CF.

[0097] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 2a It is CR 2a And R 2a It's H.

[0098] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N. In other implementations, X 4a It is N + -O - In other implementations, X 4a It is CR 4a In some implementations, R 4a It is a halogen group. In other embodiments, R 4a It is an H or a halogen group. In other embodiments, R 4a It is H or F. In other implementations, X 4a It is CF. In some implementations, X 4a It is N, N + -O - CH or C-halogen. In other embodiments, X 4a It is N, N + -O - CH or CF.

[0099] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 4a It is CR 4a And R 4a It is a halogen group.

[0100] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 5a It is N. In other implementations, X 5a It is CR 5a In some implementations, R 5aIt is H, D, a halogroup, or a C1-C6 alkyl group. In other embodiments, R 5a It is H, D, F, or CH3. In some implementations, X 5a It is N, CH, CD, C-(C1-C6 alkyl), or C-halogen. In other embodiments, X 5a It is N, CH, CD, C-CH3 or CF.

[0101] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 5a It is CR 5a And R 5a It's H.

[0102] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 6a It is N. In other implementations, X 6a It is CR 6a In some implementations, R 6a It is H, D, a halogroup, or a C1-C6 alkyl group. In other embodiments, R 6a It is H, D, F, or CH3. In some implementations, X 6a It is N, CH, CD, C-(C1-C6 alkyl), or C-halogen. In other embodiments, X 6a It is N, CH, CD, C-CH3 or CF.

[0103] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 6a It is CR 6a And R 6a It's H.

[0104] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 4b1 and R 4b2 Each is independently H or C1-C6 alkyl. In other embodiments, R 4b1 and R 4b2 Each is independently H, C1-C6 alkyl, or C3-C6 cycloalkyl. In other embodiments, R 4b1 and R 4b2 Each is independently H or CH3. In other embodiments, R 4b1 and R 4b2 Each is independently H, CH3, CH2CH3, or cyclopropyl. In other embodiments, R 4b1 It is a C1-C6 alkyl group, and R 4b2 It is H. In other implementations, R4b1 It is H, and R 4b2 It is a C1-C6 alkyl group. In other embodiments, R 4b1 It is CH3, and R 4b2 It is H. In other implementations, R 4b1 It is H, and R 4b2 It is CH3.

[0105] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 5b1 and R 5b2 Each is independently a C1-C6 alkyl or a C1-C6 haloalkyl. In other embodiments, R 5b1 and R 5b2 Each is independently H, a C1-C6 alkyl group, or a C1-C6 haloalkyl group. In other embodiments, R 5b1 and R 5b2 Each is independently H, CH3, or CF3. In other embodiments, R 5b1 and R 5b2 Each is independently H, CH3, CH2CH3, CH(CH3)2, C(CH3)3, CHF2, CF2CH3, CH2CF3, or CF3. In other embodiments, R 5b1 It is a C1-C6 alkyl group, and R 5b2 It is a C1-C6 haloalkyl group. In other embodiments, R 5b1 It is a C1-C6 haloalkyl group, and R 5b2 It is a C1-C6 alkyl group. In other embodiments, R 5b1 It is CH3 and R 5b2 It is CF3. In other implementations, R 5b1 It is CF3 and R 5b2 It is CH3.

[0106] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy. In other embodiments, R 2c It is OH, halogen, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or -L 1 -L 2 -(C3-C6 cycloalkyl), wherein the cycloalkyl group is optionally substituted with 1-2 halogen groups. In other embodiments, R 2c It is H. In other implementations, R 2c It is a C1-C6 alkoxy group. In other embodiments, R 2cIt is a C1-C6 haloalkoxy group. In other embodiments, R 2c Yes -L 1 -L 2 -(C3-C6 cycloalkyl), wherein the cycloalkyl group is optionally substituted with 1-2 halogen groups. In other embodiments, R 2c It is OH, OCH3, OCD3, OCH2CH3, or OCHF2. In other embodiments, R 2c It is H, F, CH3, CH=CH2, OH, OCH3, OCD3, OCH2CH3, OCH(CH3)2, OCHF2, In other implementations, R 2c It is OH. In other embodiments, R 2c It is OCH3. In other implementations, R 2c It is OCD3. In other implementations, R 2c It is OCH2CH3. In other implementations, R 2c It is OCHF2.

[0107] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 3c It is N. In other implementations, X 3c It is CR 3c In other implementations, R 3c It is H, a halogroup, a C1-C6 alkyl group, or a C1-C6 haloalkyl group. In other embodiments, R 3c It is H, CH3, CH2CH3, CHF2, CF3, F, or Cl. In some implementations, X 3c It is N, CH, C-CH3, C-CH2CH3, C-CHF2, C-CF3, CF, or C-Cl.

[0108] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 3c It is CR 3c And R 3c It is H, a halogroup, or a C1-C6 alkyl group. In other embodiments, R 3c It is a halogen group. In other embodiments, R 3c It is a C1-C6 alkyl group. In other embodiments, R 3c It is H, F, Cl, or CH3. In other embodiments, R 3c It is H. In other implementations, R 3c It is F. In other implementations, R 3c It is Cl. In other implementations, R 3c It is CH3.

[0109] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 4c It is N. In other implementations, X 4c It is CR 4c In other implementations, R 4c It is H, a halogroup, or a C1-C6 haloalkyl group. In other embodiments, R 4c It is H, CHF2, CF3, or F. In other embodiments, X 4c It is N, CH, C-CHF2, C-CF3 or CF.

[0110] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 4c It is CR 4a And R 4c It is a halogen group. In other embodiments, R 4c It is F.

[0111] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 5c It is N. In other implementations, X 5c It is CR 5c In other implementations, R 5c It is an H or a halogen group. In other embodiments, R 5c It is H, D, or Cl. In some implementations, X 5c It is N, CH, CD, or C-Cl.

[0112] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 5c It is CR 5c And R 5c It's H.

[0113] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 6c It is N. In other implementations, X 6c It is CR 6c In other implementations, R 6c It is an H or a halogen group. In other embodiments, R 6c It is H or F. In some implementations, X 6c It is N, CH, or CF.

[0114] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 6c It's H.

[0115] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 2a It is N, CH, CD, C-(C1-C6 alkyl) or C-halo; X 4a It is N, N + -O - , CH or C-halogen; X 5a It is N, CH, CD, C-(C1-C6 alkyl) or C-halo; X 6a It is N, CH, CD, C-(C1-C6 alkyl) or C-halogen; each R is H or CH3; R 4b1 and R 4b2 Each is independently H, C1-C6 alkyl, or C3-C6 cycloalkyl; R 5b1 and R 5b2 Each is independently H, C1-C6 alkyl, or C1-C6 haloalkyl; R 2c It is OH, halogen, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or -L 1 -L 2 -(C3-C6 cycloalkyl), wherein the cycloalkyl group is optionally substituted with 1-2 halogen groups; X 3c It is CR 3c ;R 3c It is H, a halogen, a C1-C6 alkyl group, or a C1-C6 haloalkyl group; X 4c It is CR 4c ;R 4c It is H, a halogroup, or a C1-C6 haloalkyl group; X 5c It is CR 5c ;R 5c It is H or a halo group; X 6c It is CR 6c And R 6c It is an H or a halogen group.

[0116] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; X 2a It is CR 2a ;R 2a It is H; X 5a It is CR 5a ;R 5a It is H; X 6a It is CR 6a ;R 6a It is H; R 4b1 and R 4b2Each is independently H or C1-C6 alkyl; R 5b1 and R 5b2 Each is independently a C1-C6 alkyl or a C1-C6 haloalkyl; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; X 3c It is CR 3c ;R 3c It is H, a halogroup, or a C1-C6 alkyl group; X 4c It is CR 4c ;R 4c It is a halogenated group; X 5c It is CR 5c ;R 5c It is H; X 6c It is CR 6c And R 6c It's H.

[0117] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 2a It is N, CH, CD, C-CH3 or CF; X 4a It is N, N + -O - CH or CF; X 5a It is N, CH, CD, C-CH3 or CF; X 6a It is N, CH, CD, C-CH3 or CF; each R is H or CH3; R 4b1 and R 4b2 Each is independently H, CH3, CH2CH3, or cyclopropyl; R 5b1 and R 5b2 Each is independently H, CH3, CH2CH3, CH(CH3)2, C(CH3)3, CHF2, CF2CH3, CH2CF3, or CF3; R 2c It is H, F, CH3, CH=CH2, OH, OCH3, OCD3, OCH2CH3, OCH(CH3)2, OCHF2, X 3c It is N, CH, C-CH3, C-CH2CH3, C-CHF2, C-CF3, CF, or C-Cl; X 4c It is N, CH, C-CHF2, C-CF3 or CF; X 5c It is N, CH, CD, or C-Cl; and X 6c It is N, CH, or CF.

[0118] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 4aIt is N; each R is H; X 2a It is CR 2a ;R 2a It is H; X 5a It is CR 5a ;R 5a It is H; X 6a It is CR 6a ;R 6a It is H; R 4b1 and R 4b2 Each is independently H or CH3; R 5b1 and R 5b2 Each is independently H, CH3, or CF3; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; X 3c It is CR 3c ;R 3c It is H, a halogroup, or a C1-C6 alkyl group; X 4c It is CR 4c ;R 4c It is a halogenated group; X 5c It is CR 5c ;R 5c It is H; X 6c It is CR 6c And R 6c It is H.

[0119] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; X 2a It is CR 2a ;R 2a It is H; X 5a It is CR 5a ;R 5a It is H; X 6a It is CR 6a ;R 6a It is H; R 4b1 It is a C1-C6 alkyl group; R 4b2 It is H; R 5b1 It is a C1-C6 alkyl group; R 5b2 It is a C1-C6 haloalkyl group; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; X 3c It is CR 3c ;R 3c It is H, a halogroup, or a C1-C6 alkyl group; X 4c It is CR 4c ;R 4c It is a halogenated group; X 5c It is CR 5c ;R 5cIt is H; X 6c It is CR 6c And R 6c It's H.

[0120] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; X 2a It is CR 2a ;R 2a It is H; X 5a It is CR 5a ;R 5a It is H; X 6a It is CR 6a ;R 6a It is H; R 4b1 It is H; R 4b2 It is a C1-C6 alkyl group; R 5b1 It is a C1-C6 alkyl group; R 5b2 It is a C1-C6 haloalkyl group; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; X 3c It is CR 3c ;R 3c It is H, a halogroup, or a C1-C6 alkyl group; X 4c It is CR 4c ;R 4c It is a halogenated group; X 5c It is CR 5c ;R 5c It is H; X 6c It is CR 6c And R 6c It's H.

[0121] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; X 2a It is CR 2a ;R 2a It is H; X 5a It is CR 5a ;R 5a It is H; X 6a It is CR 6a ;R 6a It is H; R 4b1 It is a C1-C6 alkyl group; R 4b2 It is H; R 5b1 It is a C1-C6 haloalkyl group; R 5b2 It is a C1-C6 alkyl group; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; X 3c It is CR3c ;R 3c It is H, a halogroup, or a C1-C6 alkyl group; X 4c It is CR 4c ;R 4c It is a halogenated group; X 5c It is CR 5c ;R 5c It is H; X 6c It is CR 6c And R 6c It's H.

[0122] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; X 2a It is CR 2a ;R 2a It is H; X 5a It is CR 5a ;R 5a It is H; X 6a It is CR 6a ;R 6a It is H; R 5b1 It is a C1-C6 haloalkyl group; R 5b2 It is a C1-C6 alkyl group; R 4b1 It is H; R 4b2 It is a C1-C6 alkyl group; R 2c It is a C1-C6 alkoxy or a C1-C6 haloalkoxy; X 3c It is CR 3c ;R 3c It is H, a halogroup, or a C1-C6 alkyl group; X 4c It is CR 4c ;R 4c It is a halogenated group; X 5c It is CR 5c ;R 5c It is H; X 6c It is CR 6c And R 6c It's H.

[0123] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; X 2a It is CR 2a ;R 2a It is H; X 5a It is CR 5a ;R 5a It is H; X 6a It is CR 6a ;R 6a It is H; R 5b1It is CH3; R 5b2 It's CF3; R 4b1 It is CH3; R 4b2 It is H; R 2c It is a C1-C6 alkoxy or a C1-C6 haloalkoxy; X 3c It is CR 3c ;R 3c It is H, a halogroup, or a C1-C6 alkyl group; X 4c It is CR 4c ;R 4c It is a halogenated group; X 5c It is CR 5c ;R 5c It is H; X 6c It is CR 6c And R 6c It is H.

[0124] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; X 2a It is CR 2a ;R 2a It is H; X 5a It is CR 5a ;R 5a It is H; X 6a It is CR 6a ;R 6a It is H; R 5b1 It is CH3; R 5b2 It's CF3; R 4b1 It is H; R 4b2 It is CH3; R 2c It is a C1-C6 alkoxy or a C1-C6 haloalkoxy; X 3c It is CR 3c ;R 3c It is H, a halogroup, or a C1-C6 alkyl group; X 4c It is CR 4c ;R 4c It is a halogenated group; X 5c It is CR 5c ;R 5c It is H; X 6c It is CR 6c And R 6c It is H.

[0125] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; X 2a It is CR 2a ;R 2a It is H; X 5aIt is CR 5a ;R 5a It is H; X 6a It is CR 6a ;R 6a It is H; R 5b1 It's CF3; R 5b2 It is CH3; R 4b1 It is CH3; R 4b2 It is H; R 2c It is a C1-C6 alkoxy or a C1-C6 haloalkoxy; X 3c It is CR 3c ;R 3c It is H, a halogroup, or a C1-C6 alkyl group; X 4c It is CR 4c ;R 4c It is a halogenated group; X 5c It is CR 5c ;R 5c It is H; X 6c It is CR 6c And R 6c It's H.

[0126] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; X 2a It is CR 2a ;R 2a It is H; X 5a It is CR 5a ;R 5a It is H; X 6a It is CR 6a ;R 6a It is H; R 5b1 It's CF3; R 5b2 It is CH3; R 4b1 It is H, and R 4b2 It is CH3; R 2c It is a C1-C6 alkoxy or a C1-C6 haloalkoxy; X 3c It is CR 3c ;R 3c It is H, a halogroup, or a C1-C6 alkyl group; X 4c It is CR 4c ;R 4c It is a halogenated group; X 5c It is CR 5c ;R 5c It is H; X 6c It is CR 6c And R 6c It's H.

[0127] In some embodiments, the present invention relates to compounds of formula (I) (including any of the foregoing embodiments thereof), i.e., compounds in non-salt form.

[0128] In some embodiments, the present invention relates to compounds of formula (IA).

[0129]

[0130] Or its pharmaceutically acceptable salt, wherein:

[0131] X 2a It is N, N + -O - or CR 2a ;

[0132] X 4a It is N, N + -O - or CR 4a ;

[0133] X 5a It is N, N + -O - or CR 5a ;

[0134] X 6a It is N, N + -O - or CR 6a ;

[0135] Each R is independently H or a C1-C6 alkyl group;

[0136] R 2a R 4a R 5a and R 6a Each is independently H, a halogen, a C1-C6 alkyl group, or a C1-C6 haloalkyl group;

[0137] R 4b1 and R 4b2 Each is independently H, C1-C6 alkyl, C3-C6 cycloalkyl, or C1-C6 haloalkyl;

[0138] R 5b1 and R 5b2 Each is independently H, C1-C6 alkyl, C3-C6 cycloalkyl, or C1-C6 haloalkyl;

[0139] X 3c Is it N or CR? 3c ;

[0140] X 4c Is it N or CR? 4c ;

[0141] X 5c Is it N or CR? 5c ;

[0142] X 6c Is it N or CR? 6c ;

[0143] R 2c It is H, OH, halogen, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or -L 1 -L 2 -(C3-C6 cycloalkyl), wherein the cycloalkyl group is optionally substituted with 1-2 halogen groups;

[0144] L 1 It is a key or an O;

[0145] L 2 It is a bond or a C1-C6 alkylene group;

[0146] R 3c It is H, a halogen, a C1-C6 alkyl group, or a C1-C6 haloalkyl group;

[0147] R 4c It is H, a halogen, a C1-C6 alkyl group, or a C1-C6 haloalkyl group;

[0148] R 5c It is H, a halogen, a C1-C6 alkyl, or a C1-C6 haloalkyl; and

[0149] R 6c It is H, a halogen, a C1-C6 alkyl group, or a C1-C6 haloalkyl group;

[0150] The constraint is X 2a X 4a X 5a and X 6a No more than two of them are N or N + -O - ;and

[0151] The constraint is X 3c X 4c X 5c and X 6c No more than one of them is N.

[0152] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 2a It is CR 2a ;X 5a It is CR 5a ;X 6aIt is CR 6a ;R 4b1 and R 4b2 Each is independently H, C1-C6 alkyl, or C1-C6 haloalkyl; R 5b1 and R 5b2 Each is independently H, C1-C6 alkyl, or C1-C6 haloalkyl; X 3c It is CR 3c ;X 4c It is CR 4c ;X 5c It is CR 5c ;X 6c It is CR 6c And R 2c It is H, OH, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C1-C6 haloalkoxy.

[0153] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein each R is H. In other embodiments, each R is independently H or CH3. In other embodiments, N(R)2 is NHCH3.

[0154] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 2a It is N. In other implementations, X 2a It is CR 2a In some implementations, R 2a It is H, D, a halogroup, or a C1-C6 alkyl group. In other embodiments, R 2a It is H, D, F, or CH3. In some implementations, X 2a It is N, CH, CD, C-(C1-C6 alkyl), or C-halogen. In other embodiments, X 2a It is N, CH, CD, C-CH3 or CF.

[0155] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 2a It is CR 2a And R 2a It's H.

[0156] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N. In other implementations, X 4a It is N + -O - In other implementations, X 4a It is CR4a In some implementations, R 4a It is a halogen group. In other embodiments, R 4a It is an H or a halogen group. In other embodiments, R 4a It is H or F. In other implementations, X 4a It is CF. In some implementations, X 4a It is N, N + -O - CH or C-halogen. In other embodiments, X 4a It is N, N + -O - CH or CF.

[0157] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 4a It is CR 4a And R 4a It is a halogen group.

[0158] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 5a It is N. In other implementations, X 5a It is CR 5a In some implementations, R 5a It is H, D, a halogroup, or a C1-C6 alkyl group. In other embodiments, R 5a It is H, D, F, or CH3. In some implementations, X 5a It is N, CH, CD, C-(C1-C6 alkyl), or C-halogen. In other embodiments, X 5a It is N, CH, CD, C-CH3 or CF.

[0159] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 5a It is CR 5a And R 5a It is H.

[0160] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 6a It is N. In other implementations, X 6a It is CR 6a In some implementations, R 6a It is H, D, a halogroup, or a C1-C6 alkyl group. In other embodiments, R 6a It is H, D, F, or CH3. In some implementations, X 6aIt is N, CH, CD, C-(C1-C6 alkyl), or C-halogen. In other embodiments, X 6a It is N, CH, CD, C-CH3 or CF.

[0161] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 6a It is CR 6a And R 6a It's H.

[0162] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein R 4b1 and R 4b2 Each is independently H or C1-C6 alkyl. In other embodiments, R 4b1 and R 4b2 Each is independently H, C1-C6 alkyl, or C3-C6 cycloalkyl. In other embodiments, R 4b1 and R 4b2 Each is independently H or CH3. In other embodiments, R 4b1 and R 4b2 Each is independently H, CH3, CH2CH3, or cyclopropyl. In other embodiments, R 4b1 It is a C1-C6 alkyl group, and R 4b2 It is H. In other implementations, R 4b1 It is H, and R 4b2 It is a C1-C6 alkyl group. In other embodiments, R 4b1 It is CH3, and R 4b2 It is H. In other implementations, R 4b1 It is H, and R 4b2 It is CH3.

[0163] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein R 5b1 and R 5b2 Each is independently a C1-C6 alkyl or a C1-C6 haloalkyl. In other embodiments, R 5b1 and R 5b2 Each is independently H, a C1-C6 alkyl group, or a C1-C6 haloalkyl group. In other embodiments, R 5b1 and R 5b2 Each is independently H, CH3, or CF3. In other embodiments, R 5b1 and R 5b2Each is independently H, CH3, CH2CH3, CH(CH3)2, C(CH3)3, CHF2, CF2CH3, CH2CF3, or CF3. In other embodiments, R 5b1 It is a C1-C6 alkyl group, and R 5b2 It is a C1-C6 haloalkyl group. In other embodiments, R 5b1 It is a C1-C6 haloalkyl group, and R 5b2 It is a C1-C6 alkyl group. In other embodiments, R 5b1 It is CH3, and R 5b2 It is CF3. In other implementations, R 5b1 It's CF3, and R 5b2 It is CH3.

[0164] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy. In other embodiments, R 2c It is OH, halogen, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or -L 1 -L 2 -(C3-C6 cycloalkyl), wherein the cycloalkyl group is optionally substituted with 1-2 halogen groups. In other embodiments, R 2c It is H. In other implementations, R 2c It is a C1-C6 alkoxy group. In other embodiments, R 2c It is a C1-C6 haloalkoxy group. In other embodiments, R 2c Yes -L 1 -L 2 -(C3-C6 cycloalkyl), wherein the cycloalkyl group is optionally substituted with 1-2 halogen groups. In other embodiments, R 2c It is OH, OCH3, OCD3, OCH2CH3, or OCHF2. In other embodiments, R 2c It is H, F, CH3, CH=CH2, OH, OCH3, OCD3, OCH2CH3, OCH(CH3)2, OCHF2, In other implementations, R 2c It is OH. In other embodiments, R 2c It is OCH3. In other implementations, R 2c It is OCD3. In other implementations, R 2c It is OCH2CH3. In other implementations, R 2c It is OCHF2.

[0165] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 3c It is N. In other implementations, X 3c It is CR 3c In other implementations, R 3c It is H, a halogroup, a C1-C6 alkyl group, or a C1-C6 haloalkyl group. In other embodiments, R 3c It is H, CH3, CH2CH3, CHF2, CF3, F, or Cl. In some implementations, X 3c It is N, CH, C-CH3, C-CH2CH3, C-CHF2, C-CF3, CF, or C-Cl.

[0166] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 3c It is CR 3c And R 3c It is H, a halogroup, or a C1-C6 alkyl group. In other embodiments, R 3c It is a halogen group. In other embodiments, R 3c It is a C1-C6 alkyl group. In other embodiments, R 3c It is H, F, Cl, or CH3. In other embodiments, R 3c It is H. In other implementations, R 3c It is F. In other implementations, R 3c It is Cl. In other implementations, R 3c It is CH3.

[0167] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 4c It is N. In other implementations, X 4c It is CR 4c In other implementations, R 4c It is H, a halogroup, or a C1-C6 haloalkyl group. In other embodiments, R 4c It is H, CHF2, CF3, or F. In some implementations, X 4c It is N, CH, C-CHF2, C-CF3 or CF.

[0168] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 4c It is CR 4c And R 4c It is a halogen group. In other embodiments, R 4c It is F.

[0169] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 5c It is N. In other implementations, X 5c It is CR 5c In other implementations, R 5c It is an H or a halogen group. In other embodiments, R 5c It is H, D, or Cl. In some implementations, X 5c It is N, CH, CD, or C-Cl.

[0170] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 5c It is CR 5c And R 5c It's H.

[0171] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 6c It is N. In other implementations, X 6c It is CR 6c In other implementations, R 6c It is an H or a halogen group. In other embodiments, R 6c It is H or F. In some implementations, X 6c It is N, CH, or CF.

[0172] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein R 6c It's H.

[0173] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 2a It is N, CH, CD, C-(C1-C6 alkyl) or C-halo; X 4a It is N, N + -O - , CH or C-halogen; X 5a It is N, CH, CD, C-(C1-C6 alkyl) or C-halo; X 6a It is N, CH, CD, C-(C1-C6 alkyl) or C-halogen; each R is H or CH3; R 4b1 and R 4b2 Each is independently H, C1-C6 alkyl, or C3-C6 cycloalkyl; R 5b1 and R 5b2 Each is independently H, C1-C6 alkyl, or C1-C6 haloalkyl; R 2cIt is OH, halogen, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or -L 1 -L 2 -(C3-C6 cycloalkyl), wherein the cycloalkyl group is optionally substituted with 1-2 halogen groups; X 3c It is CR 3c ;R 3c It is H, a halogen, a C1-C6 alkyl group, or a C1-C6 haloalkyl group; X 4c It is CR 4c ;R 4c It is H, a halogroup, or a C1-C6 haloalkyl group; X 5c It is CR 5c ;R 5c It is H or a halo group; X 6c It is CR 6c And R 6c It is an H or a halogen group.

[0174] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; X 2a It is CR 2a ;R 2a It is H; X 5a It is CR 5a ;R 5a It is H; X 6a It is CR 6a ;R 6a It is H; R 4b1 and R 4b2 Each is independently H or C1-C6 alkyl; R 5b1 and R 5b2 Each is independently a C1-C6 alkyl or a C1-C6 haloalkyl; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; X 3c It is CR 3c ;R 3c It is H, a halogroup, or a C1-C6 alkyl group; X 4c It is CR 4c ;R 4c It is a halogenated group; X 5c It is CR 5c ;R 5c It is H; X 6c It is CR 6c And R 6c It's H.

[0175] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X2a It is N, CH, CD, C-CH3 or CF; X 4a It is N, N + -O - CH or CF; X 5a It is N, CH, CD, C-CH3 or CF; X 6a It is N, CH, CD, C-CH3 or CF; each R is H or CH3; R 4b1 and R 4b2 Each is independently H, CH3, CH2CH3, or cyclopropyl; R 5b1 and R 5b2 Each is independently H, CH3, CH2CH3, CH(CH3)2, C(CH3)3, CHF2, CF2CH3, CH2CF3, or CF3; R 2c It is H, F, CH3, CH=CH2, OH, OCH3, OCD3, OCH2CH3, OCH(CH3)2, OCHF2, X 3c It is N, CH, C-CH3, C-CH2CH3, C-CHF2, C-CF3, CF, or C-Cl; X 4c It is N, CH, C-CHF2, C-CF3 or CF; X 5c It is N, CH, CD, or C-Cl; and X 6c It is N, CH, or CF.

[0176] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; X 2a It is CR 2a ;R 2a It is H; X 5a It is CR 5a ;R 5a It is H; X 6a It is CR 6a ;R 6a It is H; R 4b1 and R 4b2 Each is independently H or CH3; R 5b1 and R 5b2 Each is independently H, CH3, or CF3; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; X 3c It is CR 3c ;R 3c It is H, a halogroup, or a C1-C6 alkyl group; X 4c It is CR 4c ;R 4cIt is a halogenated group; X 5c It is CR 5c ;R 5c It is H; X 6c It is CR 6c And R 6c It's H.

[0177] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; X 2a It is CR 2a ;R 2a It is H; X 5a It is CR 5a ;R 5a It is H; X 6a It is CR 6a ;R 6a It is H; R 4b1 It is a C1-C6 alkyl group; R 4b2 It is H; R 5b1 It is a C1-C6 alkyl group; R 5b2 It is a C1-C6 haloalkyl group; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; X 3c It is CR 3c ;R 3c It is H, a halogroup, or a C1-C6 alkyl group; X 4c It is CR 4c ;R 4c It is a halogenated group; X 5c It is CR 5c ;R 5c It is H; X 6c It is CR 6c And R 6c It's H.

[0178] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; X 2a It is CR 2a ;R 2a It is H; X 5a It is CR 5a ;R 5a It is H; X 6a It is CR 6a ;R 6a It is H; R 4b1 It is H; R 4b2 It is a C1-C6 alkyl group; R 5b1 It is a C1-C6 alkyl group; R 5b2 It is a C1-C6 haloalkyl group; R2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; X 3c It is CR 3c ;R 3c It is H, a halogroup, or a C1-C6 alkyl group; X 4c It is CR 4c ;R 4c It is a halogenated group; X 5c It is CR 5c ;R 5c It is H; X 6c It is CR 6c And R 6c It is H.

[0179] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; X 2a It is CR 2a ;R 2a It is H; X 5a It is CR 5a ;R 5a It is H; X 6a It is CR 6a ;R 6a It is H; R 4b1 It is a C1-C6 alkyl group; R 4b2 It is H; R 5b1 It is a C1-C6 haloalkyl group; R 5b2 It is a C1-C6 alkyl group; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; X 3c It is CR 3c ;R 3c It is H, a halogroup, or a C1-C6 alkyl group; X 4c It is CR 4c ;R 4c It is a halogenated group; X 5c It is CR 5c ;R 5c It is H; X 6c It is CR 6c And R 6c It is H.

[0180] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; X 2a It is CR 2a ;R 2a It is H; X 5a It is CR 5a ;R 5a It is H; X6a It is CR 6a ;R 6a It is H; R 5b1 It is a C1-C6 haloalkyl group; R 5b2 It is a C1-C6 alkyl group; R 4b1 It is H; R 4b2 It is a C1-C6 alkyl group; R 2c It is a C1-C6 alkoxy or a C1-C6 haloalkoxy; X 3c It is CR 3c ;R 3c It is H, a halogroup, or a C1-C6 alkyl group; X 4c It is CR 4c ;R 4c It is a halogenated group; X 5c It is CR 5c ;R 5c It is H; X 6c It is CR 6c And R 6c It's H.

[0181] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; X 2a It is CR 2a ;R 2a It is H; X 5a It is CR 5a ;R 5a It is H; X 6a It is CR 6a ;R 6a It is H; R 5b1 It is CH3; R 5b2 It's CF3; R 4b1 It is CH3; R 4b2 It is H; R 2c It is a C1-C6 alkoxy or a C1-C6 haloalkoxy; X 3c It is CR 3c ;R 3c It is H, a halogroup, or a C1-C6 alkyl group; X 4c It is CR 4c ;R 4c It is a halogenated group; X 5c It is CR 5c ;R 5c It is H; X 6c It is CR 6c And R 6c It's H.

[0182] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X4a It is N; each R is H; X 2a It is CR 2a ;R 2a It is H; X 5a It is CR 5a ;R 5a It is H; X 6a It is CR 6a ;R 6a It is H; R 5b1 It is CH3; R 5b2 It's CF3; R 4b1 It is H; R 4b2 It is CH3; R 2c It is a C1-C6 alkoxy or a C1-C6 haloalkoxy; X 3c It is CR 3c ;R 3c It is H, a halogroup, or a C1-C6 alkyl group; X 4c It is CR 4c ;R 4c It is a halogenated group; X 5c It is CR 5c ;R 5c It is H; X 6c It is CR 6c And R 6c It is H.

[0183] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; X 2a It is CR 2a ;R 2a It is H; X 5a It is CR 5a ;R 5a It is H; X 6a It is CR 6a ;R 6a It is H; R 5b1 It's CF3; R 5b2 It is CH3; R 4b1 It is CH3; R 4b2 It is H; R 2c It is a C1-C6 alkoxy or a C1-C6 haloalkoxy; X 3c It is CR 3c ;R 3c It is H, a halogroup, or a C1-C6 alkyl group; X 4c It is CR 4c ;R 4c It is a halogenated group; X 5c It is CR 5c ;R 5c It is H; X 6cIt is CR 6c And R 6c It is H.

[0184] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; X 2a It is CR 2a ;R 2a It is H; X 5a It is CR 5a ;R 5a It is H; X 6a It is CR 6a ;R 6a It is H; R 5b1 It's CF3; R 5b2 It is CH3; R 4b1 It is H, and R 4b2 It is CH3; R 2c It is a C1-C6 alkoxy or a C1-C6 haloalkoxy; X 3c It is CR 3c ;R 3c It is H, a halogroup, or a C1-C6 alkyl group; X 4c It is CR 4c ;R 4c It is a halogenated group; X 5c It is CR 5c ;R 5c It is H; X 6c It is CR 6c And R 6c It is H.

[0185] In some embodiments, the present invention relates to compounds of formula (IA) (including any of the foregoing embodiments thereof), i.e., compounds in non-salt form.

[0186] In some embodiments, the present invention relates to compounds of formula (IA-1).

[0187]

[0188] Or its pharmaceutically acceptable salt, wherein:

[0189] X 4a It is N, N + -O - or CR 4a ;

[0190] Each R is independently H or a C1-C6 alkyl group;

[0191] R 4a It is H, a halogen, a C1-C6 alkyl group, or a C1-C6 haloalkyl group;

[0192] R 4b1 and R 4b2 Each is independently H, C1-C6 alkyl, or C1-C6 haloalkyl;

[0193] R 5b1 and R 5b2 Each is independently H, C1-C6 alkyl, or C1-C6 haloalkyl;

[0194] R 2c It is H, OH, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C1-C6 haloalkoxy;

[0195] R 3c It is H, a halogen, a C1-C6 alkyl, or a C1-C6 haloalkyl; and

[0196] R 4c It is H, halogen, C1-C6 alkyl, or C1-C6 haloalkyl.

[0197] In some embodiments, the present invention relates to a compound of formula (IA-1) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N. In other implementations, X 4a It is N + -O - In other implementations, X 4a It is CR 4a In other implementations, X 4a It's CF.

[0198] In some embodiments, the present invention relates to a compound of formula (IA-1) or a pharmaceutically acceptable salt thereof, wherein each R is H. In other embodiments, each R is independently H or CH3. In other embodiments, N(R)2 is NHCH3.

[0199] In some embodiments, the present invention relates to a compound of formula (IA-1) or a pharmaceutically acceptable salt thereof, wherein R 4a It is a halogen group.

[0200] In some embodiments, the present invention relates to a compound of formula (IA-1) or a pharmaceutically acceptable salt thereof, wherein R 4b1 and R 4b2 Each is independently H or C1-C6 alkyl. In other embodiments, R 4b1 and R 4b2 Each is independently H or CH3. In other embodiments, R 4b1 It is a C1-C6 alkyl group, and R 4b2 It is H. In other implementations, R4b1 It is H, and R 4b2 It is a C1-C6 alkyl group. In other embodiments, R 4b1 It is CH3 and R 4b2 It is H. In other implementations, R 4b1 It is H, and R 4b2 It is CH3.

[0201] In some embodiments, the present invention relates to a compound of formula (IA-1) or a pharmaceutically acceptable salt thereof, wherein R 5b1 and R 5b2 Each is independently a C1-C6 alkyl or a C1-C6 haloalkyl. In other embodiments, R 5b1 and R 5b2 Each is independently H, CH3, or CF3. In other embodiments, R 5b1 It is a C1-C6 alkyl group, and R 5b2 It is a C1-C6 haloalkyl group. In other embodiments, R 5b1 It is a C1-C6 haloalkyl group, and R 5b2 It is a C1-C6 alkyl group. In other embodiments, R 5b1 It is CH3 and R 5b2 It is CF3. In other implementations, R 5b1 It is CF3 and R 5b2 It is CH3.

[0202] In some embodiments, the present invention relates to a compound of formula (IA-1) or a pharmaceutically acceptable salt thereof, wherein R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy. In other embodiments, R 2c It is a C1-C6 alkoxy group. In other embodiments, R 2c It is a C1-C6 haloalkoxy group. In other embodiments, R 2c It is OH, OCH3, OCD3, OCH2CH3, or OCHF2. In other embodiments, R 2c It is OH. In other embodiments, R 2c It is OCH3. In other implementations, R 2c It is OCD3. In other implementations, R 2c It is OCH2CH3. In other implementations, R 2c It is OCHF2.

[0203] In some embodiments, the present invention relates to a compound of formula (IA-1) or a pharmaceutically acceptable salt thereof, wherein R 3c It is H, a halogroup, or a C1-C6 alkyl group. In other embodiments, R 3cIt is a halogen group. In other embodiments, R 3c It is a C1-C6 alkyl group. In other embodiments, R 3c It is H, F, Cl, or CH3. In other embodiments, R 3c It is H. In other implementations, R 3c It is F. In other implementations, R 3c It is Cl. In other implementations, R 3c It is CH3.

[0204] In some embodiments, the present invention relates to a compound of formula (IA-1) or a pharmaceutically acceptable salt thereof, wherein R 4c It is a halogen group. In other embodiments, R 4c It is F.

[0205] In some embodiments, the present invention relates to a compound of formula (IA-1) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; R 4b1 and R 4b2 Each is independently H or C1-C6 alkyl; R 5b1 and R 5b2 Each is independently a C1-C6 alkyl or a C1-C6 haloalkyl; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; R 3c It is H, a halogroup, or a C1-C6 alkyl group; and R 4c It is a halogen group.

[0206] In some embodiments, the present invention relates to a compound of formula (IA-1) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; R 4b1 and R 4b2 Each is independently H or CH3; R 5b1 and R 5b2 Each is independently H, CH3, or CF3; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; R 3c It is H, a halogroup, or a C1-C6 alkyl group; and R 4c It is a halogen group.

[0207] In some embodiments, the present invention relates to a compound of formula (IA-1) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; R 4b1 It is a C1-C6 alkyl group; R 4b2 It is H; R 5b1 It is a C1-C6 alkyl group; R 5b2 It is a C1-C6 haloalkyl group; R2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; R 3c It is H, a halogroup, or a C1-C6 alkyl group; and R 4c It is a halogen group.

[0208] In some embodiments, the present invention relates to a compound of formula (IA-1) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; R 4b1 It is H; R 4b2 It is a C1-C6 alkyl group; R 5b1 It is a C1-C6 alkyl group; R 5b2 It is a C1-C6 haloalkyl group; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; R 3c It is H, a halogroup, or a C1-C6 alkyl group; and R 4c It is a halogen group.

[0209] In some embodiments, the present invention relates to a compound of formula (IA-1) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; R 4b1 It is a C1-C6 alkyl group; R 4b2 It is H; R 5b1 It is a C1-C6 haloalkyl group; R 5b2 It is a C1-C6 alkyl group; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; R 3c It is H, a halogroup, or a C1-C6 alkyl group; and R 4c It is a halogen group.

[0210] In some embodiments, the present invention relates to a compound of formula (IA-1) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; R 4b1 It is H; R 4b2 It is a C1-C6 alkyl group; R 5b1 It is a C1-C6 haloalkyl group; R 5b2 It is a C1-C6 alkyl group; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; R 3c It is H, a halogroup, or a C1-C6 alkyl group; and R 4c It is a halogen group.

[0211] In some embodiments, the present invention relates to a compound of formula (IA-1) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; R 4b1 It is CH3; R 4b2 It is H; R 5b1It is CH3; R 5b2 It's CF3; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; R 3c It is H, a halogroup, or a C1-C6 alkyl group; and R 4c It is a halogen group.

[0212] In some embodiments, the present invention relates to a compound of formula (IA-1) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; R 4b1 It is H; R 4b2 It is CH3; R 5b1 It is CH3; R 5b2 It's CF3; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; R 3c It is H, a halogroup, or a C1-C6 alkyl group; and R 4c It is a halogen group.

[0213] In some embodiments, the present invention relates to a compound of formula (IA-1) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; R 4b1 It is CH3; R 4b2 It is H; R 5b1 It's CF3; R 5b2 It is CH3; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; R 3c It is H, a halogroup, or a C1-C6 alkyl group; and R 4c It is a halogen group.

[0214] In some embodiments, the present invention relates to a compound of formula (IA-1) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; R 4b1 It is H, and R 4b2 It is CH3; R 5b1 It's CF3; R 5b2 It is CH3; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; R 3c It is H, a halogroup, or a C1-C6 alkyl group; and R 4c It is a halogen group.

[0215] In some embodiments, the present invention relates to compounds of formula (IA-1) (including any of the foregoing embodiments thereof), i.e., compounds in non-salt form.

[0216] In some embodiments, the present invention relates to compounds of formula (IB).

[0217]

[0218] Or its pharmaceutically acceptable salt, wherein:

[0219] X 2a It is N, N + -O - or CR 2a ;

[0220] X 4a It is N, N + -O - or CR 4a ;

[0221] X 5a It is N, N + -O - or CR 5a ;

[0222] X 6a It is N, N + -O - or CR 6a ;

[0223] Each R is independently H or a C1-C6 alkyl group;

[0224] R 2a R 4a R 5a and R 6a Each is independently H, a halogen, a C1-C6 alkyl group, or a C1-C6 haloalkyl group;

[0225] R 4b1 and R 4b2 Each is independently H, C1-C6 alkyl, C3-C6 cycloalkyl, or C1-C6 haloalkyl;

[0226] R 5b1 and R 5b2 Each is independently H, C1-C6 alkyl, C3-C6 cycloalkyl, or C1-C6 haloalkyl;

[0227] X 3c Is it N or CR? 3c ;

[0228] X 4c Is it N or CR? 4c ;

[0229] X 5c Is it N or CR? 5c ;

[0230] X 6c Is it N or CR? 6c ;

[0231] R 2c It is H, OH, halogen, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or -L 1 -L 2 -(C3-C6 cycloalkyl), wherein the cycloalkyl group is optionally substituted with 1-2 halogen groups;

[0232] L 1 It is a key or an O;

[0233] L 2 It is a bond or a C1-C6 alkylene group;

[0234] R 3c It is H, a halogen, a C1-C6 alkyl group, or a C1-C6 haloalkyl group;

[0235] R 4c It is H, a halogen, a C1-C6 alkyl group, or a C1-C6 haloalkyl group;

[0236] R 5c It is H, a halogen, a C1-C6 alkyl, or a C1-C6 haloalkyl; and

[0237] R 6c It is H, a halogen, a C1-C6 alkyl group, or a C1-C6 haloalkyl group;

[0238] The constraint is X 2a X 4a X 5a and X 6a No more than two of them are N or N + -O - ;and

[0239] The constraint is X 3c X 4c X 5c and X 6c No more than one of them is N.

[0240] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 2a It is CR 2a ;X 5a It is CR 5a ;X 6a It is CR 6a ;R 4b1 and R 4b2 Each is independently H, C1-C6 alkyl, or C1-C6 haloalkyl; R 5b1 and R 5b2Each is independently H, C1-C6 alkyl, or C1-C6 haloalkyl; X 3c It is CR 3c ;X 4c It is CR 4c ;X 5c It is CR 5c ;X 6c It is CR 6c And R 2c It is H, OH, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C1-C6 haloalkoxy.

[0241] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein each R is H. In other embodiments, each R is independently H or CH3. In other embodiments, N(R)2 is NHCH3.

[0242] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 2a It is N. In other implementations, X 2a It is CR 2a In some implementations, R 2a It is H, D, a halogroup, or a C1-C6 alkyl group. In other embodiments, R 2a It is H, D, F, or CH3. In some implementations, X 2a It is N, CH, CD, C-(C1-C6 alkyl), or C-halogen. In other embodiments, X 2a It is N, CH, CD, C-CH3 or CF.

[0243] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 2a It is CR 2a And R 2a It's H.

[0244] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N. In other implementations, X 4a It is N + -O - In other implementations, X 4a It is CR 4a In some implementations, R 4a It is a halogen group. In other embodiments, R 4a It is an H or a halogen group. In other embodiments, R 4a It is H or F. In other implementations, X4a It is CF. In some implementations, X 4a It is N, N + -O - CH or C-halogen. In other embodiments, X 4a It is N, N + -O - CH or CF.

[0245] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 4a It is CR 4a And R 4a It is a halogen group.

[0246] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 5a It is N. In other implementations, X 5a It is CR 5a In some implementations, R 5a It is H, D, a halogroup, or a C1-C6 alkyl group. In other embodiments, R 5a It is H, D, F, or CH3. In some implementations, X 5a It is N, CH, CD, C-(C1-C6 alkyl), or C-halogen. In other embodiments, X 5a It is N, CH, CD, C-CH3 or CF.

[0247] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 5a It is CR 5a And R 5a It's H.

[0248] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 6a It is N. In other implementations, X 6a It is CR 6a In some implementations, R 6a It is H, D, a halogroup, or a C1-C6 alkyl group. In other embodiments, R 6a It is H, D, F, or CH3. In some implementations, X 6a It is N, CH, CD, C-(C1-C6 alkyl), or C-halogen. In other embodiments, X 6a It is N, CH, CD, C-CH3 or CF.

[0249] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 6a It is CR 6a And R 6a It is H.

[0250] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein R 4b1 and R 4b2 Each is independently H or C1-C6 alkyl. In other embodiments, R 4b1 and R 4b2 Each is independently H, C1-C6 alkyl, or C3-C6 cycloalkyl. In other embodiments, R 4b1 and R 4b2 Each is independently H or CH3. In other embodiments, R 4b1 and R 4b2 Each is independently H, CH3, CH2CH3, or cyclopropyl. In other embodiments, R 4b1 It is a C1-C6 alkyl group, and R 4b2 It is H. In other implementations, R 4b1 It is H, and R 4b2 It is a C1-C6 alkyl group. In other embodiments, R 4b1 It is CH3 and R 4b2 It is H. In other implementations, R 4b1 It is H, and R 4b2 It is CH3.

[0251] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein R 5b1 and R 5b2 Each is independently a C1-C6 alkyl or a C1-C6 haloalkyl. In other embodiments, R 5b1 and R 5b2 Each is independently H, a C1-C6 alkyl group, or a C1-C6 haloalkyl group. In other embodiments, R 5b1 and R 5b2 Each is independently H, CH3, or CF3. In other embodiments, R 5b1 and R 5b2 Each is independently H, CH3, CH2CH3, CH(CH3)2, C(CH3)3, CHF2, CF2CH3, CH2CF3, or CF3. In other embodiments, R 5b1 It is a C1-C6 alkyl group, and R 5b2 It is a C1-C6 haloalkyl group. In other embodiments, R 5b1 It is a C1-C6 haloalkyl group, and R 5b2It is a C1-C6 alkyl group. In other embodiments, R 5b1 It is CH3 and R 5b2 It is CF3. In other implementations, R 5b1 It is CF3 and R 5b2 It is CH3.

[0252] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy. In other embodiments, R 2c It is OH, halogen, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or -L 1 -L 2 -(C3-C6 cycloalkyl), wherein the cycloalkyl group is optionally substituted with 1-2 halogen groups. In other embodiments, R 2c It is H. In other implementations, R 2c It is a C1-C6 alkoxy group. In other embodiments, R 2c It is a C1-C6 haloalkoxy group. In other embodiments, R 2c Yes -L 1 -L 2 -(C3-C6 cycloalkyl), wherein the cycloalkyl group is optionally substituted with 1-2 halogen groups. In other embodiments, R 2c It is OH, OCH3, OCD3, OCH2CH3, or OCHF2. In other embodiments, R 2c It is H, F, CH3, CH=CH2, OH, OCH3, OCD3, OCH2CH3, OCH(CH3)2, OCHF2, In other implementations, R 2c It is OH. In other embodiments, R 2c It is OCH3. In other implementations, R 2c It is OCD3. In other implementations, R 2c It is OCH2CH3. In other implementations, R 2c It is OCHF2.

[0253] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 3c It is N. In other implementations, X 3c It is CR 3c In other implementations, R 3c It is H, a halogroup, a C1-C6 alkyl group, or a C1-C6 haloalkyl group. In other embodiments, R 3cIt is H, CH3, CH2CH3, CHF2, CF3, F, or Cl. In some implementations, X 3c It is N, CH, C-CH3, C-CH2CH3, C-CHF2, C-CF3, CF, or C-Cl.

[0254] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 3c It is CR 3c And R 3c It is H, a halogroup, or a C1-C6 alkyl group. In other embodiments, R 3c It is a halogen group. In other embodiments, R 3c It is a C1-C6 alkyl group. In other embodiments, R 3c It is H, F, Cl, or CH3. In other embodiments, R 3c It is H. In other implementations, R 3c It is F. In other implementations, R 3c It is Cl. In other implementations, R 3c It is CH3.

[0255] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 4c It is N. In other implementations, X 4c It is CR 4c In other implementations, R 4c It is H, a halogroup, or a C1-C6 haloalkyl group. In other embodiments, R 4c It is H, CHF2, CF3, or F. In some implementations, X 4c It is N, CH, C-CHF2, C-CF3 or CF.

[0256] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 4c It is CR 4c And R 4c It is a halogen group. In other embodiments, R 4c It is F.

[0257] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 5c It is N. In other implementations, X 5c It is CR 5c In other implementations, R 5c It is an H or a halogen group. In other embodiments, R 5c It is H, D, or Cl. In some implementations, X5c It is N, CH, CD, or C-Cl.

[0258] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 5c It is CR 5c And R 5c It's H.

[0259] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 6c It is N. In other implementations, X 6c It is CR 6c In other implementations, R 6c It is an H or a halogen group. In other embodiments, R 6c It is H or F. In some implementations, X 6c It is N, CH, or CF.

[0260] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein R 6c It's H.

[0261] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 2a It is N, CH, CD, C-(C1-C6 alkyl) or C-halo; X 4a It is N, N + -O - , CH or C-halogen; X 5a It is N, CH, CD, C-(C1-C6 alkyl) or C-halo; X 6a It is N, CH, CD, C-(C1-C6 alkyl) or C-halogen; each R is H or CH3; R 4b1 and R 4b2 Each is independently H, C1-C6 alkyl, or C3-C6 cycloalkyl; R 5b1 and R 5b2 Each is independently H, C1-C6 alkyl, or C1-C6 haloalkyl; R 2c It is OH, halogen, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or -L 1 -L 2 -(C3-C6 cycloalkyl), wherein the cycloalkyl group is optionally substituted with 1-2 halogen groups; X 3c It is CR 3c ;R 3c It is H, a halogen, a C1-C6 alkyl group, or a C1-C6 haloalkyl group; X4c It is CR 4c ;R 4c It is H, a halogroup, or a C1-C6 haloalkyl group; X 5c It is CR 5c ;R 5c It is H or a halo group; X 6c It is CR 6c And R 6c It is an H or a halogen group.

[0262] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; X 2a It is CR 2a ;R 2a It is H; X 5a It is CR 5a ;R 5a It is H; X 6a It is CR 6a ;R 6a It is H; R 4b1 and R 4b2 Each is independently H or C1-C6 alkyl; R 5b1 and R 5b2 Each is independently a C1-C6 alkyl or a C1-C6 haloalkyl; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; X 3c It is CR 3c ;R 3c It is H, a halogroup, or a C1-C6 alkyl group; X 4c It is CR 4c ;R 4c It is a halogenated group; X 5c It is CR 5c ;R 5c It is H; X 6c It is CR 6c And R 6c It's H.

[0263] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 2a It is N, CH, CD, C-CH3 or CF; X 4a It is N, N + -O - CH or CF; X 5a It is N, CH, CD, C-CH3 or CF; X 6a It is N, CH, CD, C-CH3 or CF; each R is H or CH3; R 4b1 and R4b2 Each is independently H, CH3, CH2CH3, or cyclopropyl; R 5b1 and R 5b2 Each is independently H, CH3, CH2CH3, CH(CH3)2, C(CH3)3, CHF2, CF2CH3, CH2CF3, or CF3; R 2c It is H, F, CH3, CH=CH2, OH, OCH3, OCD3, OCH2CH3, OCH(CH3)2, OCHF2, X 3c It is N, CH, C-CH3, C-CH2CH3, C-CHF2, C-CF3, CF, or C-Cl; X 4c It is N, CH, C-CHF2, C-CF3 or CF; X 5c It is N, CH, CD, or C-Cl; and X 6c It is N, CH, or CF.

[0264] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; X 2a It is CR 2a ;R 2a It is H; X 5a It is CR 5a ;R 5a It is H; X 6a It is CR 6a ;R 6a It is H; R 4b1 and R 4b2 Each is independently H or CH3; R 5b1 and R 5b2 Each is independently H, CH3, or CF3; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; X 3c It is CR 3c ;R 3c It is H, a halogroup, or a C1-C6 alkyl group; X 4c It is CR 4c ;R 4c It is a halogenated group; X 5c It is CR 5c ;R 5c It is H; X 6c It is CR 6c And R 6c It is H.

[0265] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 4aIt is N; each R is H; X 2a It is CR 2a ;R 2a It is H; X 5a It is CR 5a ;R 5a It is H; X 6a It is CR 6a ;R 6a It is H; R 4b1 It is a C1-C6 alkyl group; R 4b2 It is H; R 5b1 It is a C1-C6 alkyl group; R 5b2 It is a C1-C6 haloalkyl group; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; X 3c It is CR 3c ;R 3c It is H, a halogroup, or a C1-C6 alkyl group; X 4c It is CR 4c ;R 4c It is a halogenated group; X 5c It is CR 5c ;R 5c It is H; X 6c It is CR 6c And R 6c It's H.

[0266] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; X 2a It is CR 2a ;R 2a It is H; X 5a It is CR 5a ;R 5a It is H; X 6a It is CR 6a ;R 6a It is H; R 4b1 It is H; R 4b2 It is a C1-C6 alkyl group; R 5b1 It is a C1-C6 alkyl group; R 5b2 It is a C1-C6 haloalkyl group; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; X 3c It is CR 3c ;R 3c It is H, a halogroup, or a C1-C6 alkyl group; X 4c It is CR 4c ;R 4c It is a halogenated group; X 5c It is CR 5c ;R5c It is H; X 6c It is CR 6c And R 6c It is H.

[0267] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; X 2a It is CR 2a ;R 2a It is H; X 5a It is CR 5a ;R 5a It is H; X 6a It is CR 6a ;R 6a It is H; R 4b1 It is a C1-C6 alkyl group; R 4b2 It is H; R 5b1 It is a C1-C6 haloalkyl group; R 5b2 It is a C1-C6 alkyl group; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; X 3c It is CR 3c ;R 3c It is H, a halogroup, or a C1-C6 alkyl group; X 4c It is CR 4c ;R 4c It is a halogenated group; X 5c It is CR 5c ;R 5c It is H; X 6c It is CR 6c And R 6c It is H.

[0268] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; X 2a It is CR 2a ;R 2a It is H; X 5a It is CR 5a ;R 5a It is H; X 6a It is CR 6a ;R 6a It is H; R 5b1 It is a C1-C6 haloalkyl group; R 5b2 It is a C1-C6 alkyl group; R 4b1 It is H; R 4b2 It is a C1-C6 alkyl group; R 2c It is a C1-C6 alkoxy or a C1-C6 haloalkoxy; X 3cIt is CR 3c ;R 3c It is H, a halogroup, or a C1-C6 alkyl group; X 4c It is CR 4c ;R 4c It is a halogenated group; X 5c It is CR 5c ;R 5c It is H; X 6c It is CR 6c And R 6c It is H.

[0269] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; X 2a It is CR 2a ;R 2a It is H; X 5a It is CR 5a ;R 5a It is H; X 6a It is CR 6a ;R 6a It is H; R 5b1 It is CH3; R 5b2 It's CF3; R 4b1 It is CH3; R 4b2 It is H; R 2c It is a C1-C6 alkoxy or a C1-C6 haloalkoxy; X 3c It is CR 3c ;R 3c It is H, a halogroup, or a C1-C6 alkyl group; X 4c It is CR 4c ;R 4c It is a halogenated group; X 5c It is CR 5c ;R 5c It is H; X 6c It is CR 6c And R 6c It is H.

[0270] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; X 2a It is CR 2a ;R 2a It is H; X 5a It is CR 5a ;R 5a It is H; X 6a It is CR 6a ;R 6a It is H; R 5b1 It is CH3; R5b2 It's CF3; R 4b1 It is H; R 4b2 It is CH3; R 2c It is a C1-C6 alkoxy or a C1-C6 haloalkoxy; X 3c It is CR 3c ;R 3c It is H, a halogroup, or a C1-C6 alkyl group; X 4c It is CR 4c ;R 4c It is a halogenated group; X 5c It is CR 5c ;R 5c It is H; X 6c It is CR 6c And R 6c It is H.

[0271] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; X 2a It is CR 2a ;R 2a It is H; X 5a It is CR 5a ;R 5a It is H; X 6a It is CR 6a ;R 6a It is H; R 5b1 It's CF3; R 5b2 It is CH3; R 4b1 It is CH3; R 4b2 It is H; R 2c It is a C1-C6 alkoxy or a C1-C6 haloalkoxy; X 3c It is CR 3c ;R 3c It is H, a halogroup, or a C1-C6 alkyl group; X 4c It is CR 4c ;R 4c It is a halogenated group; X 5c It is CR 5c ;R 5c It is H; X 6c It is CR 6c And R 6c It is H.

[0272] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; X 2a It is CR 2a ;R 2a It is H; X 5a It is CR5a ;R 5a It is H; X 6a It is CR 6a ;R 6a It is H; R 5b1 It's CF3; R 5b2 It is CH3; R 4b1 It is H, and R 4b2 It is CH3; R 2c It is a C1-C6 alkoxy or a C1-C6 haloalkoxy; X 3c It is CR 3c ;R 3c It is H, a halogroup, or a C1-C6 alkyl group; X 4c It is CR 4c ;R 4c It is a halogenated group; X 5c It is CR 5c ;R 5c It is H; X 6c It is CR 6c And R 6c It is H.

[0273] In some embodiments, the present invention relates to compounds of formula (IB) (including any of the foregoing embodiments thereof), i.e., compounds in non-salt form.

[0274] In some embodiments, the present invention relates to compounds of formula (IB-1).

[0275]

[0276] Or its pharmaceutically acceptable salt, wherein:

[0277] X 4a It is N, N + -O - or CR 4a ;

[0278] Each R is independently H or a C1-C6 alkyl group;

[0279] R 4a It is H, a halogen, a C1-C6 alkyl group, or a C1-C6 haloalkyl group;

[0280] R 4b1 and R 4b2 Each is independently H, C1-C6 alkyl, or C1-C6 haloalkyl;

[0281] R 5b1 and R 5b2 Each is independently H, C1-C6 alkyl, or C1-C6 haloalkyl;

[0282] R 2cIt is H, OH, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C1-C6 haloalkoxy;

[0283] R 3c It is H, a halogen, a C1-C6 alkyl, or a C1-C6 haloalkyl; and

[0284] R 4c It is H, halogen, C1-C6 alkyl, or C1-C6 haloalkyl.

[0285] In some embodiments, the present invention relates to a compound of formula (IB-1) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N. In other implementations, X 4a It is N + -O - In other implementations, X 4a It is CR 4a In some implementations, R 4a It is a halogen group. In other embodiments, X 4a It's CF.

[0286] In some embodiments, the present invention relates to a compound of formula (IB-1) or a pharmaceutically acceptable salt thereof, wherein each R is H. In other embodiments, each R is independently H or CH3. In other embodiments, N(R)2 is NHCH3.

[0287] In some embodiments, the present invention relates to a compound of formula (IB-1) or a pharmaceutically acceptable salt thereof, wherein R 4a It is a halogen group.

[0288] In some embodiments, the present invention relates to a compound of formula (IB-1) or a pharmaceutically acceptable salt thereof, wherein R 4b1 and R 4b2 Each is independently H or C1-C6 alkyl. In other embodiments, R 4b1 and R 4b2 Each is independently H or CH3. In other embodiments, R 4b1 It is a C1-C6 alkyl group, and R 4b2 It is H. In other implementations, R 4b1 It is H, and R 4b2 It is a C1-C6 alkyl group. In other embodiments, R 4b1 It is CH3, and R 4b2 It is H. In other implementations, R 4b1 It is H, and R 4b2 It is CH3.

[0289] In some embodiments, the present invention relates to a compound of formula (IB-1) or a pharmaceutically acceptable salt thereof, wherein R 5b1 and R 5b2 Each is independently a C1-C6 alkyl or a C1-C6 haloalkyl. In other embodiments, R 5b1 and R 5b2 Each is independently H, CH3, or CF3. In other embodiments, R 5b1 It is a C1-C6 alkyl group, and R 5b2 It is a C1-C6 haloalkyl group. In other embodiments, R 5b1 It is a C1-C6 haloalkyl group, and R 5b2 It is a C1-C6 alkyl group. In other embodiments, R 5b1 It is CH3, and R 5b2 It is CF3. In other implementations, R 5b1 It's CF3, and R 5b2 It is CH3.

[0290] In some embodiments, the present invention relates to a compound of formula (IB-1) or a pharmaceutically acceptable salt thereof, wherein R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy. In other embodiments, R 2c It is a C1-C6 alkoxy group. In other embodiments, R 2c It is a C1-C6 haloalkoxy group. In other embodiments, R 2c It is OH, OCH3, OCD3, OCH2CH3, or OCHF2. In other embodiments, R 2c It is OH. In other embodiments, R 2c It is OCH3. In other implementations, R 2c It is OCD3. In other implementations, R 2c It is OCH2CH3. In other implementations, R 2c It is OCHF2.

[0291] In some embodiments, the present invention relates to a compound of formula (IB-1) or a pharmaceutically acceptable salt thereof, wherein R 3c It is H, a halogroup, or a C1-C6 alkyl group. In other embodiments, R 3c It is a halogen group. In other embodiments, R 3c It is a C1-C6 alkyl group. In other embodiments, R 3c It is H, F, Cl, or CH3. In other embodiments, R 3c It is H. In other implementations, R 3c It is F. In other implementations, R 3cIt is Cl. In other implementations, R 3c It is CH3.

[0292] In some embodiments, the present invention relates to a compound of formula (IB-1) or a pharmaceutically acceptable salt thereof, wherein R 4c It is a halogen group. In other embodiments, R 4c It is F.

[0293] In some embodiments, the present invention relates to a compound of formula (IB-1) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; R 4b1 and R 4b2 Each is independently H or C1-C6 alkyl; R 5b1 and R 5b2 Each is independently a C1-C6 alkyl or a C1-C6 haloalkyl; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; R 3c It is H, a halogroup, or a C1-C6 alkyl group; and R 4c It is a halogen group.

[0294] In some embodiments, the present invention relates to a compound of formula (IB-1) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; R 4b1 and R 4b2 Each is independently H or CH3; R 5b1 and R 5b2 Each is independently H, CH3, or CF3; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; R 3c It is H, a halogroup, or a C1-C6 alkyl group; and R 4c It is a halogen group.

[0295] In some embodiments, the present invention relates to a compound of formula (IB-1) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; R 4b1 It is a C1-C6 alkyl group; R 4b2 It is H; R 5b1 It is a C1-C6 alkyl group; R 5b2 It is a C1-C6 haloalkyl group; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; R 3c It is H, a halogroup, or a C1-C6 alkyl group; and R 4c It is a halogen group.

[0296] In some embodiments, the present invention relates to a compound of formula (IB-1) or a pharmaceutically acceptable salt thereof, wherein X4a It is N; each R is H; R 4b1 It is H; R 4b2 It is a C1-C6 alkyl group; R 5b1 It is a C1-C6 alkyl group; R 5b2 It is a C1-C6 haloalkyl group; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; R 3c It is H, a halogroup, or a C1-C6 alkyl group; and R 4c It is a halogen group.

[0297] In some embodiments, the present invention relates to a compound of formula (IB-1) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; R 4b1 It is a C1-C6 alkyl group; R 4b2 It is H; R 5b1 It is a C1-C6 haloalkyl group; R 5b2 It is a C1-C6 alkyl group; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; R 3c It is H, a halogroup, or a C1-C6 alkyl group; and R 4c It is a halogen group.

[0298] In some embodiments, the present invention relates to a compound of formula (IB-1) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; R 4b1 It is H; R 4b2 It is a C1-C6 alkyl group; R 5b1 It is a C1-C6 haloalkyl group; R 5b2 It is a C1-C6 alkyl group; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; R 3c It is H, a halogroup, or a C1-C6 alkyl group; and R 4c It is a halogen group.

[0299] In some embodiments, the present invention relates to a compound of formula (IB-1) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; R 4b1 It is CH3; R 4b2 It is H; R 5b1 It is CH3; R 5b2 It's CF3; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; R 3c It is H, a halogroup, or a C1-C6 alkyl group; and R 4c It is a halogen group.

[0300] In some embodiments, the present invention relates to a compound of formula (IB-1) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; R 4b1 It is H; R 4b2 It is CH3; R 5b1 It is CH3; R 5b2 It's CF3; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; R 3c It is H, a halogroup, or a C1-C6 alkyl group; and R 4c It is a halogen group.

[0301] In some embodiments, the present invention relates to a compound of formula (IB-1) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; R 4b1 It is CH3; R 4b2 It is H; R 5b1 It's CF3; R 5b2 It is CH3; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; R 3c It is H, a halogroup, or a C1-C6 alkyl group; and R 4c It is a halogen group.

[0302] In some embodiments, the present invention relates to a compound of formula (IB-1) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; R 4b1 It is H, and R 4b2 It is CH3; R 5b1 It's CF3; R 5b2 It is CH3; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; R 3c It is H, a halogroup, or a C1-C6 alkyl group; and R 4c It is a halogen group.

[0303] In some embodiments, the present invention relates to compounds of formula (IB-1) (including any of the foregoing embodiments thereof), i.e., compounds in non-salt form.

[0304] In some embodiments, the present invention relates to compounds of formula (IC).

[0305]

[0306] Or its pharmaceutically acceptable salt, wherein:

[0307] X 2a It is N, N + -O - or CR2a ;

[0308] X 4a It is N, N + -O - or CR 4a ;

[0309] X 5a It is N, N + -O - or CR 5a ;

[0310] X 6a It is N, N + -O - or CR 6a ;

[0311] Each R is independently H or a C1-C6 alkyl group;

[0312] R 2a R 4a R 5a and R 6a Each is independently H, a halogen, a C1-C6 alkyl group, or a C1-C6 haloalkyl group;

[0313] R 4b1 and R 4b2 Each is independently H, C1-C6 alkyl, C3-C6 cycloalkyl, or C1-C6 haloalkyl;

[0314] R 5b1 and R 5b2 Each is independently H, C1-C6 alkyl, C3-C6 cycloalkyl, or C1-C6 haloalkyl;

[0315] X 3c Is it N or CR? 3c ;

[0316] X 4c Is it N or CR? 4c ;

[0317] X 5c Is it N or CR? 5c ;

[0318] X 6c Is it N or CR? 6c ;

[0319] R 2c It is H, OH, halogen, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or -L 1 -L 2-(C3-C6 cycloalkyl), wherein the cycloalkyl group is optionally substituted with 1-2 halogen groups;

[0320] L 1 It is a key or an 'O';

[0321] L 2 It is a bond or a C1-C6 alkylene group;

[0322] R 3c It is H, a halogen, a C1-C6 alkyl group, or a C1-C6 haloalkyl group;

[0323] R 4c It is H, a halogen, a C1-C6 alkyl group, or a C1-C6 haloalkyl group;

[0324] R 5c It is H, a halogen, a C1-C6 alkyl, or a C1-C6 haloalkyl; and

[0325] R 6c It is H, a halogen, a C1-C6 alkyl group, or a C1-C6 haloalkyl group;

[0326] The constraint is X 2a X 4a X 5a and X 6a No more than two of them are N or N + -O - ;and

[0327] The constraint is X 3c X 4c X 5c and X 6c No more than one of them is N.

[0328] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 2a It is CR 2a ;X 5a It is CR 5a ;X 6a It is CR 6a ;R 4b1 and R 4b2 Each is independently H, C1-C6 alkyl, or C1-C6 haloalkyl; R 5b1 and R 5b2 Each is independently H, C1-C6 alkyl, or C1-C6 haloalkyl; X 3c It is CR 3c ;X 4c It is CR 4c ;X 5c It is CR 5c ;X 6c It is CR6c And R 2c It is H, OH, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C1-C6 haloalkoxy.

[0329] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein each R is H. In other embodiments, each R is independently H or CH3. In other embodiments, N(R)2 is NHCH3.

[0330] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 2a It is N. In other implementations, X 2a It is CR 2a In some implementations, R 2a It is H, D, a halogroup, or a C1-C6 alkyl group. In other embodiments, R 2a It is H, D, F, or CH3. In some implementations, X 2a It is N, CH, CD, C-(C1-C6 alkyl), or C-halogen. In other embodiments, X 2a It is N, CH, CD, C-CH3 or CF.

[0331] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 2a It is CR 2a And R 2a It's H.

[0332] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N. In other implementations, X 4a It is N + -O - In other implementations, X 4a It is CR 4a In some implementations, R 4a It is a halogen group. In other embodiments, R 4a It is an H or a halogen group. In other embodiments, R 4a It is H or F. In other implementations, X 4a It is CF. In some implementations, X 4a It is N, N + -O-, CH, or C- halogen groups. In other embodiments, X 4a It is N, N + -O - CH or CF.

[0333] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 4a It is CR 4a And R 4a It is a halogen group.

[0334] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 5a It is N. In other implementations, X 5a It is CR 5a In some implementations, R 5a It is H, D, a halogroup, or a C1-C6 alkyl group. In other embodiments, R 5a It is H, D, F, or CH3. In some implementations, X 5a It is N, CH, CD, C-(C1-C6 alkyl), or C-halogen. In other embodiments, X 5a It is N, CH, CD, C-CH3 or CF.

[0335] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 5a It is CR 5a And R 5a It's H.

[0336] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 6a It is N. In other implementations, X 6a It is CR 6a In some implementations, R 6a It is H, D, a halogroup, or a C1-C6 alkyl group. In other embodiments, R 6a It is H, D, F, or CH3. In some implementations, X 6a It is N, CH, CD, C-(C1-C6 alkyl), or C-halogen. In other embodiments, X 6a It is N, CH, CD, C-CH3 or CF.

[0337] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 6a It is CR 6a And R 6a It's H.

[0338] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein R 4b1 and R 4b2Each is independently H or C1-C6 alkyl. In other embodiments, R 4b1 and R 4b2 Each is independently H, C1-C6 alkyl, or C3-C6 cycloalkyl. In other embodiments, R 4b1 and R 4b2 Each is independently H or CH3. In other embodiments, R 4b1 and R 4b2 Each is independently H, CH3, CH2CH3, or cyclopropyl. In other embodiments, R 4b1 It is a C1-C6 alkyl group, and R 4b2 It is H. In other implementations, R 4b1 It is H, and R 4b2 It is a C1-C6 alkyl group. In other embodiments, R 4b1 It is CH3, and R 4b2 It is H. In other implementations, R 4b1 It is H, and R 4b2 It is CH3.

[0339] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein R 5b1 and R 5b2 Each is independently a C1-C6 alkyl or a C1-C6 haloalkyl. In other embodiments, R 5b1 and R 5b2 Each is independently H, a C1-C6 alkyl group, or a C1-C6 haloalkyl group. In other embodiments, R 5b1 and R 5b2 Each is independently H, CH3, or CF3. In other embodiments, R 5b1 and R 5b2 Each is independently H, CH3, CH2CH3, CH(CH3)2, C(CH3)3, CHF2, CF2CH3, CH2CF3, or CF3. In other embodiments, R 5b1 It is a C1-C6 alkyl group, and R 5b2 It is a C1-C6 haloalkyl group. In other embodiments, R 5b1 It is a C1-C6 haloalkyl group, and R 5b2 It is a C1-C6 alkyl group. In other embodiments, R 5b1 It is CH3, and R 5b2 It is CF3. In other implementations, R 5b1 It's CF3, and R 5b2 It is CH3.

[0340] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein R2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy. In other embodiments, R 2c It is OH, halogen, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or -L 1 -L 2 -(C3-C6 cycloalkyl), wherein the cycloalkyl group is optionally substituted with 1-2 halogen groups. In other embodiments, R 2c It is H. In other implementations, R 2c It is a C1-C6 alkoxy group. In other embodiments, R 2c It is a C1-C6 haloalkoxy group. In other embodiments, R 2c Yes -L 1 -L 2 -(C3-C6 cycloalkyl), wherein the cycloalkyl group is optionally substituted with 1-2 halogen groups. In other embodiments, R 2c It is OH, OCH3, OCD3, OCH2CH3, or OCHF2. In other embodiments, R 2c It is H, F, CH3, CH=CH2, OH, OCH3, OCD3, OCH2CH3, OCH(CH3)2, OCHF2, In other implementations, R 2c It is OH. In other embodiments, R 2c It is OCH3. In other implementations, R 2c It is OCD3. In other implementations, R 2c It is OCH2CH3. In other implementations, R 2c It is OCHF2.

[0341] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 3c It is N. In other implementations, X 3c It is CR 3c In other implementations, R 3c It is H, a halogroup, a C1-C6 alkyl group, or a C1-C6 haloalkyl group. In other embodiments, R 3c It is H, CH3, CH2CH3, CHF2, CF3, F, or Cl. In some implementations, X 3c It is N, CH, C-CH3, C-CH2CH3, C-CHF2, C-CF3, CF, or C-Cl.

[0342] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 3cIt is CR 3c And R 3c It is H, a halogroup, or a C1-C6 alkyl group. In other embodiments, R 3c It is a halogen group. In other embodiments, R 3c It is a C1-C6 alkyl group. In other embodiments, R 3c It is H, F, Cl, or CH3. In other embodiments, R 3c It is H. In other implementations, R 3c It is F. In other implementations, R 3c It is Cl. In other implementations, R 3c It is CH3.

[0343] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 4c It is N. In other implementations, X 4c It is CR 4c In other implementations, R 4c It is H, a halogroup, or a C1-C6 haloalkyl group. In other embodiments, R 4c It is H, CHF2, CF3, or F. In some implementations, X 4c It is N, CH, C-CHF2, C-CF3 or CF.

[0344] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 4c It is CR 4c And R 4c It is a halogen group. In other embodiments, R 4c It is F.

[0345] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 5c It is N. In other implementations, X 5c It is CR 5c In other implementations, R 5c It is an H or a halogen group. In other embodiments, R 5c It is H, D, or Cl. In some implementations, X 5c It is N, CH, CD, or C-Cl.

[0346] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 5c It is CR 5c And R 5c It's H.

[0347] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 6c It is N. In other implementations, X 6c It is CR 6c In other implementations, R 6c It is an H or a halogen group. In other embodiments, R 6c It is H or F. In some implementations, X 6c It is N, CH, or CF.

[0348] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein R 6c It is H.

[0349] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 2a It is N, CH, CD, C-(C1-C6 alkyl) or C-halo; X 4a It is N, N + -O - , CH or C-halogen; X 5a It is N, CH, CD, C-(C1-C6 alkyl) or C-halo; X 6a It is N, CH, CD, C-(C1-C6 alkyl) or C-halogen; each R is H or CH3; R 4b1 and R 4b2 Each is independently H, C1-C6 alkyl, or C3-C6 cycloalkyl; R 5b1 and R 5b2 Each is independently H, C1-C6 alkyl, or C1-C6 haloalkyl; R 2c It is OH, halogen, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or -L 1 -L 2 -(C3-C6 cycloalkyl), wherein the cycloalkyl group is optionally substituted with 1-2 halogen groups; X 3c It is CR 3c ;R 3c It is H, a halogen, a C1-C6 alkyl group, or a C1-C6 haloalkyl group; X 4c It is CR 4c ;R 4c It is H, a halogroup, or a C1-C6 haloalkyl group; X 5c It is CR 5c ;R 5c It is H or a halo group; X 6c It is CR 6c And R 6c It is an H or a halogen group.

[0350] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; X 2a It is CR 2a ;R 2a It is H; X 5a It is CR 5a ;R 5a It is H; X 6a It is CR 6a ;R 6a It is H; R 4b1 and R 4b2 Each is independently H or C1-C6 alkyl; R 5b1 and R 5b2 Each is independently a C1-C6 alkyl or a C1-C6 haloalkyl; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; X 3c It is CR 3c ;R 3c It is H, a halogroup, or a C1-C6 alkyl group; X 4c It is CR 4c ;R 4c It is a halogenated group; X 5c It is CR 5c ;R 5c It is H; X 6c It is CR 6c And R 6c It's H.

[0351] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 2a It is N, CH, CD, C-CH3 or CF; X 4a It is N, N + -O - CH or CF; X 5a It is N, CH, CD, C-CH3 or CF; X 6a It is N, CH, CD, C-CH3 or CF; each R is H or CH3; R 4b1 and R 4b2 Each is independently H, CH3, CH2CH3, or cyclopropyl; R 5b1 and R 5b2 Each is independently H, CH3, CH2CH3, CH(CH3)2, C(CH3)3, CHF2, CF2CH3, CH2CF3, or CF3; R 2cIt is H, F, CH3, CH=CH2, OH, OCH3, OCD3, OCH2CH3, OCH(CH3)2, OCHF2, X 3c It is N, CH, C-CH3, C-CH2CH3, C-CHF2, C-CF3, CF, or C-Cl; X 4c It is N, CH, C-CHF2, C-CF3 or CF; X 5c It is N, CH, CD, or C-Cl; and X 6c It is N, CH, or CF.

[0352] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; X 2a It is CR 2a ;R 2a It is H; X 5a It is CR 5a ;R 5a It is H; X 6a It is CR 6a ;R 6a It is H; R 4b1 and R 4b2 Each is independently H or CH3; R 5b1 and R 5b2 Each is independently H, CH3, or CF3; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; X 3c It is CR 3c ;R 3c It is H, a halogroup, or a C1-C6 alkyl group; X 4c It is CR 4c ;R 4c It is a halogenated group; X 5c It is CR 5c ;R 5c It is H; X 6c It is CR 6c And R 6c It is H.

[0353] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; X 2a It is CR 2a ;R 2a It is H; X 5a It is CR 5a ;R 5a It is H; X 6a It is CR 6a ;R6a It is H; R 4b1 It is a C1-C6 alkyl group; R 4b2 It is H; R 5b1 It is a C1-C6 alkyl group; R 5b2 It is a C1-C6 haloalkyl group; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; X 3c It is CR 3c ;R 3c It is H, a halogroup, or a C1-C6 alkyl group; X 4c It is CR 4c ;R 4c It is a halogenated group; X 5c It is CR 5c ;R 5c It is H; X 6c It is CR 6c And R 6c It's H.

[0354] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; X 2a It is CR 2a ;R 2a It is H; X 5a It is CR 5a ;R 5a It is H; X 6a It is CR 6a ;R 6a It is H; R 4b1 It is H; R 4b2 It is a C1-C6 alkyl group; R 5b1 It is a C1-C6 alkyl group; R 5b2 It is a C1-C6 haloalkyl group; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; X 3c It is CR 3c ;R 3c It is H, a halogroup, or a C1-C6 alkyl group; X 4c It is CR 4c ;R 4c It is a halogenated group; X 5c It is CR 5c ;R 5c It is H; X 6c It is CR 6c And R 6c It's H.

[0355] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 4aIt is N; each R is H; X 2a It is CR 2a ;R 2a It is H; X 5a It is CR 5a ;R 5a It is H; X 6a It is CR 6a ;R 6a It is H; R 4b1 It is a C1-C6 alkyl group; R 4b2 It is H; R 5b1 It is a C1-C6 haloalkyl group; R 5b2 It is a C1-C6 alkyl group; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; X 3c It is CR 3c ;R 3c It is H, a halogroup, or a C1-C6 alkyl group; X 4c It is CR 4c ;R 4c It is a halogenated group; X 5c It is CR 5c ;R 5c It is H; X 6c It is CR 6c And R 6c It is H.

[0356] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; X 2a It is CR 2a ;R 2a It is H; X 5a It is CR 5a ;R 5a It is H; X 6a It is CR 6a ;R 6a It is H; R 5b1 It is a C1-C6 haloalkyl group; R 5b2 It is a C1-C6 alkyl group; R 4b1 It is H; R 4b2 It is a C1-C6 alkyl group; R 2c It is a C1-C6 alkoxy or a C1-C6 haloalkoxy; X 3c It is CR 3c ;R 3c It is H, a halogroup, or a C1-C6 alkyl group; X 4c It is CR 4c ;R 4c It is a halogenated group; X 5c It is CR 5c ;R 5cIt is H; X 6c It is CR 6c And R 6c It's H.

[0357] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; X 2a It is CR 2a ;R 2a It is H; X 5a It is CR 5a ;R 5a It is H; X 6a It is CR 6a ;R 6a It is H; R 5b1 It is CH3; R 5b2 It's CF3; R 4b1 It is CH3; R 4b2 It is H; R 2c It is a C1-C6 alkoxy or a C1-C6 haloalkoxy; X 3c It is CR 3c ;R 3c It is H, a halogroup, or a C1-C6 alkyl group; X 4c It is CR 4c ;R 4c It is a halogenated group; X 5c It is CR 5c ;R 5c It is H; X 6c It is CR 6c And R 6c It's H.

[0358] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; X 2a It is CR 2a ;R 2a It is H; X 5a It is CR 5a ;R 5a It is H; X 6a It is CR 6a ;R 6a It is H; R 5b1 It is CH3; R 5b2 It's CF3; R 4b1 It is H; R 4b2 It is CH3; R 2c It is a C1-C6 alkoxy or a C1-C6 haloalkoxy; X 3c It is CR 3c ;R 3cIt is H, a halogroup, or a C1-C6 alkyl group; X 4c It is CR 4c ;R 4c It is a halogenated group; X 5c It is CR 5c ;R 5c It is H; X 6c It is CR 6c And R 6c It's H.

[0359] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; X 2a It is CR 2a ;R 2a It is H; X 5a It is CR 5a ;R 5a It is H; X 6a It is CR 6a ;R 6a It is H; R 5b1 It's CF3; R 5b2 It is CH3; R 4b1 It is CH3; R 4b2 It is H; R 2c It is a C1-C6 alkoxy or a C1-C6 haloalkoxy; X 3c It is CR 3c ;R 3c It is H, a halogroup, or a C1-C6 alkyl group; X 4c It is CR 4c ;R 4c It is a halogenated group; X 5c It is CR 5c ;R 5c It is H; X 6c It is CR 6c And R 6c It's H.

[0360] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; X 2a It is CR 2a ;R 2a It is H; X 5a It is CR 5a ;R 5a It is H; X 6a It is CR 6a ;R 6a It is H; R 5b1 It's CF3; R 5b2 It is CH3; R 4b1It is H, and R 4b2 It is CH3; R 2c It is a C1-C6 alkoxy or a C1-C6 haloalkoxy; X 3c It is CR 3c ;R 3c It is H, a halogroup, or a C1-C6 alkyl group; X 4c It is CR 4c ;R 4c It is a halogenated group; X 5c It is CR 5c ;R 5c It is H; X 6c It is CR 6c And R 6c It's H.

[0361] In some embodiments, the present invention relates to a compound of formula (IC) (including any of the foregoing embodiments thereof), i.e., a compound in a non-salt form.

[0362] In some embodiments, the present invention relates to compounds of formula (IC-1).

[0363]

[0364] Or its pharmaceutically acceptable salt, wherein:

[0365] X 4a It is N, N + -O - or CR 4a ;

[0366] Each R is independently H or a C1-C6 alkyl group;

[0367] R 4a It is H, a halogen, a C1-C6 alkyl group, or a C1-C6 haloalkyl group;

[0368] R 4b1 and R 4b2 Each is independently H, C1-C6 alkyl, or C1-C6 haloalkyl;

[0369] R 5b1 and R 5b2 Each is independently H, C1-C6 alkyl, or C1-C6 haloalkyl;

[0370] R 2c It is H, OH, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C1-C6 haloalkoxy;

[0371] R 3c It is H, a halogen, a C1-C6 alkyl, or a C1-C6 haloalkyl; and

[0372] R 4c It is H, halogen, C1-C6 alkyl, or C1-C6 haloalkyl.

[0373] In some embodiments, the present invention relates to a compound of formula (IC-1) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N. In other implementations, X 4a It is N + -O - In other implementations, X 4a It is CR 4a In some implementations, R 4a It is a halogen group. In other embodiments, X 4a It's CF.

[0374] In some embodiments, the present invention relates to a compound of formula (IC-1) or a pharmaceutically acceptable salt thereof, wherein each R is H. In other embodiments, each R is independently H or CH3. In other embodiments, N(R)2 is NHCH3.

[0375] In some embodiments, the present invention relates to a compound of formula (IC-1) or a pharmaceutically acceptable salt thereof, wherein R 4a It is a halogen group.

[0376] In some embodiments, the present invention relates to a compound of formula (IC-1) or a pharmaceutically acceptable salt thereof, wherein R 4b1 and R 4b2 Each is independently H or C1-C6 alkyl. In other embodiments, R 4b1 and R 4b2 Each is independently H or CH3. In other embodiments, R 4b1 It is a C1-C6 alkyl group, and R 4b2 It is H. In other implementations, R 4b1 It is H, and R 4b2 It is a C1-C6 alkyl group. In other embodiments, R 4b1 It is CH3, and R 4b2 It is H. In other implementations, R 4b1 It is H, and R 4b2 It is CH3.

[0377] In some embodiments, the present invention relates to a compound of formula (IC-1) or a pharmaceutically acceptable salt thereof, wherein R 5b1 and R 5b2 Each is independently a C1-C6 alkyl or a C1-C6 haloalkyl. In other embodiments, R 5b1 and R 5b2Each is independently H, CH3, or CF3. In other embodiments, R 5b1 It is a C1-C6 alkyl group, and R 5b2 It is a C1-C6 haloalkyl group. In other embodiments, R 5b1 It is a C1-C6 haloalkyl group, and R 5b2 It is a C1-C6 alkyl group. In other embodiments, R 5b1 It is CH3, and R 5b2 It is CF3. In other implementations, R 5b1 It's CF3, and R 5b2 It is CH3.

[0378] In some embodiments, the present invention relates to a compound of formula (IC-1) or a pharmaceutically acceptable salt thereof, wherein R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy. In other embodiments, R 2c It is a C1-C6 alkoxy group. In other embodiments, R 2c It is a C1-C6 haloalkoxy group. In other embodiments, R 2c It is OH, OCH3, OCD3, OCH2CH3, or OCHF2. In other embodiments, R 2c It is OH. In other embodiments, R 2c It is OCH3. In other implementations, R 2c It is OCD3. In other implementations, R 2c It is OCH2CH3. In other implementations, R 2c It is OCHF2.

[0379] In some embodiments, the present invention relates to a compound of formula (IC-1) or a pharmaceutically acceptable salt thereof, wherein R 3c It is H, a halogroup, or a C1-C6 alkyl group. In other embodiments, R 3c It is a halogen group. In other embodiments, R 3c It is a C1-C6 alkyl group. In other embodiments, R 3c It is H, F, Cl, or CH3. In other embodiments, R 3c It is H. In other implementations, R 3c It is F. In other implementations, R 3c It is Cl. In other implementations, R 3c It is CH3.

[0380] In some embodiments, the present invention relates to a compound of formula (IC-1) or a pharmaceutically acceptable salt thereof, wherein R 4c It is a halogen group. In other embodiments, R 4c It is F.

[0381] In some embodiments, the present invention relates to a compound of formula (IC-1) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; R 4b1 and R 4b2 Each is independently H or C1-C6 alkyl; R 5b1 and R 5b2 Each is independently a C1-C6 alkyl or a C1-C6 haloalkyl; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; R 3c It is H, a halogroup, or a C1-C6 alkyl group; and R 4c It is a halogen group.

[0382] In some embodiments, the present invention relates to a compound of formula (IC-1) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; R 4b1 and R 4b2 Each is independently H or CH3; R 5b1 and R 5b2 Each is independently H, CH3, or CF3; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; R 3c It is H, a halogroup, or a C1-C6 alkyl group; and R 4c It is a halogen group.

[0383] In some embodiments, the present invention relates to a compound of formula (IC-1) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; R 4b1 It is a C1-C6 alkyl group; R 4b2 It is H; R 5b1 It is a C1-C6 alkyl group; R 5b2 It is a C1-C6 haloalkyl group; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; R 3c It is H, a halogroup, or a C1-C6 alkyl group; and R 4c It is a halogen group.

[0384] In some embodiments, the present invention relates to a compound of formula (IC-1) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; R 4b1 It is H; R 4b2 It is a C1-C6 alkyl group; R 5b1 It is a C1-C6 alkyl group; R 5b2 It is a C1-C6 haloalkyl group; R 2cIt is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; R 3c It is H, a halogroup, or a C1-C6 alkyl group; and R 4c It is a halogen group.

[0385] In some embodiments, the present invention relates to a compound of formula (IC-1) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; R 4b1 It is a C1-C6 alkyl group; R 4b2 It is H; R 5b1 It is a C1-C6 haloalkyl group; R 5b2 It is a C1-C6 alkyl group; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; R 3c It is H, a halogroup, or a C1-C6 alkyl group; and R 4c It is a halogen group.

[0386] In some embodiments, the present invention relates to a compound of formula (IC-1) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; R 4b1 It is H; R 4b2 It is a C1-C6 alkyl group; R 5b1 It is a C1-C6 haloalkyl group; R 5b2 It is a C1-C6 alkyl group; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; R 3c It is H, a halogroup, or a C1-C6 alkyl group; and R 4c It is a halogen group.

[0387] In some embodiments, the present invention relates to a compound of formula (IC-1) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; R 4b1 It is CH3; R 4b2 It is H; R 5b1 It is CH3; R 5b2 It's CF3; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; R 3c It is H, a halogroup, or a C1-C6 alkyl group; and R 4c It is a halogen group.

[0388] In some embodiments, the present invention relates to a compound of formula (IC-1) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; R 4b1 It is H; R 4b2 It is CH3; R 5b1 It is CH3; R 5b2It's CF3; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; R 3c It is H, a halogroup, or a C1-C6 alkyl group; and R 4c It is a halogen group.

[0389] In some embodiments, the present invention relates to a compound of formula (IC-1) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; R 4b1 It is CH3; R 4b2 It is H; R 5b1 It's CF3; R 5b2 It is CH3; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; R 3c It is H, a halogroup, or a C1-C6 alkyl group; and R 4c It is a halogen group.

[0390] In some embodiments, the present invention relates to a compound of formula (IC-1) or a pharmaceutically acceptable salt thereof, wherein X 4a It is N; each R is H; R 4b1 It is H, and R 4b2 It is CH3; R 5b1 It's CF3; R 5b2 It is CH3; R 2c It is OH, C1-C6 alkoxy, or C1-C6 haloalkoxy; R 3c It is H, a halogroup, or a C1-C6 alkyl group; and R 4c It is a halogen group.

[0391] In some embodiments, the present invention relates to compounds of formula (IC-1) (including any of the foregoing embodiments thereof), i.e., compounds in non-salt form.

[0392] In some embodiments, the present invention relates to compounds selected from Table A or pharmaceutically acceptable salts thereof. In other embodiments, the present invention relates to compounds selected from Table A in a non-salt form.

[0393] Table A. Compound structures and names.

[0394]

[0395]

[0396]

[0397]

[0398]

[0399]

[0400]

[0401]

[0402]

[0403]

[0404]

[0405]

[0406]

[0407]

[0408]

[0409]

[0410]

[0411]

[0412]

[0413]

[0414]

[0415]

[0416]

[0417]

[0418]

[0419]

[0420]

[0421]

[0422] In some embodiments, the present invention relates to compounds selected from Table B or pharmaceutically acceptable salts thereof. In other embodiments, the present invention relates to compounds selected from Table B in a non-salt form.

[0423] Table B. Compound structures and names.

[0424]

[0425]

[0426]

[0427]

[0428]

[0429]

[0430]

[0431]

[0432]

[0433]

[0434]

[0435]

[0436]

[0437] In some embodiments, the present invention relates to compounds selected from Table C or pharmaceutically acceptable salts thereof. In other embodiments, the present invention relates to compounds selected from Table C in non-salt form.

[0438] Table C. Compound Names.

[0439]

[0440]

[0441]

[0442]

[0443]

[0444]

[0445]

[0446]

[0447]

[0448]

[0449]

[0450]

[0451]

[0452]

[0453]

[0454]

[0455]

[0456]

[0457]

[0458]

[0459]

[0460]

[0461]

[0462]

[0463]

[0464]

[0465]

[0466]

[0467]

[0468]

[0469]

[0470]

[0471]

[0472]

[0473]

[0474]

[0475]

[0476]

[0477]

[0478]

[0479] In some embodiments, the present invention relates to compounds of the following formula

[0480]

[0481] Or a pharmaceutically acceptable salt thereof, wherein the compound has the absolute stereochemistry of the first eluting isomer when the racemic mixture of enantiomers is separated by SFC as described in step 6 of Example 1. Such compounds are considered "compounds of the invention" as used herein.

[0482] In some embodiments, the present invention relates to compounds of the following formula

[0483]

[0484] Or a pharmaceutically acceptable salt thereof, wherein the compound has the absolute stereochemistry of the second eluting isomer when the racemic mixture of enantiomers is separated by SFC as described in step 6 of Example 1. Such compounds are considered "compounds of the invention" as used herein.

[0485] In some embodiments, the present invention relates to compounds of the following formula

[0486]

[0487] Or a pharmaceutically acceptable salt thereof, wherein the compound has the absolute stereochemistry of the first eluting isomer when separated by an SFC (Chiralpak AS-H column) as described in Example 1. Such compounds are considered "compounds of the invention" as used herein.

[0488] In some embodiments, the present invention relates to compounds of the following formula

[0489]

[0490] Or a pharmaceutically acceptable salt thereof, wherein the compound has the absolute stereochemistry of the second eluting isomer when separated by an SFC (Chiralpak AS-H column) as described in Example 1. Such compounds are considered "compounds of the invention" as used herein.

[0491] In some embodiments, the present invention relates to compounds of the following formula

[0492]

[0493] Or a pharmaceutically acceptable salt thereof, wherein the compound has the absolute stereochemistry of the first eluting isomer when the racemic mixture of enantiomers is separated by SFC as described in step 10 of Example 2. Such compounds are considered "compounds of the invention" as used herein.

[0494] In some embodiments, the present invention relates to compounds of the following formula

[0495]

[0496] Or a pharmaceutically acceptable salt thereof, wherein the compound has the absolute stereochemistry of the second eluting isomer when the racemic mixture of enantiomers is separated by SFC as described in step 10 of Example 2. Such compounds are considered "compounds of the invention" as used herein.

[0497] In some embodiments, the present invention relates to compounds of the following formula

[0498]

[0499] Or a pharmaceutically acceptable salt thereof, wherein the compound has the absolute stereochemistry of the first eluting isomer when the racemic mixture of enantiomers is separated by SFC as described in step 13 of Example 3. Such compounds are considered "compounds of the invention" as used herein.

[0500] In some embodiments, the present invention relates to compounds of the following formula

[0501]

[0502] Or a pharmaceutically acceptable salt thereof, wherein the compound has the absolute stereochemistry of the second eluting isomer when the racemic mixture of enantiomers is separated by SFC as described in step 13 of Example 3. Such compounds are considered "compounds of the invention" as used herein.

[0503] In some embodiments, the present invention relates to compounds of the following formula

[0504]

[0505] Or a pharmaceutically acceptable salt thereof. Such compounds are considered "compounds of the present invention" as used herein.

[0506] In some embodiments, the present invention relates to compounds of the following formula

[0507]

[0508] Or a pharmaceutically acceptable salt thereof. Such compounds are considered "compounds of the present invention" as used herein.

[0509] In some embodiments, the present invention relates to compounds of the following formula

[0510]

[0511] Or a pharmaceutically acceptable salt thereof, wherein the compound has the absolute stereochemistry of the first eluting isomer when the racemic mixture of enantiomers is separated by SFC as described in Example 3. Such compounds are considered "compounds of the invention" as used herein.

[0512] In some embodiments, the present invention relates to compounds of the following formula

[0513]

[0514] Or a pharmaceutically acceptable salt thereof, wherein the compound has the absolute stereochemistry of the second eluting isomer when the racemic mixture of enantiomers is separated by SFC as described in Example 3. Such compounds are considered "compounds of the invention" as used herein.

[0515] In some embodiments, the present invention relates to compounds of the following formula

[0516]

[0517] Or a pharmaceutically acceptable salt thereof. Such compounds are considered "compounds of the present invention" as used herein.

[0518] In some embodiments, the present invention relates to compounds of the following formula

[0519]

[0520] Or a pharmaceutically acceptable salt thereof. Such compounds are considered "compounds of the present invention" as used herein.

[0521] In some embodiments, the present invention relates to compounds of the following formula

[0522]

[0523] Or a pharmaceutically acceptable salt thereof. Such compounds are considered "compounds of the present invention" as used herein.

[0524] In some embodiments, the present invention relates to compounds of the following formula

[0525]

[0526] Or a pharmaceutically acceptable salt thereof. Such compounds are considered "compounds of the present invention" as used herein.

[0527] In some embodiments, the present invention relates to compounds of the following formula

[0528]

[0529] Or a pharmaceutically acceptable salt thereof. Such compounds are considered "compounds of the present invention" as used herein.

[0530] In some embodiments, the present invention relates to compounds of the following formula

[0531]

[0532] Or a pharmaceutically acceptable salt thereof, wherein the compound has the absolute stereochemistry of the first eluting isomer when separated by an SFC (Chiralpak AS-H column) as described in Example 1. Such compounds are considered "compounds of the invention" as used herein.

[0533] In some embodiments, the present invention relates to compounds of the following formula

[0534]

[0535] Or a pharmaceutically acceptable salt thereof, wherein the compound has the absolute stereochemistry of the second eluting isomer when separated by an SFC (Chiralpak AS-H column) as described in Example 1. Such compounds are considered "compounds of the invention" as used herein.

[0536] In some embodiments, the present invention relates to compounds of the following formula

[0537]

[0538] Or a pharmaceutically acceptable salt thereof, wherein the compound has the absolute stereochemistry of the first eluting isomer when the racemic mixture of enantiomers is separated by SFC as described in step 4 of Example 4. Such compounds are considered "compounds of the invention" as used herein.

[0539] In some embodiments, the present invention relates to compounds of the following formula

[0540]

[0541] Or a pharmaceutically acceptable salt thereof, wherein the compound has the absolute stereochemistry of the second eluting isomer when the racemic mixture of enantiomers is separated by SFC as described in step 4 of Example 4. Such compounds are considered "compounds of the invention" as used herein.

[0542] In some embodiments, the present invention relates to compounds of the following formula

[0543]

[0544] Or a pharmaceutically acceptable salt thereof, wherein the compound has the absolute stereochemistry of the first eluting isomer when the racemic mixture of enantiomers is separated by an SFC (Chiralpak AS-H column) as described in step 4 of Example 4. Such compounds are considered "compounds of the invention" as used herein.

[0545] In some embodiments, the present invention relates to compounds of the following formula

[0546]

[0547] Or a pharmaceutically acceptable salt thereof, wherein the compound has the absolute stereochemistry of the second eluting isomer when the racemic mixture of enantiomers is separated by an SFC (Chiralpak AS-H column) as described in step 4 of Example 4. Such compounds are considered "compounds of the invention" as used herein.

[0548] In some embodiments, the present invention relates to compounds of the following formula

[0549]

[0550] Or a pharmaceutically acceptable salt thereof. Such compounds are considered "compounds of the present invention" as used herein.

[0551] In some embodiments, the present invention relates to compounds of the following formula

[0552]

[0553] Or a pharmaceutically acceptable salt thereof. Such compounds are considered "compounds of the present invention" as used herein.

[0554] In some embodiments, the present invention relates to compounds of the following formula

[0555]

[0556] Or a pharmaceutically acceptable salt thereof, wherein the compound has the absolute stereochemistry of the first eluting isomer when a mixture of racemic diastereomers (with epimerism at the 5-position) is separated by SFC as described in step 7 of Example 6. Such compounds are considered "compounds of the invention" as used herein.

[0557] In some embodiments, the present invention relates to compounds of the following formula

[0558]

[0559] Or a pharmaceutically acceptable salt thereof, wherein the compound has the absolute stereochemistry of the second eluting isomer when a mixture of racemic diastereomers (with epimerism at the 5-position) is separated by SFC as described in step 7 of Example 6. Such compounds are considered "compounds of the invention" as used herein.

[0560] In some embodiments, the present invention relates to compounds of the following formula

[0561]

[0562] Or a pharmaceutically acceptable salt thereof. Such compounds are considered "compounds of the present invention" as used herein.

[0563] In some embodiments, the present invention relates to compounds of the following formula

[0564]

[0565] Or a pharmaceutically acceptable salt thereof, wherein the compound has the absolute stereochemistry of the third eluting isomer when a mixture of racemic diastereomers (with epimerism at the 5-position) is separated by SFC as described in step 7 of Example 6. Such compounds are considered "compounds of the invention" as used herein.

[0566] In some embodiments, the present invention relates to compounds of the following formula

[0567]

[0568] Or a pharmaceutically acceptable salt thereof, wherein the compound has the absolute stereochemistry of the fourth eluting isomer when a mixture of racemic diastereomers (with epimerism at the 5-position) is separated by SFC as described in step 7 of Example 6. Such compounds are considered "compounds of the invention" as used herein.

[0569] In some embodiments, the present invention relates to compounds of the following formula

[0570]

[0571] Or a pharmaceutically acceptable salt thereof. Such compounds are considered "compounds of the present invention" as used herein.

[0572] In some embodiments, the present invention relates to compounds of the following formula

[0573]

[0574] Or a pharmaceutically acceptable salt thereof, wherein the compound has the absolute stereochemistry of the first eluting isomer when the racemic mixture of enantiomers is separated by SFC as described in step 11 of Example 7. Such compounds are considered "compounds of the invention" as used herein.

[0575] In some embodiments, the present invention relates to compounds of the following formula

[0576]

[0577] Or a pharmaceutically acceptable salt thereof, wherein the compound has the absolute stereochemistry of the second eluting isomer when the racemic mixture of enantiomers is separated by SFC as described in step 11 of Example 7. Such compounds are considered "compounds of the invention" as used herein.

[0578] In some embodiments, the present invention relates to compounds of the following formula

[0579]

[0580] Or a pharmaceutically acceptable salt thereof. Such compounds are considered "compounds of the present invention" as used herein.

[0581] Solid form of the compound of the present invention

[0582] In another aspect, the present invention relates to the compounds of the invention or pharmaceutically acceptable salts thereof in solid form. In some embodiments, the compounds of the invention or pharmaceutically acceptable salts thereof are in crystalline solid form.

[0583] solid form of compound 7

[0584] In some embodiments, the present invention relates to compounds of the following formula

[0585]

[0586] When the racemic mixture of enantiomers is separated by SFC as described in step 13 of Example 3, the compound has the absolute stereochemistry of the second eluting isomer, wherein the compound is in crystalline solid form.

[0587] In some implementations, the crystalline solid form is form A.

[0588] In some embodiments, form A is characterized by XRPD patterns exhibiting diffraction at the following angles (2θ ± 0.2 degrees): 9.9, 13.9, 15.7, and 19.0. In other embodiments, form A is characterized by XRPD patterns exhibiting diffraction at at least one, at least two, or at least three angles (2θ ± 0.2 degrees): 9.9, 13.9, 15.7, and 19.0. In still other embodiments, form A is characterized by XRPD patterns exhibiting diffraction at the following angles (2θ ± 0.2 degrees): 7.3, 9.9, 13.9, 15.7, 19.0, 20.1, 20.3, and 25.4. In other embodiments, form A is characterized by XRPD patterns having at least one, at least two, at least three, at least four, at least five, at least six, or at least seven diffractions at the following angles (2θ ± 0.2 degrees): 7.3, 9.9, 13.9, 15.7, 19.0, 20.1, 20.3, and 25.4. In other embodiments, form A is characterized by... Figure 1 Essentially similar XRPD maps.

[0589] In some embodiments, Form A is characterized by a DSC thermogram with a melt initiation at 186°C and a peak at 187°C.

[0590] In some implementations, form A can be obtained by crystallization from methanol at 60°C.

[0591] In some implementations, the crystalline solid form is form B.

[0592] In some embodiments, form B is characterized by XRPD patterns exhibiting diffraction at the following angles (2θ ± 0.2 degrees): 12.8, 14.1, 15.2, 18.5, and 20.3. In other embodiments, form B is characterized by XRPD patterns exhibiting at least one, at least two, at least three, or at least four diffractions at the following angles (2θ ± 0.2 degrees): 12.8, 14.1, 15.2, 18.5, and 20.3. In other embodiments, form B is characterized by XRPD patterns exhibiting diffraction at the following angles (2θ ± 0.2 degrees): 12.0, 12.8, 14.1, 15.2, 16.9, 18.4, 18.5, 18.7, 19.3, and 20.3. In other embodiments, form B is characterized by XRPD patterns having at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, or at least nine diffractions at the following angles (2θ ± 0.2 degrees): 12.0, 12.8, 14.1, 15.2, 16.9, 18.4, 18.5, 18.7, 19.3, and 20.3. In other embodiments, form B is characterized by XRPD patterns with diffraction at the following angles (2θ ± 0.2 degrees): 7.6, 9.2, 12.0, 12.8, 14.1, 15.1, 15.2, 16.2, 16.9, 17.6, 18.4, 18.5, 18.7, 19.3, 20.3, 21.7, 22.0, 22.2, 22.9, 23.6, 24.0, 24.2, 25.2, 26.9, 27.0, 27.4, 28.6, and 28.9. In other embodiments, form B is characterized by having at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, at least fourteen, at least fifteen, at least sixteen, at least seventeen, at least eighteen, at least nineteen, at least twenty, at least twenty-one, at least twenty-two, at least twenty-three, or at least twenty-four at the following angles (2θ ± 0.2 degrees). XRPD patterns of at least one, at least twenty-five, at least twenty-six, or at least twenty-seven diffractions: 7.6, 9.2, 12.0, 12.8, 14.1, 15.1, 15.2, 16.2, 16.9, 17.6, 18.4, 18.5, 18.7, 19.3, 20.3, 21.7, 22.0, 22.2, 22.9, 23.6, 24.0, 24.2, 25.2, 26.9, 27.0, 27.4, 28.6, and 28.9. In other embodiments, form B is characterized by... Figure 4 Essentially similar XRPD maps.

[0593] In some implementations, form B is characterized by a solid state having a peak at the following chemical shifts. 13 C NMR spectra: 172.5, 172.1, 168.5, 168.3, 168.0, 151.5, 148.3, 147.8, 127.7, 122.7, 116.6, 115.1, 110.6, 86.5, 80.2, 63.2, 44.3, 23.0, and 13.1 ppm. In some embodiments, form B is characterized by... Figure 5 Basically similar solid-state 13 C NMR spectrum.

[0594] In some implementations, form B is characterized by a solid state having a peak at the following chemical shifts. 19 F NMR spectra: -137.1 and -152.8 ppm. In some embodiments, form B is characterized by... Figure 6 Basically similar solid-state 19 F NMR spectrum.

[0595] In some embodiments, Form B is characterized by a DSC thermogram with a melt initiation at 182°C and a peak at 183°C.

[0596] In some implementations, form B is characterized by 3501, 3356, 1684, 1565, 1505, and 1122 cm. -1 The IR spectrum has peaks at a certain location. In some embodiments, form B is characterized by... Figure 9 Basically similar IR spectra.

[0597] In some embodiments, form B is characterized by an orthorhombic crystal system, as determined by single-crystal X-ray analysis. In other embodiments, form B is characterized by space group P212121, as determined by single-crystal X-ray analysis. In still other embodiments, form B is characterized by a unit cell having the following dimensions, as determined by single-crystal X-ray analysis: α=90°; β=90°; and γ=90°.

[0598] In some embodiments, form B can be obtained by dissolving the compound in ethyl acetate and then crystallizing the compound by adding n-heptane as an antisolvent. In other embodiments, form B can be obtained by the procedure described in Example 3.

[0599] In some embodiments, the present invention relates to compounds of the following formula

[0600]

[0601] The compounds are in crystalline solid form.

[0602] In some implementations, the crystalline solid form is form A.

[0603] In some embodiments, form A is characterized by XRPD patterns exhibiting diffraction at the following angles (2θ ± 0.2 degrees): 9.9, 13.9, 15.7, and 19.0. In other embodiments, form A is characterized by XRPD patterns exhibiting diffraction at at least one, at least two, or at least three angles (2θ ± 0.2 degrees): 9.9, 13.9, 15.7, and 19.0. In still other embodiments, form A is characterized by XRPD patterns exhibiting diffraction at the following angles (2θ ± 0.2 degrees): 7.3, 9.9, 13.9, 15.7, 19.0, 20.1, 20.3, and 25.4. In other embodiments, form A is characterized by XRPD patterns having at least one, at least two, at least three, at least four, at least five, at least six, or at least seven diffractions at the following angles (2θ ± 0.2 degrees): 7.3, 9.9, 13.9, 15.7, 19.0, 20.1, 20.3, and 25.4. In other embodiments, form A is characterized by... Figure 1 Essentially similar XRPD maps.

[0604] In some embodiments, Form A is characterized by a DSC thermogram with a melt initiation at 186°C and a peak at 187°C.

[0605] In some implementations, form A can be obtained by crystallization from methanol at 60°C.

[0606] In some implementations, the crystalline solid form is form B.

[0607] In some embodiments, form B is characterized by XRPD patterns exhibiting diffraction at the following angles (2θ ± 0.2 degrees): 12.8, 14.1, 15.2, 18.5, and 20.3. In other embodiments, form B is characterized by XRPD patterns exhibiting at least one, at least two, at least three, or at least four diffractions at the following angles (2θ ± 0.2 degrees): 12.8, 14.1, 15.2, 18.5, and 20.3. In other embodiments, form B is characterized by XRPD patterns exhibiting diffraction at the following angles (2θ ± 0.2 degrees): 12.0, 12.8, 14.1, 15.2, 16.9, 18.4, 18.5, 18.7, 19.3, and 20.3. In other embodiments, form B is characterized by XRPD patterns having at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, or at least nine diffractions at the following angles (2θ ± 0.2 degrees): 12.0, 12.8, 14.1, 15.2, 16.9, 18.4, 18.5, 18.7, 19.3, and 20.3. In other embodiments, form B is characterized by XRPD patterns with diffraction at the following angles (2θ ± 0.2 degrees): 7.6, 9.2, 12.0, 12.8, 14.1, 15.1, 15.2, 16.2, 16.9, 17.6, 18.4, 18.5, 18.7, 19.3, 20.3, 21.7, 22.0, 22.2, 22.9, 23.6, 24.0, 24.2, 25.2, 26.9, 27.0, 27.4, 28.6, and 28.9. In other embodiments, form B is characterized by having at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, at least fourteen, at least fifteen, at least sixteen, at least seventeen, at least eighteen, at least nineteen, at least twenty, at least twenty-one, at least twenty-two, at least twenty-three, or at least twenty-four at the following angles (2θ ± 0.2 degrees). XRPD patterns of at least one, at least twenty-five, at least twenty-six, or at least twenty-seven diffractions: 7.6, 9.2, 12.0, 12.8, 14.1, 15.1, 15.2, 16.2, 16.9, 17.6, 18.4, 18.5, 18.7, 19.3, 20.3, 21.7, 22.0, 22.2, 22.9, 23.6, 24.0, 24.2, 25.2, 26.9, 27.0, 27.4, 28.6, and 28.9. In other embodiments, form B is characterized by... Figure 4 Essentially similar XRPD maps.

[0608] In some implementations, form B is characterized by a solid state having a peak at the following chemical shifts. 13 C NMR spectra: 172.5, 172.1, 168.5, 168.3, 168.0, 151.5, 148.3, 147.8, 127.7, 122.7, 116.6, 115.1, 110.6, 86.5, 80.2, 63.2, 44.3, 23.0, and 13.1 ppm. In other embodiments, form B is characterized by... Figure 5 Basically similar solid-state 13 C NMR spectrum.

[0609] In some implementations, form B is characterized by a solid state having a peak at the following chemical shifts. 19 F NMR spectrum: -137.1 and -152.8 ppm. In other embodiments, form B is characterized by... Figure 6 Basically similar solid-state 19 F NMR spectrum.

[0610] In some embodiments, Form B is characterized by a DSC thermogram with a melt initiation at 182°C and a peak at 183°C.

[0611] In some implementations, form B is characterized by 3501, 3356, 1684, 1565, 1505, and 1122 cm. -1 The IR spectrum has a peak at that location. In other embodiments, form B is characterized by... Figure 9 Basically similar IR spectra.

[0612] In some embodiments, form B is characterized by an orthorhombic crystal system, as determined by single-crystal X-ray analysis. In other embodiments, form B is characterized by space group P212121, as determined by single-crystal X-ray analysis. In still other embodiments, form B is characterized by a unit cell having the following dimensions, as determined by single-crystal X-ray analysis: α=90°; β=90°; and γ=90°.

[0613] In some embodiments, form B can be obtained by dissolving the compound in ethyl acetate and then crystallizing the compound by adding n-heptane as an antisolvent. In other embodiments, form B can be obtained by the procedure described in Example 3.

[0614] solid form of compound 9

[0615] In some embodiments, the present invention relates to compounds of the following formula

[0616]

[0617] The compounds are in crystalline solid form.

[0618] In some implementations, the crystalline solid form is form A.

[0619] In some embodiments, form A is characterized by an orthorhombic crystal system, as determined by single-crystal X-ray analysis. In other embodiments, form A is characterized by the I222 space group, as determined by single-crystal X-ray analysis. In still other embodiments, form A is characterized by a unit cell having the following dimensions, as determined by single-crystal X-ray analysis: α=90°; β=90°; and γ=90°.

[0620] In some embodiments, form A can be obtained by dissolving the compound in a 10 / 90 solution of dichloromethane / dichloroethane, followed by vapor diffusion of pentane. In some embodiments, form A can be obtained by the procedure described in Example 3.

[0621] solid form of compound 11

[0622] In some embodiments, the present invention relates to compounds of the following formula

[0623]

[0624] The compounds are in crystalline solid form.

[0625] In some implementations, the crystalline solid form is form A.

[0626] In some embodiments, form A is characterized by XRPD patterns exhibiting diffraction at the following angles (2θ ± 0.2 degrees): 10.1, 13.7, 14.1, 16.3, and 20.0. In other embodiments, form A is characterized by XRPD patterns exhibiting at least one, at least two, at least three, or at least four diffractions at the following angles (2θ ± 0.2 degrees): 10.1, 13.7, 14.1, 16.3, and 20.0. In other embodiments, form A is characterized by XRPD patterns exhibiting diffraction at the following angles (2θ ± 0.2 degrees): 7.3, 10.1, 13.7, 14.1, 16.0, 16.3, 20.0, 20.4, 23.7, and 24.8. In other embodiments, form A is characterized by XRPD patterns having at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, or at least nine diffractions at the following angles (2θ ± 0.2 degrees): 7.3, 10.1, 13.7, 14.1, 16.0, 16.3, 20.0, 20.4, 23.7, and 24.8. In other embodiments, form A is characterized by XRPD patterns having diffractions at the following angles (2θ ± 0.2 degrees): 7.1, 7.3, 10.1, 13.7, 14.1, 16.0, 16.3, 17.6, 18.5, 18.9, 20.0, 20.4, 21.5, 23.7, 24.8, 25.7, and 26.1. In other embodiments, form A is characterized by having XRPD patterns of at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, at least fourteen, at least fifteen, or at least sixteen diffractions at the following angles (2θ ± 0.2 degrees): 7.1, 7.3, 10.1, 13.7, 14.1, 16.0, 16.3, 17.6, 18.5, 18.9, 20.0, 20.4, 21.5, 23.7, 24.8, 25.7, and 26.1. ... Figure 12 Essentially similar XRPD maps.

[0627] In some embodiments, form A can be obtained by suspending the compound in water. In other embodiments, form A can be obtained by the procedure described in Example 4.

[0628] In some implementations, the crystalline solid form is form B.

[0629] In some embodiments, form B is characterized by XRPD patterns exhibiting diffraction at the following angles (2θ ± 0.2 degrees): 6.8, 13.2, 16.1, 20.6, and 21.3. In other embodiments, form B is characterized by XRPD patterns exhibiting at least one, at least two, at least three, or at least four diffractions at the following angles (2θ ± 0.2 degrees): 6.8, 13.2, 16.1, 20.6, and 21.3. In other embodiments, form B is characterized by XRPD patterns exhibiting diffraction at the following angles (2θ ± 0.2 degrees): 6.8, 11.5, 13.2, 13.6, 14.4, 16.1, 16.3, 18.8, 20.6, and 21.3. In other embodiments, form B is characterized by XRPD patterns having at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, or at least nine diffractions at the following angles (2θ ± 0.2 degrees): 6.8, 11.5, 13.2, 13.6, 14.4, 16.1, 16.3, 18.8, 20.6, and 21.3. In other embodiments, form B is characterized by XRPD patterns having diffractions at the following angles (2θ ± 0.2 degrees): 6.8, 11.5, 13.2, 13.6, 14.4, 15.6, 16.1, 16.3, 17.6, 18.0, 18.8, 19.4, 20.6, 21.3, 22.3, 23.3, 24.2, and 27.4. In other embodiments, form B is characterized by having XRPD patterns of at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, at least fourteen, at least fifteen, at least sixteen, or at least seventeen diffractions at the following angles (2θ ± 0.2 degrees): 6.8, 11.5, 13.2, 13.6, 14.4, 15.6, 16.1, 16.3, 17.6, 18.0, 18.8, 19.4, 20.6, 21.3, 22.3, 23.3, 24.2, and 27.4. ... Figure 13 Essentially similar XRPD maps.

[0630] In some embodiments, form A is characterized by a monoclinic crystal system, as determined by single-crystal X-ray analysis. In other embodiments, form A is characterized by a space group of P21, as determined by single-crystal X-ray analysis. In still other embodiments, form A is characterized by a unit cell having the following dimensions, as determined by single-crystal X-ray analysis: α=90°; β=90.0130(10)°; and γ=90°.

[0631] In some embodiments, form B can be obtained by recrystallization from acetonitrile. In other embodiments, form B can be obtained by the procedure described in Example 4.

[0632] Solid form of compound 19

[0633] In some embodiments, the present invention relates to compounds of the following formula

[0634]

[0635] The compounds are in crystalline solid form.

[0636] In some implementations, the crystalline solid form is form A.

[0637] In some embodiments, form A is characterized by XRPD patterns exhibiting diffraction at the following angles (2θ ± 0.2 degrees): 13.7, 15.2, and 18.2. In other embodiments, form A is characterized by XRPD patterns exhibiting at least one or at least two diffractions at the following angles (2θ ± 0.2 degrees): 13.7, 15.2, and 18.2. In other embodiments, form A is characterized by XRPD patterns exhibiting diffraction at the following angles (2θ ± 0.2 degrees): 13.7, 15.2, 18.2, 18.3, 20.8, and 23.8. In other embodiments, form A is characterized by XRPD patterns exhibiting at least one, at least two, at least three, at least four, or at least five diffractions at the following angles (2θ ± 0.2 degrees): 13.7, 15.2, 18.2, 18.3, 20.8, and 23.8. In other embodiments, form A is characterized by XRPD patterns with diffraction at the following angles (2θ ± 0.2 degrees): 13.7, 14.3, 15.2, 18.2, 18.3, 20.8, 22.5, 23.8, and 25.8. In other embodiments, form A is characterized by XRPD patterns with at least one, at least two, at least three, at least four, at least five, at least six, at least seven, or at least eight diffractions at the following angles (2θ ± 0.2 degrees): 13.7, 14.3, 15.2, 18.2, 18.3, 20.8, 22.5, 23.8, and 25.8. In other embodiments, form A is characterized by XRPD patterns with diffraction at the following angles (2θ ± 0.2 degrees): 6.8, 13.7, 14.3, 15.2, 16.1, 18.2, 18.3, 19.1, 20.6, 20.8, 22.5, 23.8, 24.0, 25.8, 26.3, and 26.6. In other embodiments, form A is characterized by having XRPD patterns of at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, at least fourteen, or at least fifteen diffractions at the following angles (2θ ± 0.2 degrees): 6.8, 13.7, 14.3, 15.2, 16.1, 18.2, 18.3, 19.1, 20.6, 20.8, 22.5, 23.8, 24.0, 25.8, 26.3, and 26. ... Figure 15 Essentially similar XRPD maps.

[0638] In some embodiments, form A is characterized by a solid state having a peak at the following chemical shifts. 13C10 NMR spectra: 171.4, 141.6, 118.0, 112.2, 23.0, and 11.6 ppm. In other embodiments, form A is characterized by solid-state molecules having peaks at the following chemical shifts. 13 C NMR spectra: 171.4, 164.2, 151.8, 149.5, 148.4, 146.6, 144.0, 141.6, 138.7, 126.2, 123.8, 118.0, 112.2, 86.4, 78.8, 63.3, 47.6, 43.8, 23.0, and 11.6 ppm. In other embodiments, form A is characterized by... Figure 16 Basically similar solid-state 13 C NMR spectrum.

[0639] In some embodiments, form A is characterized by a solid state having a peak at the following chemical shifts. 19 F NMR spectra: -74.6, -141.5, and -154.6 ppm. In other embodiments, form A is characterized by... Figure 17 Basically similar solid-state 19 FNMR spectrum.

[0640] In some embodiments, form A is characterized by a monoclinic crystal system, as determined by single-crystal X-ray analysis. In other embodiments, form A is characterized by a space group of P21, as determined by single-crystal X-ray analysis. In still other embodiments, form A is characterized by a unit cell having the following dimensions, as determined by single-crystal X-ray analysis: α=90°; β=100.3980(1)°; and γ=90°.

[0641] In some embodiments, form A can be obtained by precipitation from methanol via the addition of heptane as an antisolvent. In other embodiments, form A can be obtained by lyophilization of a suspension of the compound in ethanol, acetonitrile, and water. In other embodiments, form A can be obtained by dissolving the compound in methanol and subjecting it to slow diffusion with heptane as an antisolvent. In other embodiments, form A can be obtained via the procedure described in Example 5.

[0642] solid form of compound 22

[0643] In some embodiments, the present invention relates to compounds of the following formula

[0644]

[0645] When a mixture of racemic diastereomers (with epimerism at the 5-position) is separated by SFC as described in step 7 of Example 6, the compound has the absolute stereochemistry of the third eluting isomer, wherein the compound is in crystalline solid form.

[0646] In some implementations, the crystalline solid form is form A.

[0647] In some embodiments, form A is characterized by XRPD patterns exhibiting diffraction at the following angles (2θ ± 0.2 degrees): 9.2, 10.4, and 15.7. In other embodiments, form A is characterized by XRPD patterns exhibiting diffraction at at least one or at least two angles (2θ ± 0.2 degrees): 9.2, 10.4, and 15.7. In other embodiments, form A is characterized by XRPD patterns exhibiting diffraction at the following angles (2θ ± 0.2 degrees): 7.7, 9.2, 10.4, 12.9, 15.7, and 18.4. In other embodiments, form A is characterized by XRPD patterns exhibiting diffraction at at least one, at least two, at least three, at least four, or at least five angles (2θ ± 0.2 degrees): 7.7, 9.2, 10.4, 12.9, 15.7, and 18.4. In other embodiments, form A is characterized by XRPD patterns with diffraction at the following angles (2θ ± 0.2 degrees): 7.7, 9.2, 10.4, 12.9, 15.7, 18.4, 19.8, 21.7, and 24.0. In other embodiments, form A is characterized by XRPD patterns with at least one, at least two, at least three, at least four, at least five, at least six, at least seven, or at least eight diffractions at the following angles (2θ ± 0.2 degrees): 7.7, 9.2, 10.4, 12.9, 15.7, 18.4, 19.8, 21.7, and 24.0. In other embodiments, form A is characterized by XRPD patterns with diffraction at the following angles (2θ ± 0.2 degrees): 7.7, 9.2, 10.4, 12.9, 13.8, 14.7, 15.7, 16.1, 18.4, 19.8, 21.7, 22.3, and 24.0. In other embodiments, form A is characterized by XRPD patterns with at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, or at least twelve diffractions at the following angles (2θ ± 0.2 degrees): 7.7, 9.2, 10.4, 12.9, 13.8, 14.7, 15.7, 16.1, 18.4, 19.8, 21.7, 22.3, and 24.0. In other embodiments, form A is characterized by... Figure 19 Essentially similar XRPD maps.

[0648] In some embodiments, form A is characterized by a solid state having a peak at the following chemical shifts. 13 C NMR spectra: 167.7, 126.0, 115.9, 43.5, and 20.3 ppm. In other embodiments, form A is characterized by solid-state molecules having peaks at the following chemical shifts. 13 CNMR spectra: 172.6, 167.7, 158.7, 156.8, 151.8, 148.7, 128.6, 126.0, 115.9, 113.1, 112.3, 88.0, 85.5, 62.0, 60.5, 55.6, 43.5, 37.7, 29.6, 21.1, and 20.3 ppm. In other embodiments, form A is characterized by... Figure 20 Basically similar solid-state 13 C NMR spectrum.

[0649] In some embodiments, form A is characterized by a solid state having a peak at the following chemical shifts. 19 F NMR spectra: -82.2, -83.1, -111.7, and -114.4 ppm. In other embodiments, form A is characterized by... Figure 21 Basically similar solid-state 19 F NMR spectrum.

[0650] In some embodiments, form A can be obtained by slow evaporation of a 1:1 solution of 2-methyltetrahydrofuran / heptane. In other embodiments, form A can be obtained by the procedure described in Example 6.

[0651] solid form of compound 23

[0652] In some embodiments, the present invention relates to compounds of the following formula

[0653]

[0654] The compounds are in crystalline solid form.

[0655] In some implementations, the crystalline solid form is form A.

[0656] In some embodiments, form A is characterized by XRPD patterns exhibiting diffraction at the following angles (2θ ± 0.2 degrees): 17.2, 19.3, and 22.3. In other embodiments, form A is characterized by XRPD patterns exhibiting at least one or at least two diffractions at the following angles (2θ ± 0.2 degrees): 17.2, 19.3, and 22.3. In other embodiments, form A is characterized by XRPD patterns exhibiting diffraction at the following angles (2θ ± 0.2 degrees): 14.2, 15.8, 17.2, 19.3, 22.3, and 30.6. In other embodiments, form A is characterized by XRPD patterns exhibiting at least one, at least two, at least three, at least four, or at least five diffractions at the following angles (2θ ± 0.2 degrees): 14.2, 15.8, 17.2, 19.3, 22.3, and 30.6. In other embodiments, form A is characterized by XRPD patterns with diffraction at the following angles (2θ ± 0.2 degrees): 12.2, 14.2, 15.8, 17.2, 19.3, 22.3, 25.0, 25.1, and 30.6. In other embodiments, form A is characterized by XRPD patterns with at least one, at least two, at least three, at least four, at least five, at least six, at least seven, or at least eight diffractions at the following angles (2θ ± 0.2 degrees): 12.2, 14.2, 15.8, 17.2, 19.3, 22.3, 25.0, 25.1, and 30.6. In other embodiments, form A is characterized by XRPD patterns with diffraction at the following angles (2θ ± 0.2 degrees): 11.3, 12.2, 13.2, 14.2, 15.2, 15.8, 16.6, 17.2, 19.3, 21.1, 22.3, 22.8, 23.7, 24.6, 25.0, 25.1, 25.9, 27.1, 27.9, 30.6, 34.4, and 39.4. In other embodiments, form A is characterized by having XRPD patterns of at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, at least fourteen, at least fifteen, at least sixteen, at least seventeen, at least eighteen, at least nineteen, at least twenty, or at least twenty-one diffractions at the following angles (2θ ± 0.2 degrees): 11.3, 12.2, 13.2, 14.2, 15.2, 15.8, 16.6, 17.2, 19.3, 21.1, 22.3, 22.8, 23.7, 24.6, 25.0, 25.1, 25.9, 27.1, 27.9, 30.6, 34.4, and 39.4. In other embodiments, form A is characterized by having XRPD patterns of at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, at least fourteen, at least fifteen, at least sixteen, at least seventeen, at least eighteen, at least nineteen, at least twenty, or at least twenty-one diffractions at the following angles (2θ ± 0.2 degrees): 11.3, 12.2, 13.2, 14.2, 15.2, 15.8, 16.6, 17.2, 19.3, 21.1, 22.3, 22.8, 23.7, 24.6, 25.0, 25.1, 25.9, 27.1, 27.9, 30. Figure 22 Essentially similar XRPD maps.

[0657] In some embodiments, form A is characterized by a solid state having a peak at the following chemical shifts. 13 C NMR spectra: 171.1, 149.3, 123.3, 41.6, and 20.0 ppm. In other embodiments, form A is characterized by solid-state molecules having peaks at the following chemical shifts. 13 CNMR spectra: 171.1, 166.7, 156.8, 155.5, 151.9, 149.3, 147.3, 131.5, 123.3, 119.0, 114.2, 112.8, 86.0, 85.0, 61.7, 61.0, 44.4, 41.6, and 20.0 ppm. In other embodiments, form A is characterized by... Figure 23 Basically similar solid-state 13 C NMR spectrum.

[0658] In some embodiments, form A is characterized by a solid state having a peak at the following chemical shifts. 19 F NMR spectra: -78.2, -113.5, and -115.1 ppm. In other embodiments, form A is characterized by... Figure 24 Basically similar solid-state 19 FNMR spectrum.

[0659] In some embodiments, form A is characterized by a monoclinic crystal system, as determined by single-crystal X-ray analysis. In other embodiments, form A is characterized by a space group of P21, as determined by single-crystal X-ray analysis. In still other embodiments, form A is characterized by a unit cell having the following dimensions, as determined by single-crystal X-ray analysis: α=90°; β=98.487(2)°; and γ=90°.

[0660] In some embodiments, form A can be obtained by slow evaporation of a 1:1 solution of 2-methyltetrahydrofuran / heptane. In other embodiments, form A can be obtained by dissolving the compound in methanol and allowing slow diffusion of heptane vapor. In other embodiments, form A can be obtained by the procedure described in Example 6.

[0661] solid form of compound 25

[0662] In some embodiments, the present invention relates to compounds of the following formula

[0663]

[0664] When the racemic mixture of enantiomers is separated by SFC as described in step 11 of Example 7, the compound has the absolute stereochemistry of the second eluting isomer, wherein the compound is in crystalline solid form.

[0665] In some implementations, the crystalline solid form is form A.

[0666] In some embodiments, form A is characterized by XRPD patterns exhibiting diffraction at the following angles (2θ ± 0.2 degrees): 6.8, 7.9, and 13.8. In other embodiments, form A is characterized by XRPD patterns exhibiting diffraction at at least one or at least two angles (2θ ± 0.2 degrees): 6.8, 7.9, and 13.8. In other embodiments, form A is characterized by XRPD patterns exhibiting diffraction at the following angles (2θ ± 0.2 degrees): 6.8, 7.9, 11.0, 13.7, 13.8, and 27.4. In other embodiments, form A is characterized by XRPD patterns exhibiting diffraction at at least one, at least two, at least three, at least four, or at least five angles (2θ ± 0.2 degrees): 6.8, 7.9, 11.0, 13.7, 13.8, and 27.4. In other embodiments, form A is characterized by XRPD patterns with diffraction at the following angles (2θ ± 0.2 degrees): 6.8, 7.9, 11.0, 13.7, 13.8, 15.9, 16.3, 23.2, and 27.4. In other embodiments, form A is characterized by XRPD patterns with at least one, at least two, at least three, at least four, at least five, at least six, at least seven, or at least eight diffractions at the following angles (2θ ± 0.2 degrees): 6.8, 7.9, 11.0, 13.7, 13.8, 15.9, 16.3, 23.2, and 27.4. In other embodiments, form A is characterized by XRPD patterns with diffraction at the following angles (2θ ± 0.2 degrees): 3.2, 6.8, 7.9, 11.0, 11.8, 13.7, 13.8, 15.1, 15.9, 16.3, 17.5, 18.6, 19.0, 19.5, 21.6, 21.9, 23.2, 27.0, 27.4, 29.4, and 30.3. In other embodiments, form A is characterized by having XRPD patterns of at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, at least fourteen, at least fifteen, at least sixteen, at least seventeen, at least eighteen, at least nineteen, or at least twenty diffractions at the following angles (2θ ± 0.2 degrees): 3.2, 6.8, 7.9, 11.0, 11.8, 13.7, 13.8, 15.1, 15.9, 16.3, 17.5, 18.6, 19.0, 19.5, 21.6, 21.9, 23.2, 27.0, 27.4, 29.4, and 30.3. ... Figure 26Essentially similar XRPD maps.

[0667] In some embodiments, form A can be obtained by slow evaporation of a 1:1 solution of 2-methyltetrahydrofuran / heptane. In other embodiments, form A can be obtained by the procedure described in Example 7.

[0668] Salts, compositions, uses, formulations, administration and other reagents

[0669] Pharmaceutically acceptable salts and compositions

[0670] As discussed herein, the present invention provides compounds and pharmaceutically acceptable salts thereof that are inhibitors of voltage-gated sodium channels, and therefore the compounds and pharmaceutically acceptable salts thereof are suitable for treating diseases, symptoms, and disorders, including (but not limited to) chronic pain, intestinal pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, postoperative pain (e.g., Pain from cystectomy, hernia repair, or abdominoplasty (visceral pain, multiple sclerosis, Chuck-Mali-Dus syndrome, incontinence, pathological cough, or arrhythmia). Therefore, in another aspect of the invention, pharmaceutical compositions are provided, wherein these compositions comprise compounds as described herein or pharmaceutically acceptable salts thereof, and optionally comprise pharmaceutically acceptable carriers, adjuvants, or mediators. In some embodiments, these compositions optionally further comprise one or more other therapeutic agents. In some embodiments, the other therapeutic agent is a sodium channel inhibitor.

[0671] As used herein, the term "pharmaceutically acceptable salt" means a salt suitable for contact with tissues of humans and lower animals without undue toxicity, irritation, allergic reactions, etc., within the bounds of reasonable medical judgment, and in proportion to a reasonable benefit / risk ratio. "Pharmaceutically acceptable salt" of the compounds of the present invention includes any non-toxic salt that, upon administration to a recipient, can directly or indirectly provide the compound of the present invention or its inhibitory metabolites or residues. The salt may be in pure form, in mixture with one or more other substances (e.g., solution, suspension, or colloid), or in hydrate, solvate, or cocrystal form. As used herein, the term "inhibitory metabolites or residues" means that the metabolites or residues are also inhibitors of voltage-gated sodium channels.

[0672] Pharmaceutically acceptable salts are well known in the art. For example, SMBerge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, which is incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of the present invention include salts derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable non-toxic acid addition salts are salts formed by amino groups with inorganic acids (such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid) or organic acids (such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid), or salts formed by other methods used in the art (such as ion exchange). Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, hydrogen sulfate, borate, butyrate, camphorate, camphor sulfonate, citrate, cyclopentanepropionate, disglucuronate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucono-heptahydrate, glyceryl phosphate, gluconate, hemisulfate, heptahydrate, hexanoate, hydroiodate, 2-hydroxyethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, dihydroxynaphthalate, pectate, persulfate, 3-phenylpropionate, phosphate, picrate, p-valerate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, etc. Salts derived from suitable bases include alkali metal salts, alkaline earth metal salts, ammonium salts, and N salts. + (C 1-4 Alkyl)4 salts. Representative alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, etc. Where appropriate, other pharmaceutically acceptable salts include non-toxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, low-carbon alkyl sulfonates, and aryl sulfonates.

[0673] As described herein, pharmaceutically acceptable compositions of the present invention further comprise pharmaceutically acceptable carriers, adjuvants, or mediators, as used herein, including any and all solvents, diluents or other liquid mediators, dispersion or suspension aids, surfactants, isotonic agents, thickeners or emulsifiers, preservatives, solid binders, lubricants, etc., as suitable for the desired specific dosage form. Remington's Pharmaceutical Sciences, 16th edition, EW Martin (Mack Publishing Co., Easton, Pa., 1980) discloses various carriers for formulating pharmaceutically acceptable compositions and their known preparation techniques. The use of any conventional carrier medium is covered within the scope of this invention unless any conventional carrier medium is incompatible with the compounds of the present invention, such as by producing any unwanted biological effects or otherwise interacting in a harmful manner with any other component of the pharmaceutically acceptable composition. Some examples of materials that can serve as pharmaceutically acceptable carriers include (but are not limited to) ion exchangers, alumina, aluminum stearate; lecithin; serum proteins, such as human serum albumin; buffering substances, such as phosphates, glycine, sorbic acid, or potassium sorbate; mixtures of glycerides of saturated vegetable fatty acids; water, salts, or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts; colloidal silica; magnesium trisilicate; polyvinylpyrrolidone; polyacrylates; waxes; polyethylene-polyoxypropylene block polymers; lanolin; sugars, such as lactose, glucose... Glucose and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth gum; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol or polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffers, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethanol and phosphate buffer solutions; and other non-toxic and compatible lubricants, such as sodium lauryl sulfate and magnesium stearate; as well as colorants, release agents, coating agents, sweeteners, flavorings and aromas, preservatives and antioxidants may also be present in the composition at the discretion of the formulator.

[0674] In another aspect, the present invention provides a pharmaceutical composition comprising the compound of the present invention or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

[0675] In another aspect, the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or mediators.

[0676] Use of compounds and pharmaceutically acceptable salts and compositions

[0677] In another aspect, the present invention provides a method for inhibiting voltage-gated sodium channels in a subject, comprising administering to the subject a compound of the present invention or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof. In another aspect, voltage-gated sodium channels are Na... V 1.8.

[0678] In another aspect, the present invention provides a method for treating chronic pain, intestinal pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, and postoperative pain in subjects (e.g., Methods for treating pain during cystectomy, hernia repair, or abdominoplasty (visceral pain, multiple sclerosis, Chuck-Mali-Dus syndrome, incontinence, pathological cough, or arrhythmia, or for reducing their severity, comprising administering an effective amount of the compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0679] In another aspect, the present invention provides a method for treating chronic pain, intestinal pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, and postoperative pain in subjects. Methods for treating pain during cystectomy, pain during hernia repair, multiple sclerosis, Chuck-Mali-Dus syndrome, incontinence, or arrhythmia, or for reducing their severity, comprising administering an effective amount of the compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0680] In another aspect, the present invention provides a method for treating or reducing the severity of intestinal pain in a subject, wherein the intestinal pain includes inflammatory bowel disease pain, Crohn's disease pain, or interstitial cystitis pain, wherein the method comprises administering an effective amount of the compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0681] In another aspect, the present invention provides a method for treating or reducing the severity of neuropathic pain in a subject, comprising administering an effective amount of a compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. In some aspects, neuropathic pain includes postherpetic neuralgia, small fiber neuropathy, or idiopathic small fiber neuropathy. As used herein, the phrase "idiopathic small fiber neuropathy" should be understood to include any small fiber neuropathy. In some aspects, neuropathic pain includes diabetic neuropathy.

[0682] In another aspect, the present invention provides a method for treating or reducing the severity of neuropathic pain in a subject, wherein the neuropathic pain includes postherpetic neuralgia, diabetic neuropathy, painful HIV-associated sensory neuropathy, trigeminal neuralgia, burning mouth syndrome, post-amputation pain, phantom limb pain, painful neuroma; traumatic neuroma; Morton's neuroma; nerve entrapment injury, spinal stenosis, carpal tunnel syndrome, radicular pain, sciatica; nerve tear injury, brachial plexus tear injury; complex regional pain syndrome, drug-induced neuropathic pain, cancer chemotherapy-induced neuropathic pain, antiretroviral therapy-induced neuropathic pain; post-spinal cord injury pain, small fiber neuropathy, idiopathic small fiber neuropathy, idiopathic sensory neuropathy, or trigeminal autonomic headache, wherein the method comprises administering an effective amount of the compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0683] In another aspect, the present invention provides a method for treating or reducing the severity of musculoskeletal pain in a subject, comprising administering an effective amount of a compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. In some aspects, musculoskeletal pain includes osteoarthritis pain.

[0684] In another aspect, the present invention provides a method for treating or reducing the severity of musculoskeletal pain in a subject, wherein the musculoskeletal pain includes osteoarthritis pain, back pain, cold pain, burn pain, or toothache, wherein the method comprises administering an effective amount of a compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0685] In another aspect, the present invention provides a method for treating or reducing the severity of inflammatory pain in a subject, wherein the inflammatory pain includes rheumatoid arthritis pain or vulvar pain, wherein the method comprises administering an effective amount of the compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0686] In another aspect, the present invention provides a method for treating or reducing the severity of inflammatory pain in a subject, wherein the inflammatory pain includes rheumatoid arthritis pain, wherein the method comprises administering an effective amount of a compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0687] In another aspect, the present invention provides a method for treating or reducing the severity of idiopathic pain in a subject, wherein the idiopathic pain comprises muscle fiber pain, wherein the method comprises administering an effective amount of the compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0688] In another aspect, the present invention provides a method for treating or reducing the severity of a subject's pathological cough, wherein the method comprises administering an effective amount of the compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0689] In another aspect, the present invention provides a method for treating acute pain in a subject or reducing its severity, comprising administering an effective amount of the compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. In some aspects, acute pain includes acute postoperative pain.

[0690] In another aspect, the present invention provides a method for treating postoperative pain in a subject (e.g., Methods for reducing or alleviating pain (such as pain during cystectomy, hernia repair, or abdominoplasty) include administering an effective amount of the compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0691] In another aspect, the present invention provides a method for treating a subject. Methods for reducing pain or severity during cystectomy include administering an effective amount of the compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0692] In another aspect, the present invention provides a method for treating or reducing the severity of pain during hernia repair in a subject, comprising administering an effective amount of the compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0693] In another aspect, the present invention provides a method for treating or reducing the severity of abdominal wall repair pain in a subject, comprising administering an effective amount of the compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0694] In another aspect, the present invention provides a method for treating or reducing the severity of visceral pain in a subject, comprising administering an effective amount of a compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. In some aspects, visceral pain includes visceral pain caused by abdominoplasty.

[0695] In another aspect, the present invention provides a method for treating a subject with a neurodegenerative disease or reducing its severity, comprising administering an effective amount of a compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. In some aspects, neurodegenerative diseases include multiple sclerosis. In some aspects, neurodegenerative diseases include Pitt Hopkins Syndrome (PTHS).

[0696] In another aspect, the present invention provides a method in which a subject is treated with one or more other therapeutic agents, said one or more other therapeutic agents being administered concurrently with, before or after treatment with an effective amount of a compound, a pharmaceutically acceptable salt or a pharmaceutical composition. In some embodiments, the other therapeutic agent is a sodium channel inhibitor.

[0697] In another aspect, the present invention provides a method for inhibiting voltage-gated sodium channels in a biological sample, comprising contacting the biological sample with an effective amount of the compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. In another aspect, the voltage-gated sodium channel is Na... V 1.8.

[0698] On the other hand, the present invention provides a method for treating acute pain, chronic pain, neuropathic pain, inflammatory pain, arthritis, migraine, cluster headache, trigeminal neuralgia, herpetic neuralgia, general neuralgia, epilepsy, epileptic disorders, neurodegenerative diseases, mental illnesses, anxiety disorders, depression, bipolar disorder, myotonia, arrhythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, incontinence, pathological cough, visceral pain, osteoarthritis pain, postherpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, headache, neck pain, severe pain, intractable pain, nociceptive pain, burst pain, and postoperative pain (e.g., Methods for treating pain during cystectomy, hernia repair, or abdominoplasty, cancer pain, stroke, cerebral ischemia, traumatic brain injury, amyotrophic lateral sclerosis, stress-induced angina, exercise-induced angina, palpitations, hypertension, or abnormal gastrointestinal motility, or for reducing their severity, comprising administering an effective amount of the compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0699] On the other hand, the present invention provides a treatment for subjects suffering from femoral cancer pain; non-malignant chronic bone pain; rheumatoid arthritis; osteoarthritis; spinal stenosis; neuropathic lower back pain; myofascial pain syndrome; muscle fiber pain; temporomandibular joint pain; chronic visceral pain, abdominal pain; pancreatic pain; IBS pain; chronic and acute headache; migraine; tension headache; cluster headache; chronic and acute neuropathic pain, postherpetic neuralgia; diabetic neuropathy; HIV-related neuropathy; trigeminal neuralgia; Chuck-Mali-Dus neuropathy; hereditary sensory neuropathy; peripheral nerve injury; painful neuroma; ectopic proximal and distal discharges; nerve root lesions; chemotherapy-induced neuropathic pain; radiotherapy-induced neuropathic pain; post-mastectomy pain; central pain; spinal cord injury. Pain from injuries; post-stroke pain; thalamic pain; complex regional pain syndrome; phantom limb pain; intractable pain; acute pain, acute postoperative pain; acute musculoskeletal pain; joint pain; mechanical lower back pain; neck pain; tendinitis; injury pain; movement pain; acute visceral pain; pyelonephritis; appendicitis; cholecystitis; intestinal obstruction; hernia; chest pain, heart pain; pelvic pain, renal colic, acute labor pain, labor pain; cesarean section pain; acute inflammatory pain, burn pain, traumatic pain; acute intermittent pain, endometriosis; acute herpes zoster pain; sickle cell anemia; acute pancreatitis; breakthrough pain; orofacial pain; sinusitis pain; toothache; multiple sclerosis (MS) pain; pain in depression; leprosy pain; Behcet's disease. Pain; painful obesity; phlebitis pain; Guillain-Barré pain; leg pain and toe tremors; Haglund syndrome; erythromelalgia; Fabry's disease pain; bladder and urogenital disorders; urinary incontinence, pathological cough; hyperresponsive bladder; painful bladder syndrome; interstitial cystitis (IC); prostatitis; type I complex regional pain syndrome (CRPS), type II complex regional pain syndrome (CRPS); methods for inducing or reducing the severity of generalized pain, paroxysmal severe pain, pruritus, tinnitus, or colic, comprising administering an effective amount of the compound of the present invention, its pharmaceutically acceptable salt, or a pharmaceutical composition thereof.

[0700] Use of compounds, pharmaceutically acceptable salts, and compositions

[0701] In another aspect, the present invention provides compounds of the present invention or pharmaceutically acceptable salts or pharmaceutical compositions thereof, which are used as medicines.

[0702] In another aspect, the present invention provides compounds of the present invention or pharmaceutically acceptable salts or pharmaceutical compositions thereof for use in a method of inhibiting voltage-gated sodium channels in a subject. In another aspect, the voltage-gated sodium channel is Na... V 1.8.

[0703] On the other hand, the present invention provides compounds of the present invention or pharmaceutically acceptable salts or pharmaceutical compositions thereof for use in treating subjects with chronic pain, intestinal pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, postoperative pain (e.g., Pain during cystectomy, hernia repair, or abdominoplasty; visceral pain; multiple sclerosis; Chuck-Mali-Dus syndrome; incontinence; pathological cough; or arrhythmia, or methods to reduce their severity.

[0704] On the other hand, the present invention provides compounds of the invention, pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for treating subjects with chronic pain, intestinal pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, postoperative pain, etc. Pain during cystectomy, pain during hernia repair, multiple sclerosis, Chuck-Mali-Dus syndrome, incontinence or arrhythmia, or methods to reduce their severity.

[0705] In another aspect, the present invention provides a method for treating or alleviating intestinal pain in a subject, using the compounds of the present invention or pharmaceutically acceptable salts or pharmaceutical compositions thereof, wherein the intestinal pain includes pain from inflammatory bowel disease, Crohn's disease, or interstitial cystitis.

[0706] In another aspect, the present invention provides compounds of the invention or pharmaceutically acceptable salts or pharmaceutical compositions thereof for use in treating a subject with neuropathic pain or reducing its severity. In some aspects, neuropathic pain includes postherpetic neuralgia, small fiber neuropathy, or idiopathic small fiber neuropathy. As used herein, the phrase "idiopathic small fiber neuropathy" should be understood to include any small fiber neuropathy. In some aspects, neuropathic pain includes diabetic neuropathy.

[0707] In another aspect, the present invention provides a method for treating a subject with neuropathic pain or reducing its severity, wherein the neuropathic pain includes postherpetic neuralgia, diabetic neuropathy, painful HIV-associated sensory neuropathy, trigeminal neuralgia, burning mouth syndrome, post-amputation pain, phantom limb pain, painful neuroma; traumatic neuroma; Morton's neuroma; nerve entrapment injury, spinal stenosis, carpal tunnel syndrome, radicular pain, sciatica; nerve tear injury, brachial plexus tear injury; complex regional pain syndrome, drug-induced neuropathic pain, cancer chemotherapy-induced neuropathic pain, antiretroviral therapy-induced neuropathic pain; post-spinal cord injury pain, small fiber neuropathy, idiopathic small fiber neuropathy, idiopathic sensory neuropathy, or trigeminal autonomic headache.

[0708] In another aspect, the present invention provides compounds of the present invention or pharmaceutically acceptable salts or pharmaceutical compositions thereof for use in treating musculoskeletal pain in a subject or reducing its severity. In some aspects, musculoskeletal pain includes osteoarthritis pain.

[0709] In another aspect, the present invention provides a method for treating or reducing musculoskeletal pain in a subject, using the compounds of the present invention or pharmaceutically acceptable salts or pharmaceutical compositions thereof, wherein the musculoskeletal pain includes osteoarthritis pain, back pain, cold pain, burn pain, or toothache.

[0710] In another aspect, the present invention provides a method for treating or reducing the severity of inflammatory pain in a subject, using the compounds of the present invention or pharmaceutically acceptable salts or pharmaceutical compositions thereof, wherein the inflammatory pain includes rheumatoid arthritis pain or vulvar pain.

[0711] In another aspect, the present invention provides a method for treating inflammatory pain in a subject or reducing its severity using a compound of the present invention or a pharmaceutically acceptable salt or pharmaceutical composition thereof, wherein the inflammatory pain includes rheumatoid arthritis pain.

[0712] In another aspect, the present invention provides a method for treating a subject with idiopathic pain or reducing its severity using compounds of the present invention or pharmaceutically acceptable salts or pharmaceutical compositions thereof, wherein the idiopathic pain comprises muscle fiber pain.

[0713] In another aspect, the present invention provides compounds of the present invention or pharmaceutically acceptable salts or pharmaceutical compositions thereof for use in methods of treating a subject’s pathological cough or reducing its severity.

[0714] In another aspect, the present invention provides compounds of the invention or pharmaceutically acceptable salts or pharmaceutical compositions thereof for use in methods of treating acute pain in a subject or reducing its severity. In some aspects, acute pain includes acute postoperative pain.

[0715] On the other hand, the present invention provides compounds of the present invention or pharmaceutically acceptable salts or pharmaceutical compositions thereof for treating postoperative pain in a subject (e.g., Pain during cystectomy, hernia repair, or abdominoplasty, or methods to alleviate its severity.

[0716] In another aspect, the present invention provides compounds of the present invention or pharmaceutically acceptable salts or pharmaceutical compositions thereof for use in treating subjects. Methods to reduce pain or severity during cystectomy.

[0717] In another aspect, the present invention provides compounds of the present invention or pharmaceutically acceptable salts or pharmaceutical compositions thereof for use in a method of treating or reducing pain during hernia repair in a subject.

[0718] In another aspect, the present invention provides compounds of the present invention or pharmaceutically acceptable salts or pharmaceutical compositions thereof for use in methods of treating or reducing the severity of abdominoplasty pain in a subject.

[0719] In another aspect, the present invention provides compounds of the present invention or pharmaceutically acceptable salts or pharmaceutical compositions thereof for use in methods of treating visceral pain in a subject or reducing its severity. In some aspects, visceral pain includes visceral pain caused by abdominoplasty.

[0720] In another aspect, the present invention provides compounds of the present invention or pharmaceutically acceptable salts or pharmaceutical compositions thereof for use in methods of treating a subject with a neurodegenerative disease or reducing its severity. In some aspects, neurodegenerative diseases include multiple sclerosis. In some aspects, neurodegenerative diseases include Peter Hopkins syndrome (PTHS).

[0721] In another aspect, the present invention provides compounds of the invention or pharmaceutically acceptable salts or pharmaceutical compositions thereof for use in a method of treating a subject with one or more other therapeutic agents, said one or more other therapeutic agents being administered concurrently with, before or after treatment with an effective amount of the compound, pharmaceutically acceptable salt or pharmaceutical composition. In some embodiments, the other therapeutic agent is a sodium channel inhibitor.

[0722] In another aspect, the present invention provides a method for using the compound of the present invention or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof to inhibit voltage-gated sodium channels in a biological sample, the method comprising contacting the biological sample with an effective amount of the compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. In another aspect, the voltage-gated sodium channel is Na... V 1.8.

[0723] On the other hand, the present invention provides compounds of the present invention or pharmaceutically acceptable salts or pharmaceutical compositions thereof for use in treating subjects with acute pain, chronic pain, neuropathic pain, inflammatory pain, arthritis, migraine, cluster headache, trigeminal neuralgia, herpetic neuralgia, general neuralgia, epilepsy, epileptic disorders, neurodegenerative diseases, mental illnesses, anxiety disorders, depression, bipolar disorder, myotonia, arrhythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, incontinence, pathological cough, visceral pain, osteoarthritis pain, postherpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, headache, neck pain, severe pain, intractable pain, nociceptive pain, burst pain, postoperative pain (e.g., Pain from cystectomy, hernia repair, or abdominoplasty, cancer pain, stroke, cerebral ischemia, traumatic brain injury, amyotrophic lateral sclerosis, stress-induced angina, exercise-induced angina, palpitations, hypertension, or abnormal gastrointestinal motility, or methods to reduce their severity.

[0724] In another aspect, the present invention provides compounds of the present invention or pharmaceutically acceptable salts or pharmaceutical compositions thereof for use in treating subjects with femoral cancer pain; non-malignant chronic bone pain; rheumatoid arthritis; osteoarthritis; spinal stenosis; neuropathic lower back pain; myofascial pain syndrome; fibromuscular pain; temporomandibular joint pain; chronic visceral pain, abdominal pain; pancreatic pain; IBS pain; chronic and acute headaches; migraines; tension headaches; cluster headaches; chronic and acute neuropathic pain, postherpetic neuralgia; diabetic neuropathy; HI V-related neuropathy; trigeminal neuralgia; Chuck-Mali-Dus neuropathy; hereditary sensory neuropathy; peripheral nerve injury; painful neuroma; ectopic proximal and distal discharges; nerve root lesions; chemotherapy-induced neuropathic pain; radiation-induced neuropathic pain; post-mastectomy pain; central pain; spinal cord injury pain; post-stroke pain; thalamic pain; complex regional pain syndrome; phantom limb pain; intractable pain; acute pain; acute postoperative pain; acute musculoskeletal pain; joint pain; mechanical lower back pain; neck pain; tendinitis Pain due to injury; pain from movement; acute visceral pain; pyelonephritis; appendicitis; cholecystitis; intestinal obstruction; hernia; chest pain, heart pain; pelvic pain, renal colic, acute labor pain, labor pain; cesarean section pain; acute inflammatory pain, burn pain, traumatic pain; acute intermittent pain, endometriosis; acute herpes zoster pain; sickle cell anemia; acute pancreatitis; breakthrough pain; orofacial pain; sinusitis pain; toothache; multiple sclerosis (MS) pain; pain in depression; leprosy pain; Behcet's disease Pain; painful obesity; phlebitis pain; Guillain-Barré pain; leg pain and toe movement syndrome; Hagland syndrome; erythromelalgia; Fabry disease pain; bladder and urogenital disorders; urinary incontinence; pathological cough; hyperresponsive bladder; painful bladder syndrome; interstitial cystitis (IC); prostatitis; type I complex regional pain syndrome (CRPS), type II complex regional pain syndrome (CRPS); generalized pain, paroxysmal severe pain, pruritus, tinnitus or colic-induced pain or methods to reduce its severity.

[0725] Manufacturing drugs

[0726] In another aspect, the present invention provides the use of the compounds of the present invention or pharmaceutically acceptable salts or pharmaceutical compositions thereof for the manufacture of medicines.

[0727] In another aspect, the present invention provides the use of the compounds of the present invention or pharmaceutically acceptable salts or pharmaceutical compositions thereof for the manufacture of a medicament for inhibiting voltage-gated sodium channels. In another aspect, the voltage-gated sodium channel is a Na... V 1.8.

[0728] In another aspect, the present invention provides compounds of the present invention or pharmaceutically acceptable salts or pharmaceutical compositions thereof for use in the manufacture of treatments for subjects of chronic pain, intestinal pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, postoperative pain (e.g., Pain from cystectomy, hernia repair, or abdominoplasty; visceral pain; multiple sclerosis; Chuck-Mali-Dus syndrome; incontinence; pathological cough; or arrhythmia, or medications to reduce their severity.

[0729] In another aspect, the present invention provides the use of the compounds of the invention, their pharmaceutically acceptable salts, or pharmaceutical compositions for manufacturing treatment of chronic pain, intestinal pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, essential pain, postoperative pain, etc., in subjects. Pain from cystectomy, pain from hernia repair, multiple sclerosis, Chuck-Mali-Dus syndrome, incontinence or arrhythmia, or medications to reduce their severity.

[0730] In another aspect, the present invention provides the use of the compounds, pharmaceutically acceptable salts, or pharmaceutical compositions described herein for the manufacture of a medicament for treating or reducing the severity of intestinal pain in a subject, wherein intestinal pain includes pain from inflammatory bowel disease, Crohn's disease, or interstitial cystitis.

[0731] In another aspect, the present invention provides compounds of the invention, pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, for use in the manufacture of a medicament for treating or reducing the severity of neuropathic pain in a subject. In some aspects, neuropathic pain includes postherpetic neuralgia, small fiber neuropathy, or idiopathic small fiber neuropathy. In some aspects, neuropathic pain includes diabetic neuropathy.

[0732] In another aspect, the present invention provides the use of the compounds of the present invention or pharmaceutically acceptable salts or pharmaceutical compositions thereof for the manufacture of a medicament for treating or reducing the severity of neuropathic pain in a subject, wherein neuropathic pain includes postherpetic neuralgia, diabetic neuropathy, painful HIV-associated sensory neuropathy, trigeminal neuralgia, burning mouth syndrome, post-amputation pain, phantom limb pain, painful neuroma; traumatic neuroma; Morton's neuroma; nerve entrapment injury, spinal stenosis, carpal tunnel syndrome, radicular pain, sciatica; nerve tear injury, brachial plexus tear injury; complex regional pain syndrome, drug-induced neuropathic pain, cancer chemotherapy-induced neuropathic pain, antiretroviral therapy-induced neuropathic pain; post-spinal cord injury pain, small fiber neuropathy, idiopathic small fiber neuropathy, idiopathic sensory neuropathy, or trigeminal autonomic neuropathy.

[0733] In another aspect, the present invention provides the use of the compounds of the invention, pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, for the manufacture of a medicament for treating or reducing the severity of musculoskeletal pain in a subject. In some aspects, musculoskeletal pain includes osteoarthritis pain.

[0734] In another aspect, the present invention provides the use of the compounds of the present invention or pharmaceutically acceptable salts or pharmaceutical compositions thereof for the manufacture of a medicament for treating or reducing the severity of musculoskeletal pain in a subject, wherein musculoskeletal pain includes osteoarthritis pain, back pain, cold pain, burn pain, or toothache.

[0735] In another aspect, the present invention provides the use of the compounds of the present invention, their pharmaceutically acceptable salts, or pharmaceutical compositions thereof for the manufacture of a medicament for treating or reducing the severity of inflammatory pain in a subject, wherein the inflammatory pain includes rheumatoid arthritis pain or vulvar pain.

[0736] In another aspect, the present invention provides the use of the compounds of the present invention, their pharmaceutically acceptable salts, or pharmaceutical compositions thereof for the manufacture of a medicament for treating or reducing the severity of inflammatory pain in a subject, wherein the inflammatory pain includes rheumatoid arthritis pain.

[0737] In another aspect, the present invention provides the use of the compounds of the present invention, their pharmaceutically acceptable salts, or pharmaceutical compositions thereof for the manufacture of a medicament for treating or reducing the severity of idiopathic pain in a subject, wherein idiopathic pain comprises muscle fiber pain.

[0738] In another aspect, the present invention provides the use of the compounds of the present invention, pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, for the manufacture of a medicament for treating or reducing the severity of a subject's pathological cough.

[0739] In another aspect, the present invention provides the use of the compounds of the invention, their pharmaceutically acceptable salts, or pharmaceutical compositions thereof for the manufacture of a medicament for treating acute pain in a subject or reducing its severity. In some aspects, acute pain includes acute postoperative pain.

[0740] In another aspect, the present invention provides the use of the compounds of the invention, their pharmaceutically acceptable salts, or pharmaceutical compositions thereof for manufacture in order to treat postoperative pain in a subject (e.g., Pain from cystectomy, hernia repair, or abdominoplasty, or medications to reduce their severity.

[0741] In another aspect, the present invention provides the use of the compounds of the invention, their pharmaceutically acceptable salts, or pharmaceutical compositions thereof for the manufacture of a drug for treating a subject. Medications to relieve pain or reduce the severity of cystitis after excision.

[0742] In another aspect, the present invention provides the use of the compounds of the present invention, their pharmaceutically acceptable salts, or pharmaceutical compositions thereof for the manufacture of a medicament for treating or reducing the severity of pain during hernia repair in a subject.

[0743] In another aspect, the present invention provides the use of the compounds of the present invention, their pharmaceutically acceptable salts, or pharmaceutical compositions thereof for the manufacture of a medicament for treating or reducing the severity of abdominal wall repair pain in a subject.

[0744] In another aspect, the present invention provides the use of the compounds of the invention, their pharmaceutically acceptable salts, or pharmaceutical compositions thereof, for the manufacture of a medicament for treating or reducing visceral pain in a subject. In some aspects, visceral pain includes visceral pain caused by abdominoplasty.

[0745] In another aspect, the present invention provides compounds of the present invention or pharmaceutically acceptable salts thereof or pharmaceutical compositions thereof for use in the manufacture of a medicament for treating a subject with a neurodegenerative disease or reducing its severity. In some aspects, neurodegenerative diseases include multiple sclerosis. In some aspects, neurodegenerative diseases include Peter Hopkins syndrome (PTHS).

[0746] In another aspect, the present invention provides the use of the compounds of the invention, pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for the manufacture of a medicament for use in combination with one or more other therapeutic agents administered concurrently with, before, or after treatment with the compound or pharmaceutical composition. In some embodiments, the other therapeutic agent is a sodium channel inhibitor.

[0747] On the other hand, the present invention provides the use of the compounds of the invention, their pharmaceutically acceptable salts, or pharmaceutical compositions thereof for manufacture in order to treat acute pain, chronic pain, neuropathic pain, inflammatory pain, arthritis, migraine, cluster headache, trigeminal neuralgia, herpetic neuralgia, general neuralgia, epilepsy, epileptic disorders, neurodegenerative diseases, mental illnesses, anxiety disorders, depression, bipolar disorder, myotonia, arrhythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, incontinence, pathological cough, visceral pain, osteoarthritis pain, postherpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, headache, neck pain, severe pain, intractable pain, nociceptive pain, burst pain, postoperative pain (e.g., Pain from cystectomy, hernia repair, or abdominoplasty, cancer pain, stroke, cerebral ischemia, traumatic brain injury, amyotrophic lateral sclerosis, stress-induced angina, exercise-induced angina, palpitations, hypertension, or abnormal gastrointestinal motility, or medications to reduce their severity.

[0748] On the other hand, the present invention provides the use of the compounds of the invention, their pharmaceutically acceptable salts, or pharmaceutical compositions thereof for manufacture in order to treat femoral cancer pain; non-malignant chronic bone pain; rheumatoid arthritis; osteoarthritis; spinal stenosis; neuropathic lower back pain; myofascial pain syndrome; fibromuscular pain; temporomandibular joint pain; chronic visceral pain, abdominal pain; pancreatic pain; IBS pain; chronic and acute headaches; migraines; tension headaches; cluster headaches; chronic and acute neuropathic pain, postherpetic neuralgia; diabetic neuropathy. HIV-related neuropathy; trigeminal neuralgia; Chuck-Maley-Dus neuropathy; hereditary sensory neuropathy; peripheral nerve injury; painful neuroma; ectopic proximal and distal discharges; nerve root lesions; chemotherapy-induced neuropathic pain; radiation-induced neuropathic pain; post-mastectomy pain; central pain; spinal cord injury pain; post-stroke pain; thalamic pain; complex regional pain syndrome; phantom limb pain; intractable pain; acute pain, acute postoperative pain; acute musculoskeletal pain; joint pain; mechanical lower back pain; neck pain; muscle pain. Tendinitis; traumatic pain; exercise pain; acute visceral pain; pyelonephritis; appendicitis; cholecystitis; intestinal obstruction; hernia; chest pain, heart pain; pelvic pain, renal colic, acute labor pain, labor pain; cesarean section pain; acute inflammatory pain, burn pain, traumatic pain; acute intermittent pain, endometriosis; acute herpes zoster pain; sickle cell anemia; acute pancreatitis; breakthrough pain; orofacial pain; sinusitis pain; toothache; multiple sclerosis (MS) pain; pain in depression; leprosy pain; Behcet's disease. Pain in patients with Guillain-Barré syndrome; painful obesity; phlebitis pain; Guillain-Barré pain; leg pain and toe kinesia; Hagland syndrome; erythromelalgia; Fabry disease pain; bladder and urogenital disorders; urinary incontinence; pathological cough; hyperresponsive bladder; painful bladder syndrome; interstitial cystitis (IC); prostatitis; type I complex regional pain syndrome (CRPS); type II complex regional pain syndrome (CRPS); medications for inducing or reducing the severity of widespread pain, paroxysmal severe pain, pruritus, tinnitus, or colic.

[0749] Pharmaceutically acceptable application of salts and compositions

[0750] In some embodiments of the invention, the “effective amount” of the compound of the invention, its pharmaceutically acceptable salt, or a pharmaceutical composition thereof is an amount that can effectively treat one or more of the above-listed ailments or reduce their severity.

[0751] According to the method of the invention, compounds, salts, and compositions can be administered in any amount and via any route of administration that can effectively treat or reduce the severity of one or more of the painful or non-painful conditions listed herein. The precise amount required will vary depending on the subject's species, age and general condition, the severity of the condition, the specific agent, the mode of administration, etc. The compounds, salts, and compositions of the invention are preferably formulated in unit dosage forms for ease of administration and to achieve dose uniformity. As used herein, the term "unit dosage form" refers to a physically discrete unit of the agent suitable for the subject being treated. However, it should be understood that the total daily dosage of the compounds, salts, and compositions of the invention will be determined by the attending physician within the bounds of reasonable medical judgment. The specific effective dose level for any particular subject or organism will depend on a variety of factors, including the condition being treated and its severity; the activity of the specific compound or salt used; the specific composition used; the subject's age, weight, general health condition, sex, and diet; the time of administration, route of administration, and excretion rate of the specific compound or salt used; the duration of treatment; drugs used in combination with or concurrently with the specific compound or salt used; and similar factors well known in the medical field. As used herein, the terms “subject” or “patient” refer to an animal, preferably a mammal, and most preferably a human.

[0752] The pharmaceutically acceptable compositions of the present invention may be administered to humans and other animals, depending on the severity of the disease being treated, via oral, rectal, parenteral, intracerebrospinal, vaginal, intraperitoneal, topical (e.g., by powder, ointment, or drops), buccal (e.g., oral or nasal spray), etc. In some embodiments, the compounds, salts, and compositions of the present invention can be effectively administered at dose levels of about 0.001 mg / kg to about 100 mg / kg or about 0.01 mg / kg to about 50 mg / kg of subject body weight / day, once or more daily, orally or parenterally.

[0753] Liquid dosage forms for oral administration include (but are not limited to) pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to the active compound or salt, liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents; solubilizers and emulsifiers, such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, methyl benzoate, propylene glycol, 1,3-butanediol, dimethylformamide, oils (specifically, cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil, and sesame oil), glycerin, tetrahydrofurfuryl alcohol, polyethylene glycol, and sorbitol fatty acid esters and mixtures thereof. In addition to inert diluents, oral compositions may also include adjuvants, such as wetting agents, emulsifiers and suspending agents, sweeteners, flavoring agents, and aromatizers.

[0754] Injectable formulations, such as sterile injectable aqueous or oily suspensions, can be formulated using suitable dispersants or wetting agents and suspending agents according to known techniques. Sterile injectable formulations can also be sterile injectable solutions, suspensions, or emulsions in non-toxic, parenteral-acceptable diluents or solvents, such as solutions in 1,3-butanediol. Acceptable media and solvents that can be used include water, Ringer's solution, USP, and isotonic sodium chloride solution. Additionally, sterile, non-volatile oils are commonly used as solvents or suspension media. For this purpose, any mild, non-volatile oil can be used, including synthetic monoglycerides or diglycerides. Furthermore, fatty acids such as oleic acid can be used in the preparation of injectable formulations.

[0755] Injectable formulations can be sterilized, for example, by filtration via a bacterial trapping filter or by incorporating a sterilizing agent in the form of a sterile solid composition that can be dissolved or dispersed in sterile water or other sterile injectable media before use.

[0756] To prolong the effects of the compounds of the present invention, it is generally necessary to slow down the absorption of compounds administered subcutaneously or intramuscularly. This can be achieved by using liquid suspensions of crystalline or amorphous materials with poor water solubility. Thus, the absorption rate of the compound depends on its solubility, which in turn may depend on crystal size and crystal form. Alternatively, delayed absorption of parenteral-administered compounds can be achieved by dissolving or suspending the compound in an oil-based medium. Injectable accumulation formulations are prepared by forming microcapsule matrices of the compound in a biodegradable polymer such as polylactide-polyglycolic acid. The release rate of the compound can be controlled depending on the compound-to-polymer ratio and the properties of the specific polymer used. Examples of other biodegradable polymers include poly(orthoester) and poly(anhydride). Injectable accumulation formulations can also be prepared by encapsulating the compound in liposomes or microemulsions compatible with body tissues.

[0757] Compositions for rectal or vaginal application are preferably: suppositories, which can be prepared by mixing the compounds or salts of the present invention with suitable non-irritating excipients or carriers (such as cocoa butter, polyethylene glycol); or suppository waxes, which are solid at ambient temperature but liquid at body temperature, and thus melt in the rectal or vaginal cavity and release the active compound.

[0758] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound or salt is mixed with at least one inert, pharmaceutically acceptable excipient or carrier (such as sodium citrate or dicalcium phosphate) and / or the following: a) fillers or extenders, such as starch, lactose, sucrose, glucose, mannitol, and silica; b) binders, such as carboxymethyl cellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose, and acacia; c) humectants, such as glycerin; d) disintegrants, such as agar, calcium carbonate, potato or cassava starch, alginic acid, certain silicates, and sodium carbonate; e) solution blockers, such as paraffin; f) absorption accelerators, such as quaternary ammonium compounds; g) wetting agents, such as cetyl alcohol and glyceryl monostearate; h) adsorbents, such as kaolin and bentonite; and i) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets, and pills, the dosage form may also contain a buffer.

[0759] Similar solid compositions can also be used as fillers in soft and hard filled gelatin capsules using excipients such as lactose or toffee and high molecular weight polyethylene glycol. Solid dosage forms such as tablets, sugar-coated pills, capsules, pellets, and granules with coatings and shells (such as enteric coatings and other coatings well known in the field of pharmaceutical formulation) can be prepared. These may optionally contain light-blocking agents and may also have a composition that optionally releases the active ingredient in a delayed manner only or preferably in a portion of the intestine. Examples of encapsulation compositions that can be used include polymeric substances and waxes. Similar solid compositions can also be used as fillers in soft and hard filled gelatin capsules using excipients such as lactose or toffee and high molecular weight polyethylene glycol.

[0760] The active compound or salt may also be microencapsulated with one or more excipients as described above. Solid dosage forms, such as tablets, sugar-coated pills, capsules, pellets, and granules, can be prepared with coatings and shells (such as enteric coatings, release-controlled coatings, and other coatings well known in the field of pharmaceutical formulation). In such solid dosage forms, the active compound or salt may be mixed with at least one inert diluent (such as sucrose, lactose, or starch). As is common practice, such dosage forms may also contain substances other than inert diluents, such as tableting lubricants and other tableting aids, such as magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets, and pellets, the dosage form may also contain a buffer. It may optionally contain a light-blocking agent and may also have a composition that optionally releases the active ingredient in a delayed manner only or preferably in a portion of the intestine. Examples of encapsulation compositions that can be used include polymers and waxes.

[0761] Dosage forms for topical or transdermal application of the compounds used in this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalers, or patches. The active ingredient is mixed under sterile conditions with a pharmaceutically acceptable carrier and any desired preservatives or buffers that may be necessary. Ophthalmic formulations, ear drops, and eye drops are also contemplated within the scope of this invention. Additionally, the invention covers the use of transdermal patches, which offer the added advantage of controlled delivery of the compound to the body. Such dosage forms are prepared by dissolving or dispensing the compound in a suitable medium. Absorption enhancers may also be used to enhance the flow of the compound across the skin. The rate can be controlled by providing a rate-controlled membrane or by dispersing the compound in a polymer matrix or gel.

[0762] As generally described above, the compounds of the present invention can be used as inhibitors of voltage-gated sodium channels. In one embodiment, the compound is Na V Inhibitors of 1.8 and therefore, not wishing to be bound by any particular theory, compounds, salts, and compositions are particularly suitable for treating those containing Na+. V 1.8 Activation or excessive activity of Na is associated with disease, ailment, or condition, or may reduce its severity. V When the activation or excessive activity of 1.8 is associated with a specific disease, ailment, or condition, the disease, ailment, or condition may also be referred to as "Na". V 1.8 mediated diseases, ailments, or conditions. Therefore, in another aspect, the present invention provides a method for treating diseases, ailments, or conditions or reducing their severity, wherein the disease state is related to Na… V 1.8 is associated with activation or excessive activity.

[0763] The methods described herein and other methods known and available to those skilled in the art can be used to analyze the Na used in this invention, based on the methods generally described in International Publication No. WO 2014 / 120808 A9 and US Publication No. 2014 / 0213616A1 (both incorporated herein by reference in their entirety), other methods known and available to those skilled in the art. V The activity of compounds that inhibit 1.8.

[0764] Other treatments

[0765] It should also be understood that the compounds, salts, and pharmaceutically acceptable compositions of the present invention can be used in combination therapy form, i.e., the compounds, salts, and pharmaceutically acceptable compositions can be administered simultaneously, before, or after one or more other desired therapeutic agents or medical procedures. The specific combination of therapies (therapeutic agents or procedures) used in a combination regimen will take into account the compatibility of the desired therapeutic agents and / or procedures and the desired therapeutic effect to be achieved. It should also be understood that the therapy employed may achieve the desired effect against the same condition (e.g., the compounds of the present invention may be administered simultaneously with another agent for treating the same condition), or may achieve different effects (e.g., controlling any adverse effects). As used herein, other therapeutic agents typically administered to treat or prevent a particular disease or ailment are referred to as “suitable for the treated disease or ailment.” For example, other exemplary therapeutic agents include (but are not limited to): non-opioid analgesics (indoles, such as etodolac, indomethacin, sulindac, tolmetin; naphthyl ketones, such as nabumetone; oxicam, such as piroxicam; para-aminophenol derivatives, such as acetaminophen; propionic acid, such as fenoprofen, flurbiprofen, ibuprofen, ketoprofen, naproxen, naproxen sodium, oxaprazine; salicylates, such as aspirin, trisalicylate choline magnesium, diflunisal; fenamate, such as meclofenamic acid). Mefenamic acid; and pyrazoles, such as phenylbutazone; or opioid (narcotic) agonists (such as codeine, fentanyl, hydromorphone, levorphanol, meperidine, methadone, morphine, oxycodone, oxymorphone, propoxyphene, buprenorphine, butorphanol, dezocine, nalbuphine, and pentazocine). Additionally, non-pharmacological analgesia methods may be combined with the administration of one or more compounds of the present invention.For example, anesthetic methods (spinal infusion, nerve block), neurosurgical methods (neurolysis of the CNS pathway), neurostimulation methods (transcutaneous electrical nerve stimulation, dorsal column stimulation), physical therapy methods (physical therapy, orthotic devices, diathermy), or psychotherapy methods (cognitive methods—hypnosis, biofeedback, or behavioral methods) may also be used. Other appropriate treatments or methods are generally described in The Merck Manual, 19th edition, edited by Robert S. Porter and Justin L. Kaplan, MerckSharp & Dohme Corp., a subsidiary of Merck & Co., Inc., 2011, and on the Food and Drug Administration website, www.fda.gov, the entire contents of which are incorporated herein by reference.

[0766] In another embodiment, other suitable therapeutic agents are selected from the following:

[0767] (1) Opioid analgesics, such as morphine, heroin, hydromorphone, hydroxymorphone, levolorphan, methadone, meperidine, fentanyl, cocaine, codeine, dihydrocodeine, oxycodone, hydrocodone, propoxyphene, nalmefene, nalorphine, naloxone, naltrexone, buprenorphine, butorphanol, nalbuphine, tebuconazole, or difelikefalin;

[0768] (2) Nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin, diclofenac, diflunisal, etodoxacin, fenbufen, fenprofen, flufenisal, flurbiprofen, ibuprofen (including (but not limited to) intravenous ibuprofen (e.g.) Indomethacin, ketoibuprofen, ketorolac (including (but not limited to) ketorolac tromethamine (e.g.) Meclofenamic acid, meloxicam, intravenous meloxicam (e.g.) ), naproxen, nimesulide, nitroflurbiprofen, olsalazine, oxaprazine, phenylbutazone, piroxicam, sulfasalazine, sulindac, tometidine, or zomepirac;

[0769] (3) Barbiturate sedatives, such as amobarbital, aprobarbital, butabarbital, butalbital, mephobarbital, metharbital, methoexital, pentobarbital, phenobarbital, secobarbital, talbutal, thiamylal, or thiopental;

[0770] (4) Benzodiazepines with sedative effects For example, chlorine nitrogen (chlordiazepoxide), chlorine nitrogen Clorazepate, diazepam, flurazepam, lorazepam, oxazepam, temazepam, or triazolam;

[0771] (5) Histamine (H1) antagonists with sedative effects, such as diphenhydramine, pyrilamine, promethazine, chlorpheniramine or chlorcyclizine;

[0772] (6) Sedatives, such as glutethimide, meprobamate, methaqualone, or dichloral phenazone;

[0773] (7) Skeletal muscle relaxants, such as baclofen, carisoprodol, chlorzoxazone, cyclobenzaprine, mesocarbamol, or orphenadrine.

[0774] (8) NMDA receptor antagonists, such as dextromethorphan ((+)-3-hydroxy-N-methylmorphorphenanthranitarium) or its metabolite dextrororphan ((+)-3-hydroxy-N-methylmorphorphenanthranitarium), ketamine, memantine, pyrroloquinoline quinine, cis-4-(phosphonomethyl)-2-piperidinecarboxylic acid, budipine, EN-3231 ( A combination of morphine and dextromethorphan, topiramate, neramexane, or perzinfotel including an NR2B antagonist such as ifenprodil, traxoprodil, or (-)-(R)-6-{2-[4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]-1-hydroxyethyl-3,4-dihydro-2(1H)-quinolinone;

[0775] (9) α-Adrenergic, such as doxazosin, tamsulosin, clonidine, guanfacine, dexmedetomidine, modafinil or 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinoline-2-yl)-5-(2-pyridyl)quinazoline;

[0776] (10) Tricyclic antidepressants, such as desipramine, imipramine, amitriptyline, or nortriptyline;

[0777] (11) Anticonvulsants, such as carbamazepine Lamotrigine, topiramate, and lacosamide Or valproate;

[0778] (12) Tachykinin (NK) antagonists, especially NK-3, NK-2, or NK-1 antagonists, such as (αR,9R)-7-[3,5-bis(trifluoromethyl)benzyl]-8,9,10,11-tetrahydro-9-methyl-5-(4-methylphenyl)-7H-[1,4]diazocinot[2,1-g][1,7]-naphthyl-6-13-dione (TAK-637), 5-[[(2R, 3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy-3-(4-fluorophenyl)-4-morpholinyl]-methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one (MK-869), aprepitant, lanepitant, dapitant, or 3-[[2-methoxy-5-(trifluoromethoxy)phenyl]-methylamino]-2-phenylpiperidine (2S,3S);

[0779] (13) Muscarinic antagonists, such as oxybutynin, tolterodine, propiverine, tropsium chloride, darifenacin, solifenacin, temiverine and ipratropium;

[0780] (14) COX-2 selective inhibitors, such as celecoxib, rofecoxib, parecoxib, valdecoxib, deracoxib, etoricoxib, or lumiracoxib.

[0781] (15) Coal tar analgesics, especially paracetamol;

[0782] (16) Tranquilizers, such as droperidol, chlorpromazine, haloperidol, perphenazine, thioridazine, mesoridazine, trifluoperazine, fluphenazine, clozapine, olanzapine, risperidone, ziprasidone, quetiapine, sertindole, and aripiprazole. Sonapiprazole, blonanserin, iloperidone, perospirone, raclopride, zotepine, bifeprunox, asenapine, lurasidone, amisulpride, balaperidone, palindore, epilisarserin, osanetant, rimonabant, meclinertant Or sarizotan;

[0783] (17) Vanillin receptor agonists (e.g., resinferatoxin or civamide) or antagonists (e.g., capsazepine, GRC-15300);

[0784] (18) β-adrenergic, such as propranolol;

[0785] (19) Local anesthetics, such as mexiletine;

[0786] (20) Corticosteroids, such as dexamethasone;

[0787] (21) 5-HT receptor agonists or antagonists, especially 5-HT receptor agonists or antagonists. 1B / 1DAgonists, such as eletriptan, sumatriptan, naratriptan, zolmitriptan, or rizatriptan;

[0788] (22)5-HT 2A Receptor antagonists, such as R(+)-α-(2,3-dimethoxy-phenyl)-1-[2-(4-fluorophenylethyl)]-4-piperidinemethanol (MDL-100907);

[0789] (23) Cholinergic (nicotine) analgesics, such as ispronicline (TC-1734), (E)-N-methyl-4-(3-pyridyl)-3-buten-1-amine (RJR-2403), (R)-5-(2-azacyclobutylmethoxy)-2-chloropyridine (ABT-594) or nicotine;

[0790] (twenty four) Tramadol ER (Ultram) IV Tramadol, Tapentadol ER

[0791] (25) PDE5 inhibitors, such as 5-[2-ethoxy-5-(4-methyl-1-piperazinyl-sulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (sildenafil), (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazolo[2',l':6,l] ... pyrido[3,4-b]indol-1,4-dione (IC-351 or tadalafil), 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulfonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,lf][l,2,4]triazin-4-one (vardenafil), 5-(5-acetyl-2-butoxy-3-pyridyl)-3-ethyl-2-(l-ethyl- 3-azacyclobutane)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, 5-(5-acetyl-2-propoxy-3-pyridyl)-3-ethyl-2-(l-isopropyl-3-azacyclobutane)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, 5-[2-ethoxy-5-(4-ethylpiperazin-l-ylsulfonyl)pyridin-3-yl]-3-ethyl-2-[2-methoxyethyl]-2,6-dihydro -7H-pyrazolo[4,3-d]pyrimidin-7-one, 4-[(3-chloro-4-methoxybenzyl)amino]-2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-N-(pyrimidin-2-ylmethyl)pyrimidin-5-carboxamide, 3-(l-methyl-7-sideoxy-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzenesulfonamide;

[0792] (26) α-2-δ ligands, such as gabapentin. Gabapentin GR Gabapentin, enacarbil Pregabalin 3-Methylgabapentin, (1[α],3[α],5[α])(3-amino-methyl-bicyclo[3.2.0]hept-3-yl)acetic acid, (3S,5R)-3-aminomethyl-5-methyl-heptanoic acid, (3S,5R)-3-amino-5-methyl-heptanoic acid, (3S,5R)-3-amino-5-methyl-octanoic acid, (2S,4S)-4-(3-chlorophenoxy)proline, (2S,4S)-4-(3-fluorobenzyl)proline, [(1R,5R,6S)-6-(aminomethyl)bicyclo[3.2.0]hept-6-yl]acetic acid, 3-(1-amino-... (1,2,4)-4H-[1,2,4]oxadiazol-5-one, C-[1-(1H-tetrazol-5-ylmethyl)-cycloheptyl]-methylamine, (3S,4S)-(1-aminomethyl-3,4-dimethyl-cyclopentyl)-acetic acid, (3S,5R)-3-aminomethyl-5-methyl-octanoic acid, (3S,5R)-3-amino-5-methyl-nonanoic acid, (3S,5R)-3-amino-5-methyl-octanoic acid, (3R,4R,5R)-3-amino-4,5-dimethyl-heptanoic acid and (3R,4R,5R)-3-amino-4,5-dimethyl-octanoic acid;

[0793] (27) Cannabinoids, such as KHK-6188;

[0794] (28) Metabolic glutamate subtype 1 receptor (mGluR1) antagonists;

[0795] (29) Serotonin reuptake inhibitors, such as sertraline, sertraline metabolite demethylsertraline, fluoxetine, norfluoxetine (fluoxetine demethyl metabolite), fluvoxamine, paroxetine, citalopram, citalopram metabolite norcitalopram, escitalopram, d,l-fenfluramine, femoxetine, ifoxetine, cyanodothiepin, litoxetine, dapoxetine, nefazodone, cerilamine, and trazodone;

[0796] (30) Norepinephrine (or norepinephrine) reuptake inhibitors, such as maprotiline, lofepramine, mirtazepine, oxaprotiline, fezolamine, tomoxetine, mianserin, bupropion, bupropion metabolite hydroxybupropion, nomifensine, and viloxazine. In particular, selective norepinephrine reuptake inhibitors, such as reboxetine, especially (S,S)-reboxetine;

[0797] (31) Bisserotonin-norepinephrine reuptake inhibitors, such as venlafaxine, venlafaxine metabolite O-desmethylvenlafaxine, clomipramine, clomipramine metabolite desmethylclomipramine, and duloxetine. Milnacipran and imipramine;

[0798] (32) Inducible nitric oxide synthase (iNOS) inhibitors, such as S-[2-[(1-iminoethyl)amino]ethyl]-L-homocysteine, S-[2-[(1-iminoethyl)amino]ethyl]-4,4-disideloxy-L-cysteine, S-[2-[(1-iminoethyl)amino]ethyl]-2-methyl-L-cysteine, (2S,5Z)-2-amino-2-methyl-7-[(1-iminoethyl)amino]-5-heptenoic acid, 2-[[(1R,3S)-3-amino-4-hydroxy-1-(5-thiazolyl)-butyl]thio]-S-chloro-S-pyridinecarboxylate, 2-[[(1R,3S)-3-amino-4-hydroxy-1-(5-thiazolyl)-butyl]thio]-S-chloro-S-pyridinecarboxylate, 2-[[(1R (1R,3S)-3-amino-4-hydroxy-1-(5-thiazolyl)butyl]thio]-4-chlorobenzonitrile, (2S,4R)-2-amino-4-[[2-chloro-5-(trifluoromethyl)phenyl]thio]-5-thiazolylbutanol, 2-[[(1R,3S)-3-amino-4-hydroxy-1-(5-thiazolyl)butyl]thio]-6-(trifluoromethyl)-3-pyridinecarboxynitrile, 2-[[(1R,3S)-3-amino-4-hydroxy-1-(5-thiazolyl)butyl]thio]-5-chlorobenzonitrile, N-[4-[2-(3-chlorobenzylamino)ethyl]phenyl]thiophene-2-formamidinium, NXN-462 or ethyl disulfide guanidine;

[0799] (33) Acetylcholinesterase inhibitors, such as donepezil;

[0800] (34) Prostaglandin E2 subtype 4 (EP4) antagonists, such as N-[({2-[4-(2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)phenyl]ethyl}amino)-carbonyl]-4-methylbenzenesulfonamide or 4-[(15)-1-({[5-chloro-2-(3-fluorophenoxy)pyridin-3-yl]carbonyl}amino)ethyl]benzoic acid;

[0801] (35) Leukotriene B4 antagonists, such as 1-(3-biphenyl-4-ylmethyl-4-hydroxy-chroman-7-yl)-cyclopentanecarboxylic acid (CP-105696), 5-[2-(2-carboxyethyl)-3-[6-(4-methoxyphenyl)-5E-hexenyl]oxyphenoxy]valerate (ONO-4057) or DPC-11870;

[0802] (36) 5-Lipooxygenase inhibitors, such as zileuton, 6-[(3-fluoro-5-[4-methoxy-3,4,5,6-tetrahydro-2H-pyran-4-yl])phenoxy-methyl]-1-methyl-2-quinolone (ZD-2138) or 2,3,5-trimethyl-6-(3-pyridylmethyl)-1,4-benzoquinone (CV-6504);

[0803] (37) Sodium channel blockers, such as lidocaine, lidocaine plus tetracaine cream (ZRS-201) or eslicarbazepine acetate.

[0804] (38)Na V1.7 Blockers, such as XEN-402, XEN403, TV-45070, PF-05089771, CNV1014802, GDC-0276, RG7893, BIIB-074 (Vixotrigine), BIIB-095, ASP-1807, DSP-3905, OLP-1002, RQ-00432979, FX-301, DWP-17061, IMB-110, IMB-111, IMB-112 and such as WO2011 / 140425 (US2011 / 30660) 7) The blocking agents disclosed in WO2012 / 106499 (US2012196869), WO2012 / 112743 (US2012245136), WO2012 / 125613 (US2012264749), WO2012 / 116440 (US2014187533), WO2011026240 (US2012220605), US8883840, US8466188 or WO2013 / 109521 (US2015005304), the entire contents of each of which are incorporated herein by reference;

[0805] (38a)Na V1.7 Blockers, such as (2-benzylspiro[3,4-dihydropyrrolo[1,2-a]pyrazin-1,4'-piperidine]-1'-yl)-(4-isopropoxy-3-methyl-phenyl) ketone, 2,2,2-trifluoro-1-[1'-[3-methoxy-4-[2-(trifluoromethoxy)ethoxy]benzoyl]-2,4-dimethyl-spiro[3,4-dihydropyrrolo[1,2-a]pyrazin-1,4'-piperidine]-6-yl] ethyl ketone, [8-fluoro-2-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazin-1,4'-piperidine]-1'-yl]-(4-isobutoxy-3-methoxy-phenyl) ketone, 1-(4-diphenylmethylpiperidine-1-yl) )-3-[2-(3,4-dimethylphenoxy)ethoxy]prop-2-ol, (4-butoxy-3-methoxy-phenyl)-[2-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazin-1,4'-piperidine]-1'-yl] methyl ketone, [8-fluoro-2-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazin-1,4'-piperidine]-1'-yl]-(5-isopropoxy-6-methyl-2-pyridyl) methyl ketone, (4-isopropoxy-3-methyl-phenyl)-[2-methyl-6-(1,1,2,2,2-pentafluoroethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazin-1,4'-piperidine]-1'-yl] [3,4-dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-1'-carbonyl]phenyl]pyridine-2-carboxylonitrile, (4-isopropoxy-3-methyl-phenyl)-[6-(trifluoromethyl)spiro[3,4-dihydro-2H-pyrrolo[1,2-a]pyrazine-1,4'-piperidine]-1'-yl] ketone, 2,2,2-trifluoro-1-[1'-[3-methoxy-4-[2-(trifluoromethoxy)ethoxy]benzoyl]-2-methyl-spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-6-yl] acetone, 2,2,2-trifluoro-1- [1'-(5-isopropoxy-6-methyl-pyridine-2-carbonyl)-3,3-dimethyl-spiro[2,4-dihydropyrrolo[1,2-a]pyrazin-1,4'-piperidine]-6-yl] acetone, 2,2,2-trifluoro-1-[1'-(5-isopentyloxypyridine-2-carbonyl)-2-methyl-spiro[3,4-dihydropyrrolo[1,2-a]pyrazin-1,4'-piperidine]-6-yl] acetone, (4-isopropoxy-3-methoxy-phenyl)-[2-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazin-1,4'-piperidine]-1'-yl] acetone, 2,2,2-trifluoro-1-[1'-(5-isopentyloxypyridine-2-carbonyl)-2,4-Dimethyl-spiro[3,4-dihydropyrrolo[1,2-a]pyrazin-1,4'-piperidine]-6-yl] acetone, 1-[(3S)-2,3-dimethyl-1'-[4-(3,3,3-trifluoropropoxymethyl)benzoyl]spiro[3,4-dihydropyrrolo[1,2-a]pyrazin-1,4'-piperidine]-6-yl]-2,2,2-trifluoro-acetone, [8-fluoro-2-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[ [1,2-a]pyrazine-1,4'-piperidin]-1'-yl]-[3-methoxy-4-[(1R)-1-methylpropoxy]phenyl] ketone, 2,2,2-trifluoro-1-[1'-(5-isopropoxy-6-methyl-pyridin-2-carbonyl)-2,4-dimethyl-spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidin]-6-yl] acetone, 1-[1'-[4-methoxy-3-(trifluoromethyl)benzoyl]- 2-Methyl-spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-6-yl]-2,2-dimethyl-prop-1-one, (4-isopropoxy-3-methyl-phenyl)-[2-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-1'-yl] methyl ketone, [2-methyl-6-(1-methylcyclopropanecarbonyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine] [-1,4'-piperidin]-1'-yl]-[4-(3,3,3-trifluoropropoxymethyl)phenyl] ketone, 4-bromo-N-(4-bromophenyl)-3-[(1-methyl-2-oxo-4-piperidinyl)aminosulfonyl]benzamide or (3-chloro-4-isopropoxy-phenyl)-[2-methyl-6-(1,1,2,2,2-pentafluoroethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazin-1,4'-piperidin]-1'-yl] ketone;

[0806] (39)Na V1.8 Inhibitors, such as PF-04531083, PF-06372865, and such as WO2008 / 135826 (US2009048306), WO2006 / 011050 (US2008312235), WO2013 / 061205 (US2014296313), US20130303535, WO2013131018, US8466188, WO2013114250 (US2013274243), WO2014 / 120808 (US2014213616), WO2014 / 120815 (US2014228371), WO2014 The blocking agents disclosed in WO2014 / 20820 (US2014221435), WO2015 / 010065 (US20160152561), WO2015 / 089361 (US20150166589), WO2019014352 (US20190016671), WO2018 / 213426, WO2020 / 146682, WO2020 / 146612, WO2020 / 014243, WO2020 / 014246, WO2020 / 092187 and WO2020 / 092667 (US2020140411), the entire contents of each of these applications are incorporated herein by reference;

[0807] (39a)Na V1.8 Blockers, such as 4,5-dichloro-2-(4-fluoro-2-methoxyphenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)benzamide, 2-(4-fluoro-2-methoxyphenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)-4-(perfluoroethyl)benzamide, 4,5-dichloro-2-(4-fluorophenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)benzamide, 4,5-dichloro-2-(3-fluoro-4-methoxyphenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)benzamide, 2-(4-fluoro-2 ... N-(2-oxo-1,2-dihydropyridin-4-yl)-5-(trifluoromethyl)benzamide, N-(2-oxo-1,2-dihydropyridin-4-yl)-2-(4-(trifluoromethoxy)phenoxy)-4-(trifluoromethyl)benzamide, 2-(4-fluorophenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)-4-(perfluoroethyl)benzamide, 5-chloro-2-(4-fluoro-2-methoxyphenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)benzamide, N-(2-oxo-1,2-dihydropyridin-4-yl)-2-(4-(trifluoromethoxy)phenoxy)-5-(trifluoromethyl)benzamide, 2-( 4-Fluoro-2-methylphenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)-5-(trifluoromethyl)benzamide, 2-(2-chloro-4-fluorophenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)-5-(trifluoromethyl)benzamide, 5-chloro-2-(4-fluoro-2-methylphenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)benzamide, 4-chloro-2-(4-fluoro-2-methylphenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)benzamide, 5-chloro-2-(2-chloro-4-fluorophenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)benzamide Benzamide, 2-((5-fluoro-2-hydroxybenzyl)oxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)-4-(trifluoromethyl)benzamide, N-(2-oxo-1,2-dihydropyridin-4-yl)-2-(o-tolyloxy)-5-(trifluoromethyl)benzamide, 2-(2,4-difluorophenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)-4-(trifluoromethyl)benzamide, N-(2-oxo-1,2-dihydropyridin-4-yl)-2-(2-(trifluoromethoxy)phenoxy)-5-(trifluoromethyl)benzamide, 2-(4-fluorophenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)-2-(2-(trifluoromethoxy)phenoxy)-5-(trifluoromethyl)benzamide, 2-(4-fluorophenoxy)-N-(2-oxo-1,2-Dihydropyridin-4-yl)-5-(trifluoromethyl)benzamide, 2-(4-fluoro-2-methyl-phenoxy)-N-(2-oxo-1H-pyridin-4-yl)-4-(trifluoromethyl)benzamide, dihydro[4-[[2-(4-fluoro-2-methyl-phenoxy)-4-(trifluoromethyl)benzoyl]amino]-2-oxo-1-pyridyl]methyl ester, 2-(4-fluoro-2-(methyl-d3)phenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)-4-(trifluoromethyl)benzamide, dihydro(4-(2-(4-fluoro-2-(methyl-d3)phenoxy)-4-(trifluoromethyl)benzamido)-2-oxopyridin-1(2H)-yl) 3-(4-fluoro-2-methoxyphenoxy)-N-(3-(methylsulfonyl)phenyl)quinoxaline-2-carboxamide, 3-(2-chloro-4-fluorophenoxy)-N-(3-aminosulfonylphenyl)quinoxaline-2-carboxamide, 3-(2-chloro-4-methoxyphenoxy)-N-(3-aminosulfonylphenyl)quinoxaline-2-carboxamide, 3-(4-chloro-2-methoxyphenoxy)-N-(3-aminosulfonylphenyl)quinoxaline-2-carboxamide, 4-(3-(4-(trifluoromethoxy)phenoxy)quinoxaline-2-carboxamido)pyridinecarboxylic acid, 2-(2,4-difluorophenoxy)-N-(3-aminosulfonylphenyl)quinoxaline-3-carboxamide, 2-(4-fluoro-2-methoxyphenoxy) 3-(2,4-difluorophenoxy)-N-(3-aminosulfonylphenyl)quinoline-3-carboxamide, 3-(3-aminosulfonylphenyl)-N-(4-(trifluoromethoxy)phenoxy)quinoline-3-carboxamide, N-(3-aminosulfonylphenyl)-3-(4-(trifluoromethoxy)phenoxy)quinoline-2-carboxamide, 3-(4-chloro-2-methylphenoxy)-N-(3-aminosulfonylphenyl)quinoline-2-carboxamide, 5-(3-(4-(trifluoromethoxy)phenoxy)quinoline-2-carboxamido)pyridinecarboxylic acid, 3-(4-fluoro-2-methoxyphenoxy)-N-(2-oxo-2,3-dihydro-1H- Benzimidazole-5-yl)quinoxaline-2-carboxamide, 3-(4-fluoro-2-methoxyphenoxy)-N-(pyridin-4-yl)quinoxaline-2-carboxamide, 3-(4-fluorophenoxy)-N-(3-aminosulfonylphenyl)quinoxaline-2-carboxamide, N-(3-cyanophenyl)-3-(4-fluoro-2-methoxyphenoxy)quinoxaline-2-carboxamide, N-(4-carbamoylphenyl)-3-(4-fluoro-2-methoxyphenoxy)quinoxaline-2-carboxamide, 4-(3-(4-(trifluoromethoxy)phenoxy)quinoxaline-2-carboxamido)benzoic acid, N-(4-cyanophenyl)-3-(4-fluoro-2-methoxyphenoxy)quinoxaline-2-carboxamide, 5-(4,5-Dichloro-2-(4-fluoro-2-methoxyphenoxy)benzamido)pyridinecarboxylic acid, 5-(2-(2,4-dimethoxyphenoxy)-4,6-bis(trifluoromethyl)benzamido)pyridinecarboxylic acid, 4-(4,5-dichloro-2-(4-fluoro-2-methoxyphenoxy)benzamido)benzoic acid, 5-(2-(4-fluoro-2-methoxyphenoxy)-4,6-bis(trifluoromethyl)benzamido)pyridinecarboxylic acid, 4-(2-(4-fluoro-2-methoxyphenoxy)-4-(perfluoroethyl) 5-(2-(4-fluoro-2-methoxyphenoxy)-4-(perfluoroethyl)benzamido)pyridinecarboxylic acid, 4-(2-(4-fluoro-2-methylphenoxy)-4-(trifluoromethyl)benzamido)benzoic acid, 5-(4,5-dichloro-2-(4-fluoro-2-methoxyphenoxy)benzamido)pyridinecarboxylic acid, 4-(2-(2-chloro-4-fluorophenoxy)-4-(perfluoroethyl)benzamido)benzoic acid, 4-(2-(4-fluoro-2-methylphenoxy)- 4-(perfluoroethyl)benzamido)benzoic acid, 4-(4,5-dichloro-2-(4-(trifluoromethoxy)phenoxy)benzamido)benzoic acid, 4-(4,5-dichloro-2-(4-chloro-2-methylphenoxy)benzamido)benzoic acid, 5-(4-(tert-butyl)-2-(4-fluoro-2-methoxyphenoxy)benzamido)pyridinecarboxylic acid, 5-(4,5-dichloro-2-(4-(trifluoromethoxy)phenoxy)benzamido)pyridinecarboxylic acid, 4-(4,5-dichloro-2-(4-) 5-(4,5-dichloro-2-(2,4-dimethoxyphenoxy)benzamido)benzoic acid, 5-(4,5-dichloro-2-(2,4-dimethoxyphenoxy)benzamido)pyridinecarboxylic acid, 5-(4,5-dichloro-2-(2-chloro-4-fluorophenoxy)benzamido)pyridinecarboxylic acid, 5-(4,5-dichloro-2-(4-fluoro-2-methylphenoxy)benzamido)pyridinecarboxylic acid, 4-(4,5-dichloro-2-(4-chloro-2-methoxyphenoxy)benzamido)benzoic acid, 5-(4,5-dichloro-2-(2,4-dimethyl ...4-Difluorophenoxy)benzamido)pyridinecarboxylic acid, 2-(4-fluorophenoxy)-N-(3-aminosulfonylphenyl)-5-(trifluoromethyl)benzamide, 2-(4-fluorophenoxy)-N-(3-aminosulfonylphenyl)-4-(trifluoromethyl)benzamide, 2-(2-chloro-4-fluorophenoxy)-N-(3-aminosulfonylphenyl)-5-(trifluoromethyl)benzamide, 2-(4-fluorophenoxy)-N-(3-aminosulfonylphenyl)-4-(trifluoromethyl)benzamide, 2-(2-chloro-4-fluorophenoxy)-N -(3-aminosulfonylphenyl)-6-(trifluoromethyl)benzamide, 2-(2-chloro-4-fluorophenoxy)-5-(difluoromethyl)-N-(3-aminosulfonylphenyl)benzamide, 2-(4-fluorophenoxy)-4-(perfluoroethyl)-N-(3-aminosulfonylphenyl)benzamide, 2-(4-chloro-2-methoxyphenoxy)-4-(perfluoroethyl)-N-(3-aminosulfonylphenyl)benzamide, 2-(4-fluoro-2-methoxyphenoxy)-N-(3-aminosulfonylphenyl)-5-(trifluoromethyl)benzamide 5-Chloro-2-(4-fluoro-2-methylphenoxy)-N-(3-aminosulfonylphenyl)benzamide, 4,5-dichloro-2-(4-fluoro-2-methoxyphenoxy)-N-(3-aminosulfonylphenyl)benzamide, 2,4-dichloro-6-(4-chloro-2-methoxyphenoxy)-N-(3-aminosulfonylphenyl)benzamide, 2,4-dichloro-6-(4-fluoro-2-methylphenoxy)-N-(3-aminosulfonylphenyl)benzamide, 2-(4-fluoro-2-methoxyphenoxy)-N-(3-aminosulfonylphenyl)benzamide 4,6-bis(trifluoromethyl)benzamide, 2-(4-fluoro-2-methylphenoxy)-N-(3-aminosulfonylphenyl)-4,6-bis(trifluoromethyl)benzamide, 5-chloro-2-(2-chloro-4-fluorophenoxy)-N-(3-aminosulfonylphenyl)benzamide, 2-(4-fluoro-2-methoxyphenoxy)-N-(3-aminosulfonylphenyl)-4-(trifluoromethoxy)benzamide, 2-(4-fluoro-2-methoxyphenoxy)-N-(3-aminosulfonylphenyl)-4-(trifluoromethyl)benzamide, 4,5-Dichloro-2-(4-fluorophenoxy)-N-(3-aminosulfonylphenyl)benzamide, 2-(4-fluoro-2-methoxyphenoxy)-4-(perfluoroethyl)-N-(3-aminosulfonylphenyl)benzamide, 5-fluoro-2-(4-fluoro-2-methylphenoxy)-N-(3-aminosulfonylphenyl)benzamide, 2-(2-chloro-4-fluorophenoxy)-4-cyano-N-(3-aminosulfonylphenyl)benzamide, N-(3-aminosulfonylphenyl)-2-(4-(trifluoromethoxy)phenoxy)-4-(trifluoromethyl)benzamide, N-(3-aminomethyl) Acyl-4-fluoro-phenyl)-2-fluoro-6-[2-(trideuteroxy)-4-(trifluoromethoxy)phenoxy]-3-(trifluoromethyl)benzamide, N-(3-carbamoyl-4-fluoro-phenyl)-2-fluoro-6-[2-(trideuteroxy)-4-(trifluoromethoxy)phenoxy]-3-(trifluoromethyl)benzamide, N-(3-carbamoyl-4-fluoro-phenyl)-2-fluoro-6-[2-(trideuteroxy)-4-(trifluoromethoxy)phenoxy]-3-(trifluoromethoxy)benzamide, 4-[[2-fluoro-6-[2-methoxy-4-(trifluoromethyl)] [[3-chloro-2-fluoro-6-[2-methoxy-4-(trifluoromethoxy)phenoxy]amino]pyridine-2-carboxamide, 4-[[2-fluoro-6-[2-(trideuteroxy)-4-(trifluoromethoxy)phenoxy]-3-(trifluoromethyl)benzoyl]amino]pyridine-2-carboxamide, N-(3-carbamoyl-4-fluoro-phenyl)-3-(difluoromethyl)-2-fluoro-6-[2-methoxy-4-(trifluoromethoxy)phenoxy]benzoyl Amine, 4-[[2-fluoro-6-[2-(trideuteroxy)-4-(trifluoromethoxy)phenoxy]-3-(trifluoromethoxy)benzoyl]amino]pyridine-2-carboxamide, N-(3-carbamoyl-4-fluoro-phenyl)-6-[2-chloro-4-(trifluoromethoxy)phenoxy]-2-fluoro-3-(trifluoromethyl)benzamide, N-(3-carbamoyl-4-fluoro-phenyl)-2-fluoro-6-[2-methyl-4-(trifluoromethoxy)phenoxy]-3-(trifluoromethyl)benzamide, N-(3-carbamoyl-4-fluoro-phenyl)-2,3,4-Trifluoro-6-[2-methoxy-4-(trifluoromethoxy)phenoxy]benzamide, N-(2-carbamoyl-4-pyridyl)-3-fluoro-5-[2-methoxy-4-(trifluoromethoxy)phenoxy]-2-(trifluoromethyl)pyridine-4-carboxamide, 4-[[6-[2-(difluoromethoxy)-4-(trifluoromethoxy)phenoxy]-2-fluoro-3-(trifluoromethyl)benzoyl]amino]pyridine-2-carboxamide, N-(3-carbamoyl-4-fluoro-phenyl)-6-[3-chloro-4-(trifluoromethoxy)phenoxy]-2-fluoro-3-(trifluoromethyl)benzamide, N-(3-carbamoyl-4- (Fluoro-phenyl)-2-fluoro-6-[4-(trifluoromethoxy)phenoxy]-3-(trifluoromethyl)benzamide, N-(4-carbamoyl-3-fluoro-phenyl)-2-fluoro-6-[2-methoxy-4-(trifluoromethoxy)phenoxy]-3-(trifluoromethyl)benzamide, 4-[[2-fluoro-6-[2-(trideuteroxy)-4-(trifluoromethoxy)phenoxy]-4-(trifluoromethyl)benzoyl]amino]pyridine-2-carboxamide, N-(3-carbamoyl-4-fluoro-phenyl)-2-fluoro-6-[3-fluoro-4-(trifluoromethoxy)phenoxy]-3-(trifluoromethyl)benzamide, N-(3-carbamoyl) (4-fluoro-phenyl)-2-[2-methoxy-4-(trifluoromethoxy)phenoxy]-5-(1,1,2,2,2-pentafluoroethyl)benzamide, 4-[[4-(difluoromethoxy)-2-fluoro-6-[2-methoxy-4-(trifluoromethoxy)phenoxy]benzoyl]amino]pyridine-2-carboxamide, N-(3-carbamoyl-4-fluoro-phenyl)-2-fluoro-6-[2-fluoro-4-(trifluoromethoxy)phenoxy]-3-(trifluoromethyl)benzamide, 4-[[4-cyclopropyl-2-fluoro-6-[2-methoxy-4-(trifluoromethoxy)phenoxy]benzoyl]amino]pyridine-2-carboxamide, N- (3-Carbamoyl-4-fluoro-phenyl)-5-fluoro-2-[2-methoxy-4-(trifluoromethoxy)phenoxy]-4-(trifluoromethyl)benzamide, 5-[[2-fluoro-6-[2-(trideuteroxy)-4-(trifluoromethoxy)phenoxy]-3-(trifluoromethyl)benzoyl]amino]pyridine-2-carboxamide, N-(3-carbamoyl-4-fluoro-phenyl)-2-fluoro-6-(4-fluorophenoxy)-3-(trifluoromethyl)benzamide, or 4-[[2-fluoro-6-[3-fluoro-2-methoxy-4-(trifluoromethoxy)phenoxy]-3-(trifluoromethyl)benzoyl]amino]pyridine-2-carboxamide;

[0808] (40) Combinatorial Na V 1.7 and Na V1.8 Blockers, such as DSP-2230, Lohocla201, or BL-1021;

[0809] (41) 5-HT3 antagonists, such as ondansetron;

[0810] (42) TPRV 1 receptor agonists, such as capsaicin. and its pharmaceutically acceptable salts and solvates;

[0811] (43) Nicotine receptor antagonists, such as varenicline;

[0812] (44) N-type calcium channel antagonists, such as Z-160;

[0813] (45) Nerve growth factor antagonists, such as tanezumab;

[0814] (46) Endopeptidase stimulants, such as senrebotase;

[0815] (47) Angiotensin II antagonists, such as EMA-401;

[0816] (48) Acetaminophen (including (but not limited to) intravenous acetaminophen (e.g.) ));

[0817] (49) Bupivacaine (including (but not limited to) bupivacaine liposome injectable suspensions (e.g.) Bupivacaine ER (Posimir), Bupivacaine collagen (Xaracoll), and transdermal bupivacaine );as well as

[0818] (50) Bupivacaine and meloxicam combination (e.g., HTX-011).

[0819] In one implementation, other suitable therapeutic agents are selected from V-116517, pregabalin, controlled-release pregabalin, and ezogabine. Ketamine / amitriptyline topical cream AVP-923, Perampanel (E-2007), Ralfinamide, Transdermal Bupivacaine CNV1014802, JNJ-10234094 (Carisbamat e), BMS-954561 or ARC-4558.

[0820] In another embodiment, other suitable therapeutic agents are selected from N-(6-amino-5-(2,3,5-trichlorophenyl)pyridin-2-yl)acetamide; N-(6-amino-5-(2-chloro-5-methoxyphenyl)pyridin-2-yl)-1-methyl-1H-pyrazole-5-carboxamide; or 3-((4-(4-(trifluoromethoxy)phenyl)-1H-imidazol-2-yl)methyl)oxetane-3-amine.

[0821] In another embodiment, the other therapeutic agents are selected from GlyT2 / 5HT2 inhibitors, such as Operasensin (VVZ149); TRPV modulators, such as CA008, CMX-020, NEO6860, FTABS, CNTX4975, MCP101, MDR16523, or MDR652; EGR1 inhibitors, such as Brigoglide (AYX1); NGF inhibitors, such as tanizumab, fasinumab, ASP6294, or MEDI7352; Mu opioid agonists, such as cibapadol or NKTR181 (oxycodegol); CB-1 agonists, such as NEO1940 (AZN1940); imidazoline 12 agonists, such as CR4056; or p75NTR-Fc modulators, such as LEVI-04.

[0822] In another implementation, the other therapeutic agent is oliceridine or ropivacaine (TLC590).

[0823] In another embodiment, the other therapeutic agent is Na. V 1.7 Blockers, such as ST-2427, and therapeutic agents disclosed in WO2010129864, WO2015157559, WO2017059385, WO2018183781, WO2018183782 and WO2020072835, the entire contents of each of which are incorporated herein by reference.

[0824] In another embodiment, other therapeutic agents are ASP18071, CC-8464, ANP-230, ANP-231, NOC-100, NTX-1175, ASN008, NW3509, AM-6120, AM-8145, AM-0422, BL-017881, NTM-006, and Opiran serin (Unafra). TM ), Brivoligide, SR419, NRD.E1, LX9211, LY3016859, ISC-17536, NFX-88, LAT-8881, AP-235, NYX 2925, CNTX-6016, S-600918, S-637880, RQ-00434739, KLS-2031, ME DI 7352 or XT-150.

[0825] In another embodiment, the other therapeutic agent is a sodium channel inhibitor (also known as a sodium channel blocker), such as the sodium channel identified above. V 1.7 and Na V 1.8 Blockers.

[0826] The amount of other therapeutic agents present in the compositions of the present invention may not exceed the amount typically applied in a composition containing said therapeutic agent as the sole active agent. The amount of other therapeutic agents in the compositions disclosed in the present invention may range from about 10% to 100% of the amount typically present in a composition containing said agent as the sole active agent.

[0827] The compounds and salts of the present invention, or pharmaceutically acceptable compositions thereof, may also be incorporated into compositions for coating implantable medical devices, such as prostheses, artificial valves, vascular grafts, endovascular stents, and catheters. Thus, in one aspect, the present invention includes a composition for coating an implantable device comprising a compound or salt of the present invention as generally described above and in the categories and subclasses herein, and a carrier suitable for coating said implantable device. In yet another aspect, the present invention includes an implantable device coated with a composition comprising a compound or salt of the present invention as generally described above and in the categories and subclasses herein, and a carrier suitable for coating said implantable device. General methods of preparing suitable coatings and coated implantable devices are described in U.S. Patents 6,099,562, 5,886,026, and 5,304,121. Coatings are typically biocompatible polymeric materials, such as hydrogel polymers, polymethyldisiloxane, polycaprolactone, polyethylene glycol, polylactic acid, ethylene vinyl acetate, and mixtures thereof. The coating may optionally be further covered by an outer coating of a suitable fluorosiloxane, polysaccharide, polyethylene glycol, phospholipid, or combination thereof, thereby imparting controlled release characteristics to the composition.

[0828] Another aspect of the present invention relates to inhibiting Na in biological samples or subjects. V 1.8 Activity, the method comprising administering to a subject a compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, or contacting the biological sample with a compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. As used herein, the term “biological sample” includes (but is not limited to) cell cultures or extracts thereof; biopsy material obtained from mammals or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other bodily fluids or extracts thereof.

[0829] Na in biological samples V 1.8 Inhibition of activity can be used for a variety of purposes known to those skilled in the art. Examples of such purposes include (but are not limited to) the study of sodium channels in biological and pathological phenomena; and the comparative evaluation of novel sodium channel inhibitors.

[0830] Synthesis of the compounds of the present invention

[0831] The compounds of this invention can be prepared from known materials by the methods described in the examples, other similar methods, and other methods known to those skilled in the art. As will be understood by those skilled in the art, the functional groups of the intermediate compounds may need to be protected by suitable protecting groups. Protecting groups can be added or removed according to standard techniques well known to those skilled in the art. The use of protecting groups is described in detail in TGMWuts et al., Greene's Protective Groups in Organic Synthesis (4th edition, 2006).

[0832] Radiolabeled analogues of the compounds of the present invention

[0833] In another aspect, the present invention relates to radiolabeled analogues of the compounds of the present invention. As used herein, the term "radiolabeled analogue of the compounds of the present invention" refers to a compound (including all embodiments thereof) that is identical to the compounds of the present invention as described herein, except that one or more atoms have been replaced by radioactive isotopes of atoms present in the compounds of the present invention.

[0834] As used herein, the term "radioactive isotope" refers to an isotope of an element that is known to undergo spontaneous radioactive decay. Examples of radioactive isotopes include... 3 H, 14 C 32 P, 35 S, 18 F, 36Cl et al., and isotopes of decay patterns identified in VS Shirley and CM Lederer, Isotopes Project, Nuclear Science Division, Lawrence Berkeley Laboratory, Table of Nuclides (January 1980).

[0835] Radiolabeled analogues can be used in a variety of advantageous ways, including for various types of assays, such as substrate tissue distribution assays. For example, tritium ( 3 H) and / or carbon-14 (H) and / or carbon-14 14 C) Labeled compounds can be used for a variety of assays, such as substrate tissue distribution assays, due to their relatively simple preparation and excellent detectability.

[0836] On the other hand, according to any embodiment described herein with respect to the compounds of the present invention, the present invention relates to pharmaceutically acceptable salts of radiolabeled analogues.

[0837] On the other hand, according to any embodiment described herein with respect to the compounds of the present invention, the present invention relates to pharmaceutical compositions comprising a radiolabeled analogue or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, adjuvant or mediator.

[0838] On the other hand, according to any embodiment described herein with respect to the compounds of the present invention, the present invention relates to methods for inhibiting voltage-gated sodium channels and methods for treating or reducing the severity of various diseases and conditions (including pain) in subjects, comprising administering an effective amount of a radiolabeled analog, a pharmaceutically acceptable salt thereof, and a pharmaceutical composition thereof.

[0839] On the other hand, according to any embodiment described herein with respect to the compounds of the present invention, the present invention relates to radiolabeled analogues for use, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof.

[0840] On the other hand, according to any embodiment described herein with respect to the compounds of the present invention, the present invention relates to the use of radiolabeled analogues or pharmaceutically acceptable salts thereof and pharmaceutical compositions thereof for the manufacture of pharmaceuticals.

[0841] On the other hand, according to any embodiment described herein with respect to the compounds of the present invention, radiolabeled analogs, their pharmaceutically acceptable salts, and their pharmaceutical compositions may be used in combination therapy.

[0842] Example

[0843] General method. Obtained in solution form in a suitable deuterated solvent (such as dimethyl sulfoxide-d6 (DMSO-d6)). 1 1H NMR (400MHz) spectrum.

[0844] Analytical supercritical fluid chromatography (SFC) separation of various heterogeneous mixtures was achieved using the Waters UPC2-SFC instrument, which includes a phase manager, sample manager, binary solvent manager, column manager-30S, PDA detector, isocratic solvent manager, and QDa detector. The columns used were manufactured by Regis Technologies (e.g., R'RWhelk 0-1, 3.5 μm particle size, 5.0 cm × 3.0 mm dimensions), with the mobile phase consisting of solvent A: liquid CO2 (58-60 bar / 40 °C) and solvent B: HPLC-grade methanol containing 20 mM NH3, at a flow rate of 2 ml / min and an injection volume of 2 μl. Gradients: A:B at 0 min (95:5), A:B at 3.5 min (50:50), A:B at 3.55 min (40:60), A:B at 3.95 min (40:60), and A:B at 4.0 min (95:5). Samples for analytical SFC were dissolved in methanol at a concentration of approximately 0.5 mg / mL.

[0845] Preparative SFC uses the same stationary and mobile phases as described above for analytical SFC, but employs different instruments and gradient methods to purify the samples. Preparative SFC separation of various isomeric mixtures is achieved using a Waters Prep-100 SFC instrument, which includes a back pressure regulator, a 2767 sample manager, a 2545 quaternary gradient module, a column oven, a 2998 PDA detector, an isocratic solvent manager, a P-200 CO2 pump, an SFC splitter-100, three heat exchangers, a Series III LC pump, and a QDa detector. The columns used included those manufactured by Regis Technologies (e.g., R'R Whelk 0-1, 5.0 μm particle size, 25.0 cm × 21.1 mm dimensions), with the mobile phase consisting of solvent A: liquid CO2 (58-60 bar / 40 °C) and solvent B: HPLC-grade methanol containing 20 mM NH3. The flow rate was 100 mL / min and the injection volume was 500 μl (50 mg crude substance loading). A 2:1 ratio of methanol and dichloroethane was used for compatibilization of the crude compound and SFC injection. For the 500 μl / 50 mg loading, the following methods were used: isocratic: (80:20) A:B from 0 min to 7.6 min, gradient: (75:25) A:B from 8.1 min, isocratic: (75:25) (A:B) from 8.2 to 10.6 min, gradient: (80:20) A:B from 10.7 min, and isocratic: (80:20) (A:B) from 11 min. For the 1500 μl / 150 mg loading, the following methods were used: isocratic: (80:20) A:B from 0 min to 7.5 min, gradient: (75:25) A:B from 7.6 min, gradient: (60:40) A:B from 8.1 min, isocratic: (60:40) A:B from 8.7 min to 10.6 min, gradient: (80:20) A:B from 10.7 min, and isocratic: (80:20) A:B from 12 min.

[0846] LC / MS Method: LC / MS analysis was performed using a Waters Acquity UPLC BEH C8 column (50 × 2.1 mm, 1.7 μm particles) (pn: 186002877) with a guard column (pn: 186003978) and a dual gradient run from 2% to 98% mobile phase B over 4.45 min. Mobile phase A = H₂O (10 mM ammonium formate containing 0.05% ammonium hydroxide). Mobile phase B = acetonitrile. Flow rate = 0.6 mL / min, injection volume = 2 μL, and column temperature = 45 °C.

[0847] X-ray powder diffraction (XRPD) analysis was performed at room temperature in transmission mode using a PANalytical Empyrean system (Malvern PANalytical Inc., Westborough, Massachusetts) equipped with a sealed tube source and a PIXcel 1D Medipix-3 detector. Analysis was conducted via copper radiation. The X-ray generator was operated at 45 kV and 40 mA. The powder sample was placed on a 96-well sample holder with a Mylar film and loaded into the instrument. The sample was scanned in a range of approximately 3° to approximately 40°2θ at a step size of 0.0131303° and a step size of 49 seconds.

[0848] Solid-state NMR analysis was performed using a Bruker-Biospin 400MHz wide-aperture spectrometer equipped with a Bruker-Biospin 4mm HFX probe. The sample was encapsulated in a 4mm ZrO2 rotor and rotated under magic angle rotation (MAS) conditions, with the rotation speed typically set to 12.5 kHz. 1 The HMAS T1 saturated recovery relaxation experiment was used to measure proton relaxation time in order to establish... 13 Appropriate cyclic delay for C-cross polarization (CP) MAS experiments. 19 The FMAS T1 saturated recovery relaxation experiment was used to measure the fluorine relaxation time in order to establish... 19 Appropriate cycling delay was applied to the F MAS experiment. The CP contact time for the carbon CPMAS experiment was set to 2 ms. A CP proton pulse with a linear slope (50% to 100%) was used. Carbon Hartmann-Hahn matching was optimized for an external reference sample (glycine). Carbon and fluorine spectra were recorded using a TPPM15 decoupled sequence (with a field intensity of approximately 100 kHz) under proton decoupling.

[0849] Thermogravimetric analysis (TGA) data were collected using a TA Discovery thermogravimetric analyzer or equivalent instrument. Samples weighing approximately 1–5 mg were scanned from 25 °C to 350 °C at a heating rate of 10 °C / min. Data were collected using Thermal Advantage QSeries™ software and analyzed using Trios and / or Universal Analysis software (TA Instruments, New Castle, DE).

[0850] Acquire differential scanning calorimetry (DSC) data using a TA Instruments Q2000 or equivalent instrument. Weigh a sample weighing between 1 and 10 mg into an aluminum crucible. Place this crucible in the sample position within the calorimeter unit. Place an empty crucible in the reference position. Seal the calorimeter unit and allow a nitrogen flow through it. Set the heating program to heat the sample to 300 °C at a heating rate of 10 °C / min. Upon completion of the run, analyze the data using Trios and / or UniversalAnalysis software (TA Instruments, New Castle, DE).

[0851] Infrared (IR) spectra were collected using a Thermo Scientific Nicolet iS50 spectrometer equipped with a diamond ATR sampling accessory.

[0852] Equipped with Cu K α radiation X-ray diffraction data were acquired using a Bruker diffractometer with a CCD detector. The structure was analyzed and improved using the SHELX program (Sheldrick, GM, Acta Cryst., (2008) A64, 112-122).

[0853] abbreviation

[0854] Unless otherwise stated or indicated by the context, the following abbreviations shall be understood to have the following meanings:

[0855] abbreviation meaning

[0856] NMR (Nuclear Magnetic Resonance)

[0857] ESI-MS Electro-injection mass spectrometry analysis

[0858] LC / MS (Liquid Chromatography-Mass Spectrometry)

[0859] UPLC (Ultra-High Performance Liquid Chromatography)

[0860] HPLC / MS / MS High Performance Liquid Chromatography / Combined Mass Spectrometry Analysis

[0861] IS Internal Standard

[0862] HPLC (High Performance Liquid Chromatography)

[0863] SFC Supercritical Fluid Chromatography

[0864] MDAP quality-guided automated purification

[0865] ESI Electrospray Ionization

[0866] LED Light Emitting Diode

[0867] g gram

[0868] mg

[0869] L rise

[0870] mL

[0871] μL

[0872] nL nanoliter

[0873] mmol millimole

[0874] hr, h hours

[0875] min minutes

[0876] ms (milliseconds)

[0877] mm

[0878] μm micrometer

[0879] nm nanometer

[0880] MHz

[0881] Hz Hertz

[0882] N equivalent (concentration)

[0883] M moles (concentration)

[0884] mM (millimolecular concentration)

[0885] μM (micromolar concentration)

[0886] ppm (parts per million)

[0887] % w / v weight-volume concentration

[0888] ArBPin 2-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,4,5,5-tetra-

[0889] Methyl-1,3,2-dioxoboronyl pentane

[0890] t-BuOH tert-butanol

[0891] DAST Diethylaminosulfonium trifluoride

[0892] DCM dichloromethane

[0893] DCE dichloroethane

[0894] DIEA, DIPEA N,N-diisopropylethylamine

[0895] DMA N,N-dimethylacetamide

[0896] DMF N,N-dimethylformamide

[0897] DMSO (dimethyl sulfoxide)

[0898] DRG dorsal root ganglion

[0899] EtOH (ethanol)

[0900] EtOAc (ethyl acetate)

[0901] HATU 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazole

[0902] [4,5-b]pyronin 3-oxide hexafluorophosphate

[0903] EDCI 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide

[0904] amine

[0905] T3P is propylphosphonic anhydride, namely, 2,4,6-tripropyl-1,3,5,2,4,6-

[0906] Trioxane 2,4,6-trioxide

[0907] TCFH N,N,N',N'-Tetramethylchloromethylammonium hexafluorophosphate

[0908] MeOH (methanol)

[0909] MTBE (methyl tert-butyl ether)

[0910] NMP N-methylpyrrolidone

[0911] THF Tetrahydrofuran

[0912] TEA Triethylamine

[0913] RB round-bottom (flask)

[0914] RT room temperature

[0915] ca. approximately (about)

[0916] E-VIPR Electrically Stimulated Voltage Ion Probe Reader

[0917] HEK human embryonic kidney

[0918] KIR2.1 Inwardly Rectifying Potassium Ion Channel 2.1

[0919] DMEM (Dalberg-modified Eagle's medium)

[0920] (Dulbecco's Modified Eagle's Medium)

[0921] FBS Fetal Bovine Serum

[0922] NEAA (Non-essential amino acids)

[0923] HEPES 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid

[0924] DiSBAC6(3) bis(1,3-dihexyl-thiobarbituric acid)tetramethyl

[0925] Oxylenol

[0926] CC2-DMPE Chlorocoumarin-2-Dimyristoylphosphatidylethanolamine

[0927] VABSC-1 voltage measurement background suppression compound

[0928] HS human serum

[0929] BSA (Bovine Serum Albumin)

[0930] Example 1

[0931] rel-(2S,3R,4R,5S)-4-[[3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide (1) and rel-(2R,3S,4S,5R)-4-[[3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide (2)

[0932]

[0933] Step 1:

[0934] A mixture of ethyl rac-(2S,3R)-2,3-dimethyl-2-(trifluoromethyl)-4-(trifluoromethylsulfonyloxy)-3H-furan-5-carboxylate (3.0 g, 7.77 mmol), 2-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxoboropentane (“ArBPin”, 2.33 g, 8.09 mmol), Pd(PPh3)4 (380 mg, 0.33 mmol), and sodium carbonate (16 mL, 2 M, 32.00 mmol) in dioxane (60 mL) was heated at 100 °C for 1 hour. The solution was diluted with EtOAc and water, the layers were separated, and the organic layer was washed with brine, dried (MgSO4), filtered, and concentrated under vacuum. Purification by rapid chromatography (220 g SiO2, 0 to 30% EtOAc / petroleum ether) yielded ethyl rac-(2S,3R)-4-[2-(difluoromethoxy)-4-fluoro-phenyl]-2,3-dimethyl-2-(trifluoromethyl)-3H-furan-5-carboxylic acid (2.0 g, 65%). 1 ¹H NMR (500MHz, chloroform-d) δ 7.19 (dd, J = 8.5, 6.4Hz, 1H), 6.99–6.89 (m, 2H), 6.44 (t, J = 73.3Hz, 1H), 4.14 (qd, J = 7.1, 1.7Hz, 2H), 3.45 (q, J = 7.4Hz, 1H), 1.72–1.65 (m, 3H), 1.14 (t, J = 7.1Hz, 3H), 1.12–1.08 (m, 3H) ppm. ESI-MS m / z calculated value 398.09528, experimental value 399.0 (M+1). + .

[0935] Step 2:

[0936] Magnesium shavings (3.5 g, 144.0 mmol) were ground in a mortar and added to a solution of ethyl rac-(2S,3R)-4-[2-(difluoromethoxy)-4-fluoro-phenyl]-2,3-dimethyl-2-(trifluoromethyl)-3H-furan-5-carboxylic acid (2.0 g, 5.02 mmol) in MeOH (60 mL). The flask was purged with nitrogen and the reaction was stirred at ambient temperature until exothermic termination was observed (30 min). The reaction was then heated at 90 °C for 3 h, followed by cooling to 0 °C and quenching, and acidification by careful addition of 2 M HCl. The mixture was concentrated under vacuum and extracted with DCM (3 × 100 mL). The combined organic layers were dried (MgSO4), filtered, and concentrated under vacuum to give methyl rac-(3R,4R,5S)-3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid (1.7 g, 88%), which was a mixture of epimers adjacent to the ester (preliminary stereochemical partitioning). ESI-MS m / z calculated value 386.09528, experimental value 387.0 (M+1). + .

[0937] Step 3:

[0938] KOt-Bu (4.25 g, 37.87 mmol) was added to a solution of rac-(3R,4R,5S)-3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid methyl ester (3.2 g, 8.28 mmol) in t-BuOH (80 mL). The reaction was stirred overnight at ambient temperature, then quenched by adding saturated aqueous NH4Cl solution and diluted with EtOAc. The aqueous layer was separated and extracted with EtOAc, and the combined organic layer was dried (MgSO4), filtered, and concentrated under vacuum. The residue was dissolved in EtOH (20 mL) and LiOH (15 mL, 2 M, 30.00 mmol) and the mixture was stirred at 110 °C for 1 hour. The reaction was quenched by adding saturated aqueous NH4Cl solution and diluted with EtOAc. The aqueous layer was separated and extracted with EtOAc, and the combined organic layer was dried (MgSO4), filtered, and concentrated under vacuum. Purification by rapid chromatography (80 g SiO2, 0 to 100% EtOAc / heptane) yielded rac-(3R,4R,5S)-3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid (2.2 g, 71%), presenting as a mixture of epimers adjacent to the ester (stereochemical partitioning assay). ESI-MS calculated m / z 372.07962, experimental 371.2 (M⁻¹). - .

[0939] Step 4:

[0940] DMF (50 μL, 0.65 mmol) and oxaloyl chloride (400 μL, 4.59 mmol) were added to a solution of rac-(3R,4R,5S)-3-[2-(difluoromethoxy)-4-fluorophenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid (650 mg, 1.75 mmol) in DCM (24 mL) under stirring at 0 °C. The reaction was allowed to proceed to ambient temperature over 30 minutes and then concentrated under vacuum. The residue was dried under high vacuum for 5 minutes to obtain a white foam, which was dissolved in DCM (24 mL) and added dropwise at 0 °C to a solution of methyl 4-aminopyridine-2-carboxylic acid (305 mg, 2.01 mmol) and NEt3 (800 μL, 5.74 mmol) in DCM (9 mL) under stirring. The reaction was heated to ambient temperature over 4 hours, then quenched by the addition of MeOH (2 mL) and concentrated under vacuum. Purification by rapid chromatography (12 g SiO2, 0 to 70% EtOAc / heptane, loaded in DCM) yielded methyl rac-(3R,4R,5S)-4-[[3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxylic acid (840 mg, 95%) as a mixture of 85:15 epimers adjacent to the amide (stereochemical partitioning assay). ESI-MS m / z calculated value 506.12766, experimental value 507.9 (M+1). + .

[0941] Step 5:

[0942] A solution of methyl rac-(3R,4R,5S)-4-[[3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxylic acid (740 mg, 1.46 mmol) in methanol-ammonia (15 mL, 7 M, 105.0 mmol) was concentrated under vacuum to give rac-(3R,4R,5S)-4-[[3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide (700 mg, 98%) as a mixture of epimers at positions adjacent to the amide (stereochemical partitioning assay). ESI-MS calculated m / z value: 491.12796; experimental value: 491.7 (M+1) + .

[0943] Step 6:

[0944] rac-(3R,4R,5S)-4-[[3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide (400 mg, 0.81 mmol) was purified by chiral SFC using a Daicel Chiralpak IC column, 5 μm particle size, 25 cm × 20 mm, to obtain:

[0945] First eluted isomer (rt = 3.40 min): rel-(2S,3R,4R,5S)-4-[[3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide (1, 150 mg, 74%) (stereochemical partitioning assay). 1 H NMR (500MHz, methanol-d4) δ8.48(d,J=5.5Hz,1H),8.25(d,J=2.2Hz,1H),7.90(dd,J=5.5,2.2Hz,1H),7.49(dd,J=9.0,6.3Hz,1H),7.01(dd,J=9.0,6.7Hz ,2H),7.14-6.74(m,1H),5.14(d,J=10.3Hz,1H),4.33(dd,J=10.3,7.9Hz ,1H),2.83(p,J=7.6Hz,1H),1.66(s,3H),0.83(dd,J=7.7,2.3Hz,3H)ppm. ESI-MS calculated m / z value: 491.12796; experimental value: 492.2 (M+1) + 490.3 (M-1) - .

[0946] Second eluting isomer (rt = 4.28 min): The second eluting isomer was further purified by reversed-phase preparative HPLC (alkaline eluent) to obtain rel-(2R,3S,4S,5R)-4-[[3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide (2, 100 mg, 50%) (stereochemical partition assay). 1H NMR (500MHz, methanol-d4) δ8.49(d,J=5.5Hz,1H),8.27-8.23(m,1H),7.90(dd,J=5.5,2.2Hz,1H),7.49(dd,J=9.1,6.4Hz,1H),7.06-6.99(m,2H),7.16 -6.69(m,1H),5.14(d,J=10.3Hz,1H),4.33(dd,J=10.3,7.9Hz,1H),2.83(p,J=7.6Hz,1H),1.66(d,J=1.3Hz,3H),0.83(dd,J=7.6,2.3Hz,3H)ppm. ESI-MS calculated m / z value: 491.12796; experimental value: 492.1 (M+1) + .

[0947] The following compounds were prepared using a method similar to that described in Example 1, but without performing SFC separation step 6 at the end of the synthesis, and were separated as racemates:

[0948]

[0949]

[0950] The following compound was prepared using a method similar to that described in Example 1, but in step 5, methylamine was used at 40°C. The conditions for epimerization / hydrolysis step 3 followed those described in step 5 of Example 11. Purification in step 6 was performed by chiral SFC using a Chiralpak AS-H column from Daicel, 5 μm particle size, 25 cm × 10 mm, on a Minigram SFC instrument from Berger Instruments.

[0951]

[0952] The following compounds were prepared using a method similar to that described in Example 1, except that 5-amino-2-fluorobenzamide was used as the coupling partner in step 4 and step 5 was omitted. The conditions for epimerization / hydrolysis step 3 followed those described in step 5 of Example 11. Purification in step 6 was performed by chiral SFC using a Chiralpak AS-H column from Daicel, 5 μm particle size, 25 cm × 10 mm, on a Minigram SFC instrument from Berger Instruments.

[0953]

[0954] The following compounds were prepared using a method similar to that described in Example 1, but with magnesium activated by catalytic 1,2-dibromoethane in step 2, and without separation of the racemic compound by chiral SFC in step 6:

[0955]

[0956]

[0957] The following compound was prepared using a method similar to that described in Example 1, but with magnesium activated by catalytic 1,2-dibromoethane in step 2 and without the addition of LiOH / EtOH in step 3. Purification in step 6 was performed by SFC on a Waters Corp. SFC 100 instrument using a DEAP column from Princeton Chromatography Inc., 5 μm particle size, 25 cm × 21.2 mm, followed by chiral SFC on a Berger Instruments Minigram SFC instrument using a Daicel Chiralpak AS-H column, 5 μm particle size, 25 cm × 10 mm. Compound 3a was further purified by chiral SFC on a Berger Instruments Minigram SFC instrument using a Daicel Chiralpak OD-H column, 5 μm particle size, 25 cm × 10 mm. Compounds 38 and 39 were separated by chiral SFC using a (R,R)-Whelk-O1 column from Regis Technologies, with a particle size of 5 μm and a diameter of 25 cm × 21.2 mm.

[0958]

[0959]

[0960]

[0961] The following compounds were prepared using a method similar to that described in Example 1, but with magnesium activated by catalytic 1,2-dibromoethane in step 2 and without the addition of LiOH / EtOH in step 3. Purification in step 6 was performed by SFC on a Minigram SFC instrument from Berger Instruments using a LuxCellulose-2 column from Phenomenex (5 μm particle size, 25 cm × 10 mm) on an SFC 100 instrument from Waters Corp.:

[0962]

[0963] The following compounds were prepared using a method similar to that described in Example 1, but without the addition of LiOH / EtOH in step 3. Amide coupling step 4 was performed using T3P instead of oxaloyl chloride as the activator. Purification in step 6 was carried out via SFC on a Minigram SFC instrument from Berger Instruments and an SFC 100 instrument from Waters Corp. using a Luxi-Cellulose-5 column from Phenomenex, 5 μm particle size, 25 cm × 10 mm.

[0964]

[0965] Except for the use of methylamine instead of ammonia in step 5, the following compounds were prepared using a method similar to that described in Example 1. In step 6, purification was performed by chiral SFC using a Chiralpak AS-H column from Daicel (5 μm particle size, 25 cm × 10 mm) on a Minigram SFC instrument from Berger Instruments.

[0966]

[0967]

[0968] Example 2

[0969] rel-(2S,3R,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide (4) and rel-(2R,3S,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide (5)

[0970]

[0971] Step 1:

[0972] Triethylamine (8.05 g, 11.2 mL, 78.8 mmol) was added to a solution of ethyl 2-diazo-3-oxo-butyrate (5.0 g, 31.4 mmol) stirred at 0 °C in DCM (50 mL). TBSOTf (9.24 g, 8.2 mL, 34.3 mmol) was slowly added, and the reaction mixture was stirred at 0 °C for 30 min. The reaction mixture was washed with 30% NaHCO3 solution (200 mL). The organic layer was separated and washed with water (500 mL), then dried over MgSO4. The solvent was evaporated to give ethyl 3-[tert-butyl(dimethyl)silyl]oxy-2-diazo-but-3-enoate (8.22 g, 97%), which was used in the next step without further purification.

[0973] Step 2:

[0974] A solution of 1,1,1-trifluoroprop-2-one (33.8 g, 27 mL, 301.2 mmol) in 150 mL of DCM was stirred at -78 °C, and TiCl4 (56.8 g, 33 mL, 299.2 mmol) was added dropwise. The reaction was maintained at -78 °C for 10 min, and then a solution of ethyl 3-[tert-butyl(dimethyl)silyl]oxy-2-diazo-but-3-enoate (64 g, 236.7 mmol) in 150 mL of DCM was added dropwise. The reaction was maintained at -78 °C for 1 h, and then a saturated NaHCO3 solution was added and the mixture was diluted with DCM. The organic layer was dried over MgSO4, concentrated under vacuum, and the residue was purified by column chromatography (0 to 30% EtOAc / hexane) to give ethyl 2-diazo-6,6,6-trifluoro-5-hydroxy-5-methyl-3-oxo-hexanoate (39 g, 61%) as a pale yellow liquid. 1 ¹H NMR (400MHz, chloroform-d) δ 4.92 (s, 1H), 4.32 (q, J = 7.1Hz, 2H), 3.63 (d, J = 15.5Hz, 1H), 2.84 (d, J = 15.5Hz, 1H), 1.41 (s, 3H), 1.33 (t, J = 7.1Hz, 3H) ppm.

[0975] Step 3:

[0976] Rhodium(II) acetate (643 mg, 1.45 mmol) was loaded into a dried double-necked flask. Toluene (970 mL) was added and the solution was stirred at 100 °C for 10 min. The solution was briefly removed from the oil bath while a solution of ethyl 2-diazo-6,6,6-trifluoro-5-hydroxy-5-methyl-3-oxo-hexanoate (39 g, 145.4 mmol) in toluene (200 mL) was added dropwise, and the reaction was heated under reflux for 1 h. The reaction mixture was filtered through filter paper and the filtrate was concentrated under vacuum to give ethyl 5-methyl-3-oxo-5-(trifluoromethyl)tetrahydrofuran-2-carboxylate (30.89 g, 88%). 1 ¹H NMR (400MHz, chloroform-d) δ 4.68 (s, 1H), 4.35–4.17 (m, 2H), 2.89 (d, J = 18.8, 1H), 2.58 (d, J = 18.8, 1H), 1.70 (s, 3H), 1.30 (t, J = 7.2, Hz, 3H) ppm.

[0977] Step 4:

[0978] At -78 °C, trifluoromethanesulfonic anhydride (6.0 mL, 35.7 mmol) was added dropwise to a solution of 5-methyl-3-oxo-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid ethyl ester (6.5 g, 27.1 mmol) and DIPEA (14 mL, 80.4 mmol) in DCM (150 mL), and the mixture was stirred for 2.5 h. Then, a saturated aqueous solution of NH4Cl (75 mL) was added. The mixture was heated to ambient temperature, the layers were separated, and the aqueous layer was extracted with DCM (2 × 30 mL). The combined organic extracts were dried (MgSO4), filtered, and concentrated under vacuum to give 2-methyl-2-(trifluoromethyl)-4-(trifluoromethylsulfonyloxy)-3H-furan-5-carboxylic acid ethyl ester (10.1 g, 100%), which was used directly in the next reaction.

[0979] Step 5:

[0980] K3PO4 (13 mL, 2 M aqueous solution, 26.0 mmol) was added to a stirred solution of (3,4-difluoro-2-methoxy-phenyl)boronic acid (2.0 g, 10.6 mmol) and ethyl 2-methyl-2-(trifluoromethyl)-4-(trifluoromethylsulfonyloxy)-3H-furan-5-carboxylate (3 g, 7.90 mmol) in toluene (80 mL). The mixture was degassed with N2 for 20 min, followed by the addition of Pd(PPh3)4 (466 mg, 0.40 mmol) and then heated to 100 °C and held for 1 h. The mixture was filtered through a diatomaceous earth mat, the filtrate was diluted with water (50 mL), and the aqueous layer was extracted with EtOAc (50 × 2 mL). The organic layer was dried (MgSO4), filtered, and evaporated. The residue was purified by column chromatography (SiO2, 0-2% EtOAc / hexane) to give ethyl 4-(3,4-difluoro-2-methoxy-phenyl)-2-methyl-2-(trifluoromethyl)-3H-furan-5-carboxylic acid (2.5 g, 85%) as a pale yellow liquid. 1 ¹H NMR (400MHz, chloroform-d) δ 6.87 (pd, J = 8.8, 6.2Hz, 2H), 4.15 (q, J = 7.1Hz, 2H), 3.89 (s, 3H), 3.42 (d, J = 17.4Hz, 1H), 2.93 (d, J = 17.4Hz, 1H), 1.65 (s, 3H), 1.14 (t, J = 7.1Hz, 3H) ppm. ESI-MS m / z calculated value 366.089, experimental value 367.2 (M+1). + .

[0981] Step 6:

[0982] EtOH (200 mL) was added to ethyl 4-(3,4-difluoro-2-methoxy-phenyl)-2-methyl-2-(trifluoromethyl)-3H-furan-5-carboxylate (5.51 g, 15.0 mmol) and Pd / C (10 wt%, 2.2 g, 2.067 mmol). The mixture was degassed and stirred under H2 balloon for 96 h. The catalyst was removed by filtration, the solid was washed with EtOH (50 mL), and the filtrate was concentrated under vacuum. Another portion of Pd / C (10 wt%, 2.2 g, 2.07 mmol) was added to the residue, followed by EtOH (200 mL), and the reaction mixture was stirred under H2 balloon at ambient temperature for 24 h. The catalyst was removed by filtration, the solid was washed with EtOH (50 mL), and the filtrate was concentrated under vacuum. Another portion of Pd / C (10% wt%, 2.2 g, 2.07 mmol) was added to the residue, followed by the addition of EtOH (200 mL) and stirring of the reaction mixture at ambient temperature for 4 days under H2 balloon conditions. The catalyst was removed by filtration, the solid was washed with EtOH (50 mL), and the filtrate was concentrated under vacuum to give ethyl rac-(2S,3S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylate (5.19 g, 94%) as a white solid in a single diastereomeric form. 1 H NMR (500MHz, chloroform-d) δ6.89-6.86(m,1H),6.82-6.77(m,1H),4.93(d,J=8.9Hz,1H),4.23(dt,J=13.0,7.6Hz,1H),4.08(d,J=2 .9Hz,3H),3.85-3.71(m,2H),2.82(t,J=12.5Hz,1H),2.04(dd,J=12.0,6.7Hz,1H),1.53(s,3H),0.94(t,J=7.1Hz,3H)ppm; 19 F NMR (471MHz, chloroform-d) δ -80.15, -136.84 (d, J = 19.4Hz), -154.77 (d, J = 19.6Hz) ppm.

[0983] Step 7:

[0984] Ethyl rac-(2S,3S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid (5.19 g, 14.09 mmol) was dissolved in ethanol (100 mL). Cesium carbonate (7.1 g, 21.8 mmol) was added and the suspension was stirred at 50 °C for 2 hours. The reaction mixture was concentrated under vacuum and the residue was partitioned between 1 M HCl and MTBE. The layers were separated and the aqueous layer was extracted twice with MTBE. The combined organic extracts were dried (MgSO4), filtered, and concentrated under vacuum to give rac-(2R,3S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid (5.11 g, 96%) as a colorless oil in a single diastereomeric form. 1 ¹H NMR (500MHz, chloroform-d) δ 6.99–6.96 (m, 1H), 6.92–6.87 (m, 1H), 4.68 (d, J = 10.5 Hz, 1H), 4.00 (d, J = 2.7 Hz, 3H), 3.90 (ddd, J = 12.0, 10.6, 8.2 Hz, 1H), 2.58 (t, J = 12.5 Hz, 1H), 2.31 (dd, J = 13.0, 8.2 Hz, 1H), 1.60 (s, 3H) ppm; 19 F NMR (471 MHz, chloroform-d) δ -81.56, -136.40 (d, J = 19.6 Hz), -153.60 (d, J = 19.5 Hz) ppm. ESI-MS m / z calculated value 340.0734, experimental value 339.5 (M⁻¹). - .

[0985] Step 8:

[0986] DMF (5 μL, 0.065 mmol) and oxaloyl chloride (620 μL, 7.11 mmol) were added sequentially to a solution of rac-(2R,3S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid (1.5 g, 4.41 mmol) in DCM (30 mL) cooled to -10 °C. The reaction mixture was stirred for 4 h, then heated to ambient temperature, and oxaloyl chloride (300 μL, 3.55 mmol) was added. The reaction mixture was stirred for another hour and then concentrated under vacuum. The residue was dissolved in DCM (30 mL) and the solution was cooled in an ice bath. TEA (600 μL, 4.31 mmol) and methyl 4-aminopyridine-2-carboxylic acid (663.7 mg, 4.36 mmol) were added sequentially, and the mixture was stirred for 30 min, then quenched with MeOH and concentrated under vacuum. Purification by rapid chromatography (40 g SiO2, 0 to 60% ethyl acetate / heptane, loaded in DCM) yielded methyl rac-(2R,3S,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxylic acid (827.6 mg, 74%). 1 ¹H NMR (500MHz, chloroform-d) δ 8.63 (d, J = 5.5Hz, 1H), 8.46 (s, 1H), 8.07 (d, J = 2.1Hz, 1H), 7.94 (dd, J = 5.5, 2.2Hz, 1H), 7.00 (ddd, J = 8.0, 5.5, 2.1Hz, 1H), 6.90 (td, J = 9.1, 7.3Hz) 4.75 (d, J = 10.7 Hz, 1H), 4.01 (s, 3H), 3.99 (d, J = 2.6 Hz, 3H), 3.83 (td, J = 11.4, 8.3 Hz, 1H), 2.61 (t, J = 12.5 Hz, 1H), 2.34 (dd, J = 13.1, 8.2 Hz, 1H), 1.65 (s, 3H) ppm. ESI-MS m / z calculated value: 474.1214, experimental value: 474.7 (M+1). + And 473.2(M-1) - .

[0987] Step 9:

[0988] Methyl rac-(2R,3S,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxylic acid (1.9 g, 4.01 mmol) was dissolved in ammonia methanol (20 mL, 7 M, 140.0 mmol) and stirred overnight at ambient temperature. Ammonia methanol (5 mL, 7 M, 35.0 mmol) was then added and stirred for another 3 hours at ambient temperature. The mixture was then concentrated under vacuum to give rac-(2R,3S,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide (1.94 g, 99%). 1 H NMR (500MHz, methanol-d4) δ8.49 (dd, J=5.5, 0.6Hz, 1H), 8.26 (dd, J=2.2, 0.6Hz, 1H), 7. 88(dd,J=5.5,2.2Hz,1H),7.14(ddd,J=8.3,5.7,2.3Hz,1H),6.99(ddd,J=9.9,8. 9,7.5Hz,1H),4.67(d,J=10.3Hz,1H),4.10-4.01(m,1H),3.92(d,J=2.3Hz,3H),3 .35(s,3H),2.62(t,J=12.4Hz,1H),2.40(dd,J=12.8,8.2Hz,1H),1.63(s,3H)ppm. ESI-MS calculated m / z value: 459.12173; experimental value: 460.2 (M+1) + And 458.3 (M-1) - .

[0989] Step 10:

[0990] Using a (R,R)-Whelk-O1 column from Regis Technologies, 5 μm particle size, 25 cm × 21.2 mm, rac-(2R,3S,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide (1.9 g, 3.89 mmol) by chiral SFC, two single isomers with unknown absolute configurations were obtained:

[0991] First eluted isomer (rt = 5.05 min): rel-(2S,3R,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide (4,724 mg, 38%); ESI-MS m / z calculated 459.12173, experimental 460.2 (M+1) + And 458.3 (M-1) - . 1 H NMR (500MHz, methanol-d4) δ8.36 (d, J = 5.5 Hz, 1H), 8.13 (d, J = 2.1 Hz, 1H), 7.75 (dd, J = 5. 5,2.2Hz,1H),7.00(ddd,J=8.2,5.6,2.2Hz,1H),6.86(td,J=9.3,7.5Hz,1H),4.5 5(d,J=10.3Hz,1H),3.92(ddd,J=12.2,10.4,8.2Hz,1H),3.79(d,J=2.3Hz,3H),3 .22(s,1H),2.49(t,J=12.4Hz,1H),2.27(dd,J=12.8,8.2Hz,1H),1.50(s,3H)ppm.

[0992] Second eluted isomer (rt = 7.36 min): rel-(2R,3S,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide (5,749 mg, 39%); ESI-MS m / z calculated 459.12173, experimental 460.2 (M+1) + And 458.3 (M-1) - . 1 H NMR (500MHz, methanol-d4) δ8.36(d,J=5.5Hz,1H),8.13(d,J=2.2Hz,1H),7.75(dd,J=5. 5,2.2Hz,1H),7.01(ddd,J=8.3,5.6,2.2Hz,1H),6.86(td,J=9.4,7.5Hz,1H),4.5 5(d,J=10.2Hz,1H),3.92(ddd,J=12.0,10.4,8.2Hz,1H),3.79(d,J=2.3Hz,3H),3 .22(s,3H),2.49(t,J=12.4Hz,1H),2.27(dd,J=12.9,8.2Hz,1H),1.50(s,3H)ppm.

[0993] Except for the use of 5-amino-2-fluorobenzamide as a coupling partner in step 8 and the omission of step 9, the following compounds were prepared using a method similar to that described in Example 2:

[0994]

[0995]

[0996] Example 3

[0997] (2S,3R,4R,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide (6) and (2R,3S,4S,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide (7)

[0998]

[0999] Step 1:

[1000] Under nitrogen atmosphere and at 0°C, NEt3 (7.7 mL, 55.2 mmol) was added with stirring to a solution of ethyl 2-diazo-3-oxo-pentanoate (6.69 g, 39.3 mmol) in DCM (80 mL). Trimethylsilane trifluoromethanesulfonate (8.5 mL, 47.0 mmol) was added dropwise over 5 minutes, and the mixture was stirred again at 0°C for 30 minutes. The reaction mixture was diluted with pentane (100 mL), the layers were separated, and the organic phase was washed with ...

Claims

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof, in: X 2a Yes N, N + -O - or CR 2a ; X 4a Yes N, N + -O - or CR 4a ; X 5a Yes N, N + -O - or CR 5a ; X 6a Yes N, N + -O - or CR 6a ; Each R is independently H or C 1 -C 6 alkyl; R 2a , R 4a , R 5a and R 6a are independently H, halogen, C 1 -C 6 Alkyl or C 1 -C 6 Haloalkyl; R 4b1 and R 4b2 Each independently is H, C 1 -C 6 Alkyl, C 3 -C 6 Cycloalkyl or C 1 -C 6 Haloalkyl; R 5b1 and R 5b2 Each independently is H, C 1 -C 6 Alkyl, C 3 -C 6 Cycloalkyl or C 1 -C 6 Haloalkyl; X 3c Is N or CR 3c ; X 4c Is N or CR 4c ; X 5c Is N or CR 5c ; X 6c Is N or CR 6c ; R 2c It is H, OH, halogen, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Alkoxy, C 1 -C 6 Haloalkoxy or -L 1 -L 2 -(C 3 -C 6 Cycloalkyl), wherein the cycloalkyl is optionally substituted by 1-2 halo groups; L 1 is a key or O; L 2 is key or C 1 -C 6 Alkylene; R 3c H, halogen, C 1 -C 6 Alkyl or C 1 -C 6 Haloalkyl; R 4c H, halogen, C 1 -C 6 Alkyl or C 1 -C 6 Haloalkyl; R 5c H, halogen, C 1 -C 6 Alkyl or C 1 -C 6 haloalkyl; and R 6c H, halogen, C 1 -C 6 Alkyl or C 1 -C 6 Haloalkyl; The constraint is X 2a , X 4a , X 5a and X 6a No more than two of them are N or N + -O - ;and The constraint is X 3c , X 4c , X 5c and X 6c No more than one of them is N.

2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, in: X 2a Yes CR 2a ; X 5a Yes CR 5a ; X 6a Yes CR 6a ; R 4b1 and R 4b2 Each independently is H, C 1 -C 6 Alkyl or C 1 -C 6 Haloalkyl; R 5b1 and R 5b2 Each independently is H, C 1 -C 6 Alkyl or C 1 -C 6 Haloalkyl; X 3c Yes CR 3c ; X 4c Yes CR 4c ; X 5c Yes CR 5c ; X 6c Yes CR 6c ;and R 2c It is H, OH, halogen, C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Alkoxy or C 1 -C 6 Halogenated alkoxy.

3. The compound of claim 1 or 2, wherein the compound has formula (IA) or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 or 2, wherein the compound has formula (IB) or a pharmaceutically acceptable salt thereof.

5. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, wherein X 4a Yes CR 4a ; and R 4a is H or a halogen group.

6. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, wherein X 4a It is N.

7. A compound or a pharmaceutically acceptable salt thereof as described in any one of claims 1 to 6, wherein each R is H or CH 3 .

8. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein each R is H.

9. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 8, wherein X 2a Yes CR 2a ; and R 2a is H, halogen or C 1 -C 6 alkyl.

10. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 5, wherein X 2a Yes CR 2a ; and R 2a It's H.

11. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 10, wherein X 5a Yes CR 5a ; and R 5a is H, halogen or C 1 -C 6 alkyl.

12. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 10, wherein X 5a Yes CR 5a ; and R 5a It's H.

13. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 12, wherein X 6a Yes CR 6a ; and R 6a is H, halogen or C 1 -C 6 alkyl.

14. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 12, wherein X 6a Yes CR 6a ; and R 6a It's H.

15. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 14, wherein R 4b1 and R 4b2 Each independently is H, C 1 -C 6 Alkyl or C 3 -C 6 Cycloalkyl.

16. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 14, wherein R 4b1 and R 4b2 Each independently is H or C 1 -C 6 alkyl.

17. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 14, wherein R 4b1 and R 4b2 are each independently H or CH 3 .

18. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 14, wherein R 4b1 It is C 1 -C 6 Alkyl, and R 4b2 It's H.

19. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 14, wherein R 4b1 is H, and R 4b2 It is C 1 -C 6 alkyl.

20. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 14, wherein R 4b1 Yes CH 3 , and R 4b2 It's H.

21. A compound or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 14, wherein R 4b1 is H, and R 4b2 Yes CH 3 .

22. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 21, wherein R 5b1 and R 5b2 Each independently is H, C 1 -C 6 Alkyl or C 1 -C 6 Halogenated alkyl.

23. A compound or a pharmaceutically acceptable salt thereof as described in any one of claims 1 to 21, wherein R 5b1 and R 5b2 Each is independently C 1 -C 6 Alkyl or C 1 -C 6 Halogenated alkyl.

24. A compound or a pharmaceutically acceptable salt thereof as described in any one of claims 1 to 21, wherein R 5b1 and R 5b2 are independently H, CH 3 or CF 3 .

25. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 21, wherein R 5b1 It is C 1 -C 6 Alkyl, and R 5b2 It is C 1 -C 6 Halogenated alkyl.

26. A compound or a pharmaceutically acceptable salt thereof as described in any one of claims 1 to 21, wherein R 5b1 It is C 1 -C 6 haloalkyl, and R 5b2 It is C 1 -C 6 alkyl.

27. A compound or a pharmaceutically acceptable salt thereof as described in any one of claims 1 to 21, wherein R 5b1 Yes CH 3 , and R 5b2 It is CF 3 .

28. A compound or a pharmaceutically acceptable salt thereof as described in any one of claims 1 to 21, wherein R 5b1 It is CF 3 , and R 5b2 Yes CH 3 .

29. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 28, wherein R 2c It is OH, C 1 -C 6 Alkoxy or C 1 -C 6 Halogenated alkoxy.

30. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 29, wherein X 3c Yes CR 3c .

31. The compound of claim 30 or a pharmaceutically acceptable salt thereof, wherein R 3c is H, halogen or C 1 -C 6 alkyl.

32. A compound or a pharmaceutically acceptable salt thereof as described in any one of claims 1 to 31, wherein X 4c Yes CR 4c ; and R 4c is H, halogen or C 1 -C 6 Halogenated alkyl.

33. The compound of claim 32 or a pharmaceutically acceptable salt thereof, wherein R 4c It is a halogen group.

34. A compound or a pharmaceutically acceptable salt thereof as described in any one of claims 1 to 33, wherein X 5c Yes CR 5c ; and R 5c is H or a halogen group.

35. The compound of claim 34 or a pharmaceutically acceptable salt thereof, wherein R 5c It's H.

36. A compound or a pharmaceutically acceptable salt thereof as described in any one of claims 1 to 35, wherein X 6c Yes CR 6c ; and R 6c is H or a halogen group.

37. The compound of claim 36 or a pharmaceutically acceptable salt thereof, wherein R 6c It's H.

38. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is selected from 39. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is selected from (2R,3R,4R,5R)-4-[[3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-N-methyl-pyridine-2-carboxamide, (2R,3R,4R,5S)-4-[[3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-N-methyl-pyridine-2-carboxamide, (2R,3R,4S,5R)-4-[[3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-N-methyl-pyridine-2-carboxamide, (2R,3S,4R,5R)-4-[[3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-N-methyl-pyridine-2-carboxamide, (2S,3R,4R,5R)-4-[[3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-N-methyl-pyridine-2-carboxamide, (2R,3R,4S,5S)-4-[[3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-N-methyl-pyridine-2-carboxamide, (2R,3S,4R,5S)-4-[[3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-N-methyl-pyridine-2-carboxamide, (2S,3R,4R,5S)-4-[[3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-N-methyl-pyridine-2-carboxamide, (2R,3S,4S,5R)-4-[[3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-N-methyl-pyridine-2-carboxamide, (2S,3R,4S,5R)-4-[[3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-N-methyl-pyridine-2-carboxamide, (2S,3S,4R,5R)-4-[[3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-N-methyl-pyridine-2-carboxamide, (2R,3S,4S,5S)-4-[[3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-N-methyl-pyridine-2-carboxamide, (2S,3R,4S,5S)-4-[[3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-N-methyl-pyridine-2-carboxamide, (2S,3S,4R,5S)-4-[[3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-N-methyl-pyridine-2-carboxamide, (2S,3S,4S,5R)-4-[[3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-N-methyl-pyridine-2-carboxamide, (2S,3S,4S,5S)-4-[[3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-N-methyl-pyridine-2-carboxamide, (2R,3R,4R,5R)-N-(3-carbamoyl-4-fluoro-phenyl)-3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2R,3R,4R,5S)-N-(3-carbamoyl-4-fluoro-phenyl)-3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2R,3R,4S,5R)-N-(3-carbamoyl-4-fluoro-phenyl)-3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2R,3S,4R,5R)-N-(3-carbamoyl-4-fluoro-phenyl)-3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2S,3R,4R,5R)-N-(3-carbamoyl-4-fluoro-phenyl)-3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2R,3R,4S,5S)-N-(3-carbamoyl-4-fluoro-phenyl)-3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2R,3S,4R,5S)-N-(3-carbamoyl-4-fluoro-phenyl)-3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2S,3R,4R,5S)-N-(3-carbamoyl-4-fluoro-phenyl)-3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2R,3S,4S,5R)-N-(3-carbamoyl-4-fluoro-phenyl)-3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2S,3R,4S,5R)-N-(3-carbamoyl-4-fluoro-phenyl)-3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2S,3S,4R,5R)-N-(3-carbamoyl-4-fluoro-phenyl)-3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2R,3S,4S,5S)-N-(3-carbamoyl-4-fluoro-phenyl)-3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2S,3R,4S,5S)-N-(3-carbamoyl-4-fluoro-phenyl)-3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2S,3S,4R,5S)-N-(3-carbamoyl-4-fluoro-phenyl)-3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2S,3S,4S,5R)-N-(3-carbamoyl-4-fluoro-phenyl)-3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2S,3S,4S,5S)-N-(3-carbamoyl-4-fluoro-phenyl)-3-[2-(difluoromethoxy)-4-fluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2R,3R,4R,5R)-4-[[3-[2-methoxy-3-(trifluoromethyl)phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4R,5S)-4-[[3-[2-methoxy-3-(trifluoromethyl)phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4S,5R)-4-[[3-[2-methoxy-3-(trifluoromethyl)phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4R,5R)-4-[[3-[2-methoxy-3-(trifluoromethyl)phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4R,5R)-4-[[3-[2-methoxy-3-(trifluoromethyl)phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4S,5S)-4-[[3-[2-methoxy-3-(trifluoromethyl)phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4R,5S)-4-[[3-[2-methoxy-3-(trifluoromethyl)phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4R,5S)-4-[[3-[2-methoxy-3-(trifluoromethyl)phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4S,5R)-4-[[3-[2-methoxy-3-(trifluoromethyl)phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4S,5R)-4-[[3-[2-methoxy-3-(trifluoromethyl)phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4R,5R)-4-[[3-[2-methoxy-3-(trifluoromethyl)phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4S,5S)-4-[[3-[2-methoxy-3-(trifluoromethyl)phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4S,5S)-4-[[3-[2-methoxy-3-(trifluoromethyl)phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4R,5S)-4-[[3-[2-methoxy-3-(trifluoromethyl)phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4S,5R)-4-[[3-[2-methoxy-3-(trifluoromethyl)phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4S,5S)-4-[[3-[2-methoxy-3-(trifluoromethyl)phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4R,5R)-4-[[3-[3-(difluoromethyl)-4-fluoro-2-methoxy-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4R,5S)-4-[[3-[3-(difluoromethyl)-4-fluoro-2-methoxy-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4S,5R)-4-[[3-[3-(difluoromethyl)-4-fluoro-2-methoxy-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4R,5R)-4-[[3-[3-(difluoromethyl)-4-fluoro-2-methoxy-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4R,5R)-4-[[3-[3-(difluoromethyl)-4-fluoro-2-methoxy-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4S,5S)-4-[[3-[3-(difluoromethyl)-4-fluoro-2-methoxy-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4R,5S)-4-[[3-[3-(difluoromethyl)-4-fluoro-2-methoxy-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4R,5S)-4-[[3-[3-(difluoromethyl)-4-fluoro-2-methoxy-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4S,5R)-4-[[3-[3-(difluoromethyl)-4-fluoro-2-methoxy-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4S,5R)-4-[[3-[3-(difluoromethyl)-4-fluoro-2-methoxy-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4R,5R)-4-[[3-[3-(difluoromethyl)-4-fluoro-2-methoxy-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4S,5S)-4-[[3-[3-(difluoromethyl)-4-fluoro-2-methoxy-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4S,5S)-4-[[3-[3-(difluoromethyl)-4-fluoro-2-methoxy-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4R,5S)-4-[[3-[3-(difluoromethyl)-4-fluoro-2-methoxy-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4S,5R)-4-[[3-[3-(difluoromethyl)-4-fluoro-2-methoxy-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4S,5S)-4-[[3-[3-(difluoromethyl)-4-fluoro-2-methoxy-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,5R)-N-(3-carbamoyl-4-fluoro-phenyl)-3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2R,3R,5S)-N-(3-carbamoyl-4-fluoro-phenyl)-3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2R,3S,5R)-N-(3-carbamoyl-4-fluoro-phenyl)-3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2S,3R,5R)-N-(3-carbamoyl-4-fluoro-phenyl)-3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2R,3S,5S)-N-(3-carbamoyl-4-fluoro-phenyl)-3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2S,3R,5S)-N-(3-carbamoyl-4-fluoro-phenyl)-3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2S,3S,5R)-N-(3-carbamoyl-4-fluoro-phenyl)-3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2S,3S,5S)-N-(3-carbamoyl-4-fluoro-phenyl)-3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2R,3R,4R,5R)-N-(3-carbamoylphenyl)-3-[2-(difluoromethoxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2R,3R,4R,5S)-N-(3-carbamoylphenyl)-3-[2-(difluoromethoxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2R,3R,4S,5R)-N-(3-carbamoylphenyl)-3-[2-(difluoromethoxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2R,3S,4R,5R)-N-(3-carbamoylphenyl)-3-[2-(difluoromethoxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2S,3R,4R,5R)-N-(3-carbamoylphenyl)-3-[2-(difluoromethoxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2R,3R,4S,5S)-N-(3-carbamoylphenyl)-3-[2-(difluoromethoxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2R,3S,4R,5S)-N-(3-carbamoylphenyl)-3-[2-(difluoromethoxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2S,3R,4R,5S)-N-(3-carbamoylphenyl)-3-[2-(difluoromethoxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2R,3S,4S,5R)-N-(3-carbamoylphenyl)-3-[2-(difluoromethoxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2S,3R,4S,5R)-N-(3-carbamoylphenyl)-3-[2-(difluoromethoxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2S,3S,4R,5R)-N-(3-carbamoylphenyl)-3-[2-(difluoromethoxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2R,3S,4S,5S)-N-(3-carbamoylphenyl)-3-[2-(difluoromethoxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2S,3R,4S,5S)-N-(3-carbamoylphenyl)-3-[2-(difluoromethoxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2S,3S,4R,5S)-N-(3-carbamoylphenyl)-3-[2-(difluoromethoxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2S,3S,4S,5R)-N-(3-carbamoylphenyl)-3-[2-(difluoromethoxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2S,3S,4S,5S)-N-(3-carbamoylphenyl)-3-[2-(difluoromethoxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2R,3R,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, (2R,3R,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, (2R,3S,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, (2S,3R,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, (2R,3S,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, (2S,3R,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, (2S,3S,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, (2S,3S,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, (2R,3R,4R,5R)-4-[[3-(2-ethoxy-3,4-difluoro-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, (2R,3R,4R,5S)-4-[[3-(2-ethoxy-3,4-difluoro-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, (2R,3R,4S,5R)-4-[[3-(2-ethoxy-3,4-difluoro-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, (2R,3S,4R,5R)-4-[[3-(2-ethoxy-3,4-difluoro-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, (2S,3R,4R,5R)-4-[[3-(2-ethoxy-3,4-difluoro-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, (2R,3R,4S,5S)-4-[[3-(2-ethoxy-3,4-difluoro-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, (2R,3S,4R,5S)-4-[[3-(2-ethoxy-3,4-difluoro-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, (2S,3R,4R,5S)-4-[[3-(2-ethoxy-3,4-difluoro-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, (2R,3S,4S,5R)-4-[[3-(2-ethoxy-3,4-difluoro-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, (2S,3R,4S,5R)-4-[[3-(2-ethoxy-3,4-difluoro-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, (2S,3S,4R,5R)-4-[[3-(2-ethoxy-3,4-difluoro-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, (2R,3S,4S,5S)-4-[[3-(2-ethoxy-3,4-difluoro-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, (2S,3R,4S,5S)-4-[[3-(2-ethoxy-3,4-difluoro-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, (2S,3S,4R,5S)-4-[[3-(2-ethoxy-3,4-difluoro-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, (2S,3S,4S,5R)-4-[[3-(2-ethoxy-3,4-difluoro-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, (2S,3S,4S,5S)-4-[[3-(2-ethoxy-3,4-difluoro-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, 4-[[(2R,3R,4R,5R)-3-[3,4-difluoro-2-(trideuteromethoxy)phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, 4-[[(2R,3R,4R,5S)-3-[3,4-difluoro-2-(trideuteromethoxy)phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, 4-[[(2R,3R,4S,5R)-3-[3,4-difluoro-2-(trideuteromethoxy)phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, 4-[[(2R,3S,4R,5R)-3-[3,4-difluoro-2-(trideuteromethoxy)phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, 4-[[(2S,3R,4R,5R)-3-[3,4-difluoro-2-(trideuteromethoxy)phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, 4-[[(2R,3R,4S,5S)-3-[3,4-difluoro-2-(trideuteromethoxy)phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, 4-[[(2R,3S,4R,5S)-3-[3,4-difluoro-2-(trideuteromethoxy)phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, 4-[[(2S,3R,4R,5S)-3-[3,4-difluoro-2-(trideuteromethoxy)phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, 4-[[(2R,3S,4S,5R)-3-[3,4-difluoro-2-(trideuteromethoxy)phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, 4-[[(2S,3R,4S,5R)-3-[3,4-difluoro-2-(trideuteromethoxy)phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, 4-[[(2S,3S,4R,5R)-3-[3,4-difluoro-2-(trideuteromethoxy)phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, 4-[[(2R,3S,4S,5S)-3-[3,4-difluoro-2-(trideuteriomethoxy)phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, 4-[[(2S,3R,4S,5S)-3-[3,4-difluoro-2-(trideuteromethoxy)phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, 4-[[(2S,3S,4R,5S)-3-[3,4-difluoro-2-(trideuteromethoxy)phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, 4-[[(2S,3S,4S,5R)-3-[3,4-difluoro-2-(trideuteromethoxy)phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, 4-[[(2S,3S,4S,5S)-3-[3,4-difluoro-2-(trideuteromethoxy)phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, 4-[[(2R,3R,4R,5R)-3-(3,4-difluoro-2-hydroxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, 4-[[(2R,3R,4R,5S)-3-(3,4-difluoro-2-hydroxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, 4-[[(2R,3R,4S,5R)-3-(3,4-difluoro-2-hydroxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, 4-[[(2R,3S,4R,5R)-3-(3,4-difluoro-2-hydroxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, 4-[[(2S,3R,4R,5R)-3-(3,4-difluoro-2-hydroxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, 4-[[(2R,3R,4S,5S)-3-(3,4-difluoro-2-hydroxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, 4-[[(2R,3S,4R,5S)-3-(3,4-difluoro-2-hydroxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, 4-[[(2S,3R,4R,5S)-3-(3,4-difluoro-2-hydroxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, 4-[[(2R,3S,4S,5R)-3-(3,4-difluoro-2-hydroxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, 4-[[(2S,3R,4S,5R)-3-(3,4-difluoro-2-hydroxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, 4-[[(2S,3S,4R,5R)-3-(3,4-difluoro-2-hydroxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, 4-[[(2R,3S,4S,5S)-3-(3,4-difluoro-2-hydroxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, 4-[[(2S,3R,4S,5S)-3-(3,4-difluoro-2-hydroxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, 4-[[(2S,3S,4R,5S)-3-(3,4-difluoro-2-hydroxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, 4-[[(2S,3S,4S,5R)-3-(3,4-difluoro-2-hydroxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, 4-[[(2S,3S,4S,5S)-3-(3,4-difluoro-2-hydroxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-1-oxo-pyridin-1-ium-2-carboxamide, (2R,3R,4R,5R)-4-[[3-(3-chloro-4-fluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-N-methyl-pyridine-2-carboxamide, (2R,3R,4R,5S)-4-[[3-(3-chloro-4-fluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-N-methyl-pyridine-2-carboxamide, (2R,3R,4S,5R)-4-[[3-(3-chloro-4-fluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-N-methyl-pyridine-2-carboxamide, (2R,3S,4R,5R)-4-[[3-(3-chloro-4-fluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-N-methyl-pyridine-2-carboxamide, (2S,3R,4R,5R)-4-[[3-(3-chloro-4-fluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-N-methyl-pyridine-2-carboxamide, (2R,3R,4S,5S)-4-[[3-(3-chloro-4-fluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-N-methyl-pyridine-2-carboxamide, (2R,3S,4R,5S)-4-[[3-(3-chloro-4-fluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-N-methyl-pyridine-2-carboxamide, (2S,3R,4R,5S)-4-[[3-(3-chloro-4-fluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-N-methyl-pyridine-2-carboxamide, (2R,3S,4S,5R)-4-[[3-(3-chloro-4-fluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-N-methyl-pyridine-2-carboxamide, (2S,3R,4S,5R)-4-[[3-(3-chloro-4-fluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-N-methyl-pyridine-2-carboxamide, (2S,3S,4R,5R)-4-[[3-(3-chloro-4-fluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-N-methyl-pyridine-2-carboxamide, (2R,3S,4S,5S)-4-[[3-(3-chloro-4-fluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-N-methyl-pyridine-2-carboxamide, (2S,3R,4S,5S)-4-[[3-(3-chloro-4-fluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-N-methyl-pyridine-2-carboxamide, (2S,3S,4R,5S)-4-[[3-(3-chloro-4-fluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-N-methyl-pyridine-2-carboxamide, (2S,3S,4S,5R)-4-[[3-(3-chloro-4-fluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-N-methyl-pyridine-2-carboxamide, (2S,3S,4S,5S)-4-[[3-(3-chloro-4-fluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-N-methyl-pyridine-2-carboxamide, (2R,3R,4R,5R)-4-[[3-(4-fluoro-2-hydroxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4R,5S)-4-[[3-(4-fluoro-2-hydroxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4S,5R)-4-[[3-(4-fluoro-2-hydroxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4R,5R)-4-[[3-(4-fluoro-2-hydroxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4R,5R)-4-[[3-(4-fluoro-2-hydroxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4S,5S)-4-[[3-(4-fluoro-2-hydroxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4R,5S)-4-[[3-(4-fluoro-2-hydroxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4R,5S)-4-[[3-(4-fluoro-2-hydroxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4S,5R)-4-[[3-(4-fluoro-2-hydroxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4S,5R)-4-[[3-(4-fluoro-2-hydroxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4R,5R)-4-[[3-(4-fluoro-2-hydroxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4S,5S)-4-[[3-(4-fluoro-2-hydroxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4S,5S)-4-[[3-(4-fluoro-2-hydroxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4R,5S)-4-[[3-(4-fluoro-2-hydroxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4S,5R)-4-[[3-(4-fluoro-2-hydroxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4S,5S)-4-[[3-(4-fluoro-2-hydroxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-ethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-ethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-ethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-ethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-ethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-ethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-ethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-ethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,5R)-4-[[5-tert-butyl-3-(3,4-difluoro-2-methoxy-phenyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,5S)-4-[[5-tert-butyl-3-(3,4-difluoro-2-methoxy-phenyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,5R)-4-[[5-tert-butyl-3-(3,4-difluoro-2-methoxy-phenyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,5R)-4-[[5-tert-butyl-3-(3,4-difluoro-2-methoxy-phenyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,5S)-4-[[5-tert-butyl-3-(3,4-difluoro-2-methoxy-phenyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,5S)-4-[[5-tert-butyl-3-(3,4-difluoro-2-methoxy-phenyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,5R)-4-[[5-tert-butyl-3-(3,4-difluoro-2-methoxy-phenyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,5S)-4-[[5-tert-butyl-3-(3,4-difluoro-2-methoxy-phenyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,5R)-4-[[3-(4-fluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,5S)-4-[[3-(4-fluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,5R)-4-[[3-(4-fluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,5R)-4-[[3-(4-fluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,5S)-4-[[3-(4-fluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,5S)-4-[[3-(4-fluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,5R)-4-[[3-(4-fluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,5S)-4-[[3-(4-fluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,5R)-4-[[3-(4-fluoro-2-methoxy-3-methyl-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,5S)-4-[[3-(4-fluoro-2-methoxy-3-methyl-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,5R)-4-[[3-(4-fluoro-2-methoxy-3-methyl-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,5R)-4-[[3-(4-fluoro-2-methoxy-3-methyl-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,5S)-4-[[3-(4-fluoro-2-methoxy-3-methyl-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,5S)-4-[[3-(4-fluoro-2-methoxy-3-methyl-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,5R)-4-[[3-(4-fluoro-2-methoxy-3-methyl-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,5S)-4-[[3-(4-fluoro-2-methoxy-3-methyl-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,5R)-4-[[3-[2-(difluoromethoxy)-4-fluoro-phenyl]-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,5S)-4-[[3-[2-(difluoromethoxy)-4-fluoro-phenyl]-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,5R)-4-[[3-[2-(difluoromethoxy)-4-fluoro-phenyl]-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,5R)-4-[[3-[2-(difluoromethoxy)-4-fluoro-phenyl]-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,5S)-4-[[3-[2-(difluoromethoxy)-4-fluoro-phenyl]-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,5S)-4-[[3-[2-(difluoromethoxy)-4-fluoro-phenyl]-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,5R)-4-[[3-[2-(difluoromethoxy)-4-fluoro-phenyl]-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,5S)-4-[[3-[2-(difluoromethoxy)-4-fluoro-phenyl]-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,5R)-4-[[3-(2,4-difluoro-3-methyl-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,5S)-4-[[3-(2,4-difluoro-3-methyl-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,5R)-4-[[3-(2,4-difluoro-3-methyl-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,5R)-4-[[3-(2,4-difluoro-3-methyl-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,5S)-4-[[3-(2,4-difluoro-3-methyl-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,5S)-4-[[3-(2,4-difluoro-3-methyl-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,5R)-4-[[3-(2,4-difluoro-3-methyl-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,5S)-4-[[3-(2,4-difluoro-3-methyl-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,5R)-4-[[3-(3-ethyl-4-fluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,5S)-4-[[3-(3-ethyl-4-fluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,5R)-4-[[3-(3-ethyl-4-fluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,5R)-4-[[3-(3-ethyl-4-fluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,5S)-4-[[3-(3-ethyl-4-fluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,5S)-4-[[3-(3-ethyl-4-fluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,5R)-4-[[3-(3-ethyl-4-fluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,5S)-4-[[3-(3-ethyl-4-fluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,5R)-4-[[3-(2-fluoro-6-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,5S)-4-[[3-(2-fluoro-6-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,5R)-4-[[3-(2-fluoro-6-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,5R)-4-[[3-(2-fluoro-6-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,5S)-4-[[3-(2-fluoro-6-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,5S)-4-[[3-(2-fluoro-6-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,5R)-4-[[3-(2-fluoro-6-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,5S)-4-[[3-(2-fluoro-6-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(2,2,2-trifluoroethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(2,2,2-trifluoroethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(2,2,2-trifluoroethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(2,2,2-trifluoroethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(2,2,2-trifluoroethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(2,2,2-trifluoroethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(2,2,2-trifluoroethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(2,2,2-trifluoroethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,5R)-4-[[5-(1,1-difluoroethyl)-3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,5S)-4-[[5-(1,1-difluoroethyl)-3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,5R)-4-[[5-(1,1-difluoroethyl)-3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,5R)-4-[[5-(1,1-difluoroethyl)-3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,5S)-4-[[5-(1,1-difluoroethyl)-3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,5S)-4-[[5-(1,1-difluoroethyl)-3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,5R)-4-[[5-(1,1-difluoroethyl)-3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,5S)-4-[[5-(1,1-difluoroethyl)-3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4R,5R)-4-[[3-(3,4-difluoro-2-isopropoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4R,5S)-4-[[3-(3,4-difluoro-2-isopropoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4S,5R)-4-[[3-(3,4-difluoro-2-isopropoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4R,5R)-4-[[3-(3,4-difluoro-2-isopropoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4R,5R)-4-[[3-(3,4-difluoro-2-isopropoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4S,5S)-4-[[3-(3,4-difluoro-2-isopropoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4R,5S)-4-[[3-(3,4-difluoro-2-isopropoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4R,5S)-4-[[3-(3,4-difluoro-2-isopropoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4S,5R)-4-[[3-(3,4-difluoro-2-isopropoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4S,5R)-4-[[3-(3,4-difluoro-2-isopropoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4R,5R)-4-[[3-(3,4-difluoro-2-isopropoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4S,5S)-4-[[3-(3,4-difluoro-2-isopropoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4S,5S)-4-[[3-(3,4-difluoro-2-isopropoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4R,5S)-4-[[3-(3,4-difluoro-2-isopropoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4S,5R)-4-[[3-(3,4-difluoro-2-isopropoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4S,5S)-4-[[3-(3,4-difluoro-2-isopropoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4R,5R)-4-[[3-(3,4-difluorophenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4R,5S)-4-[[3-(3,4-difluorophenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4S,5R)-4-[[3-(3,4-difluorophenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4R,5R)-4-[[3-(3,4-difluorophenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4R,5R)-4-[[3-(3,4-difluorophenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4S,5S)-4-[[3-(3,4-difluorophenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4R,5S)-4-[[3-(3,4-difluorophenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4R,5S)-4-[[3-(3,4-difluorophenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4S,5R)-4-[[3-(3,4-difluorophenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4S,5R)-4-[[3-(3,4-difluorophenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4R,5R)-4-[[3-(3,4-difluorophenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4S,5S)-4-[[3-(3,4-difluorophenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4S,5S)-4-[[3-(3,4-difluorophenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4R,5S)-4-[[3-(3,4-difluorophenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4S,5R)-4-[[3-(3,4-difluorophenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4S,5S)-4-[[3-(3,4-difluorophenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4R,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4-ethyl-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4R,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4-ethyl-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4S,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4-ethyl-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4R,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4-ethyl-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4R,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4-ethyl-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4S,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4-ethyl-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4R,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4-ethyl-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4R,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4-ethyl-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4S,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4-ethyl-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4S,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4-ethyl-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4R,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4-ethyl-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4S,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4-ethyl-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4S,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4-ethyl-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4R,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4-ethyl-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4S,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4-ethyl-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4S,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4-ethyl-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4R,5R)-4-[[4-cyclopropyl-3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4R,5S)-4-[[4-cyclopropyl-3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4S,5R)-4-[[4-cyclopropyl-3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4R,5R)-4-[[4-cyclopropyl-3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4R,5R)-4-[[4-cyclopropyl-3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4S,5S)-4-[[4-cyclopropyl-3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4R,5S)-4-[[4-cyclopropyl-3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4R,5S)-4-[[4-cyclopropyl-3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4S,5R)-4-[[4-cyclopropyl-3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4S,5R)-4-[[4-cyclopropyl-3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4R,5R)-4-[[4-cyclopropyl-3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4S,5S)-4-[[4-cyclopropyl-3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4S,5S)-4-[[4-cyclopropyl-3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4R,5S)-4-[[4-cyclopropyl-3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4S,5R)-4-[[4-cyclopropyl-3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4S,5S)-4-[[4-cyclopropyl-3-(3,4-difluoro-2-methoxy-phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4R,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-(difluoromethyl)-4,5-dimethyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4R,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-(difluoromethyl)-4,5-dimethyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4S,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-(difluoromethyl)-4,5-dimethyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4R,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-(difluoromethyl)-4,5-dimethyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4R,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-(difluoromethyl)-4,5-dimethyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4S,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-(difluoromethyl)-4,5-dimethyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4R,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-(difluoromethyl)-4,5-dimethyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4R,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-(difluoromethyl)-4,5-dimethyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4S,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-(difluoromethyl)-4,5-dimethyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4S,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-(difluoromethyl)-4,5-dimethyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4R,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-(difluoromethyl)-4,5-dimethyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4S,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-(difluoromethyl)-4,5-dimethyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4S,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-(difluoromethyl)-4,5-dimethyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4R,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-(difluoromethyl)-4,5-dimethyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4S,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-(difluoromethyl)-4,5-dimethyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4S,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-(difluoromethyl)-4,5-dimethyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5,5-trimethyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5,5-trimethyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5,5-trimethyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5,5-trimethyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5,5-trimethyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5,5-trimethyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5,5-trimethyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5,5-trimethyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4R,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4R,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4S,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4R,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4R,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4S,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4R,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4R,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4S,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4S,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4R,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4S,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4S,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4R,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4S,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4S,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,5S)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,5R)-4-[[3-(4-fluoro-2-methoxy-3-methyl-phenyl)-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,5S)-4-[[3-(4-fluoro-2-methoxy-3-methyl-phenyl)-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,5R)-4-[[3-(4-fluoro-2-methoxy-3-methyl-phenyl)-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,5R)-4-[[3-(4-fluoro-2-methoxy-3-methyl-phenyl)-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,5S)-4-[[3-(4-fluoro-2-methoxy-3-methyl-phenyl)-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,5S)-4-[[3-(4-fluoro-2-methoxy-3-methyl-phenyl)-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,5R)-4-[[3-(4-fluoro-2-methoxy-3-methyl-phenyl)-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,5S)-4-[[3-(4-fluoro-2-methoxy-3-methyl-phenyl)-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-5-isopropyl-4-methyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-5-isopropyl-4-methyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-5-isopropyl-4-methyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-5-isopropyl-4-methyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-5-isopropyl-4-methyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-5-isopropyl-4-methyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-5-isopropyl-4-methyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-5-isopropyl-4-methyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-5-isopropyl-4-methyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-5-isopropyl-4-methyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-5-isopropyl-4-methyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-5-isopropyl-4-methyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-5-isopropyl-4-methyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-5-isopropyl-4-methyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-5-isopropyl-4-methyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-5-isopropyl-4-methyl-tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 6-[[(2R,3R,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 6-[[(2R,3R,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 6-[[(2R,3R,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 6-[[(2R,3S,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 6-[[(2S,3R,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 6-[[(2R,3R,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 6-[[(2R,3S,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 6-[[(2S,3R,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 6-[[(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 6-[[(2S,3R,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 6-[[(2S,3S,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 6-[[(2R,3S,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 6-[[(2S,3R,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 6-[[(2S,3S,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 6-[[(2S,3S,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 6-[[(2S,3S,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 6-[[(2R,3R,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyrazine-2-carboxamide, 6-[[(2R,3R,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyrazine-2-carboxamide, 6-[[(2R,3R,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyrazine-2-carboxamide, 6-[[(2R,3S,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyrazine-2-carboxamide, 6-[[(2S,3R,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyrazine-2-carboxamide, 6-[[(2R,3R,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyrazine-2-carboxamide, 6-[[(2R,3S,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyrazine-2-carboxamide, 6-[[(2S,3R,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyrazine-2-carboxamide, 6-[[(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyrazine-2-carboxamide, 6-[[(2S,3R,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyrazine-2-carboxamide, 6-[[(2S,3S,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyrazine-2-carboxamide, 6-[[(2R,3S,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyrazine-2-carboxamide, 6-[[(2S,3R,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyrazine-2-carboxamide, 6-[[(2S,3S,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyrazine-2-carboxamide, 6-[[(2S,3S,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyrazine-2-carboxamide, 6-[[(2S,3S,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyrazine-2-carboxamide, 5-[[(2R,3R,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-3-carboxamide 5-[[(2R,3R,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-3-carboxamide 5-[[(2R,3R,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-3-carboxamide 5-[[(2R,3S,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-3-carboxamide 5-[[(2S,3R,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-3-carboxamide 5-[[(2R,3R,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-3-carboxamide 5-[[(2R,3S,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-3-carboxamide 5-[[(2S,3R,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-3-carboxamide 5-[[(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-3-carboxamide 5-[[(2S,3R,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-3-carboxamide 5-[[(2S,3S,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-3-carboxamide 5-[[(2R,3S,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-3-carboxamide 5-[[(2S,3R,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-3-carboxamide 5-[[(2S,3S,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-3-carboxamide 5-[[(2S,3S,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-3-carboxamide 5-[[(2S,3S,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-3-carboxamide 4-[[(2R,3R,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-methyl-pyridine-2-carboxamide, 4-[[(2R,3R,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-methyl-pyridine-2-carboxamide, 4-[[(2R,3R,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-methyl-pyridine-2-carboxamide, 4-[[(2R,3S,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-methyl-pyridine-2-carboxamide, 4-[[(2S,3R,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-methyl-pyridine-2-carboxamide, 4-[[(2R,3R,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-methyl-pyridine-2-carboxamide, 4-[[(2R,3S,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-methyl-pyridine-2-carboxamide, 4-[[(2S,3R,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-methyl-pyridine-2-carboxamide, 4-[[(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-methyl-pyridine-2-carboxamide, 4-[[(2S,3R,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-methyl-pyridine-2-carboxamide, 4-[[(2S,3S,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-methyl-pyridine-2-carboxamide, 4-[[(2R,3S,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-methyl-pyridine-2-carboxamide, 4-[[(2S,3R,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-methyl-pyridine-2-carboxamide, 4-[[(2S,3S,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-methyl-pyridine-2-carboxamide, 4-[[(2S,3S,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-methyl-pyridine-2-carboxamide, 4-[[(2S,3S,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-methyl-pyridine-2-carboxamide, 2-[[(2R,3R,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-4-carboxamide, 2-[[(2R,3R,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-4-carboxamide, 2-[[(2R,3R,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-4-carboxamide, 2-[[(2R,3S,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-4-carboxamide, 2-[[(2S,3R,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-4-carboxamide, 2-[[(2R,3R,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-4-carboxamide, 2-[[(2R,3S,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-4-carboxamide, 2-[[(2S,3R,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-4-carboxamide, 2-[[(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-4-carboxamide, 2-[[(2S,3R,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-4-carboxamide, 2-[[(2S,3S,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-4-carboxamide, 2-[[(2R,3S,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-4-carboxamide, 2-[[(2S,3R,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-4-carboxamide, 2-[[(2S,3S,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-4-carboxamide, 2-[[(2S,3S,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-4-carboxamide, 2-[[(2S,3S,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-4-carboxamide, 6-[[(2R,3R,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyrimidine-4-carboxamide, 6-[[(2R,3R,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyrimidine-4-carboxamide, 6-[[(2R,3R,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyrimidine-4-carboxamide, 6-[[(2R,3S,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyrimidine-4-carboxamide, 6-[[(2S,3R,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyrimidine-4-carboxamide, 6-[[(2R,3R,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyrimidine-4-carboxamide, 6-[[(2R,3S,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyrimidine-4-carboxamide, 6-[[(2S,3R,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyrimidine-4-carboxamide, 6-[[(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyrimidine-4-carboxamide, 6-[[(2S,3R,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyrimidine-4-carboxamide, 6-[[(2S,3S,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyrimidine-4-carboxamide, 6-[[(2R,3S,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyrimidine-4-carboxamide, 6-[[(2S,3R,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyrimidine-4-carboxamide, 6-[[(2S,3S,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyrimidine-4-carboxamide, 6-[[(2S,3S,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyrimidine-4-carboxamide, 6-[[(2S,3S,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyrimidine-4-carboxamide, 4-[[(2R,3R,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-fluoro-pyridine-2-carboxamide, 4-[[(2R,3R,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-fluoro-pyridine-2-carboxamide, 4-[[(2R,3R,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-fluoro-pyridine-2-carboxamide, 4-[[(2R,3S,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-fluoro-pyridine-2-carboxamide, 4-[[(2S,3R,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-fluoro-pyridine-2-carboxamide, 4-[[(2R,3R,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-fluoro-pyridine-2-carboxamide, 4-[[(2R,3S,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-fluoro-pyridine-2-carboxamide, 4-[[(2S,3R,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-fluoro-pyridine-2-carboxamide, 4-[[(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-fluoro-pyridine-2-carboxamide, 4-[[(2S,3R,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-fluoro-pyridine-2-carboxamide, 4-[[(2S,3S,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-fluoro-pyridine-2-carboxamide, 4-[[(2R,3S,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-fluoro-pyridine-2-carboxamide, 4-[[(2S,3R,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-fluoro-pyridine-2-carboxamide, 4-[[(2S,3S,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-fluoro-pyridine-2-carboxamide, 4-[[(2S,3S,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-fluoro-pyridine-2-carboxamide, 4-[[(2S,3S,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-fluoro-pyridine-2-carboxamide, (2R,3R,4R,5R)-N-(3-carbamoyl-4-fluoro-phenyl)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2R,3R,4R,5S)-N-(3-carbamoyl-4-fluoro-phenyl)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2R,3R,4S,5R)-N-(3-carbamoyl-4-fluoro-phenyl)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2R,3S,4R,5R)-N-(3-carbamoyl-4-fluoro-phenyl)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2S,3R,4R,5R)-N-(3-carbamoyl-4-fluoro-phenyl)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2R,3R,4S,5S)-N-(3-carbamoyl-4-fluoro-phenyl)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2R,3S,4R,5S)-N-(3-carbamoyl-4-fluoro-phenyl)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2S,3R,4R,5S)-N-(3-carbamoyl-4-fluoro-phenyl)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2R,3S,4S,5R)-N-(3-carbamoyl-4-fluoro-phenyl)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2S,3R,4S,5R)-N-(3-carbamoyl-4-fluoro-phenyl)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2S,3S,4R,5R)-N-(3-carbamoyl-4-fluoro-phenyl)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2R,3S,4S,5S)-N-(3-carbamoyl-4-fluoro-phenyl)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2S,3R,4S,5S)-N-(3-carbamoyl-4-fluoro-phenyl)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2S,3S,4R,5S)-N-(3-carbamoyl-4-fluoro-phenyl)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2S,3S,4S,5R)-N-(3-carbamoyl-4-fluoro-phenyl)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, (2S,3S,4S,5S)-N-(3-carbamoyl-4-fluoro-phenyl)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, 5-deuterium-4-[[(2R,3R,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 5-deuterium-4-[[(2R,3R,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 5-deuterium-4-[[(2R,3R,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 5-deuterium-4-[[(2R,3S,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 5-deuterium-4-[[(2S,3R,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 5-deuterium-4-[[(2R,3R,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 5-deuterium-4-[[(2R,3S,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 5-deuterium-4-[[(2S,3R,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 5-deuterium-4-[[(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 5-deuterium-4-[[(2S,3R,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 5-deuterium-4-[[(2S,3S,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 5-deuterium-4-[[(2R,3S,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 5-deuterium-4-[[(2S,3R,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 5-deuterium-4-[[(2S,3S,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 5-deuterium-4-[[(2S,3S,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 5-deuterium-4-[[(2S,3S,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3R,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-3-fluoro-pyridine-2-carboxamide, 4-[[(2R,3R,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-3-fluoro-pyridine-2-carboxamide, 4-[[(2R,3R,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-3-fluoro-pyridine-2-carboxamide, 4-[[(2R,3S,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-3-fluoro-pyridine-2-carboxamide, 4-[[(2S,3R,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-3-fluoro-pyridine-2-carboxamide, 4-[[(2R,3R,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-3-fluoro-pyridine-2-carboxamide, 4-[[(2R,3S,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-3-fluoro-pyridine-2-carboxamide, 4-[[(2S,3R,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-3-fluoro-pyridine-2-carboxamide, 4-[[(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-3-fluoro-pyridine-2-carboxamide, 4-[[(2S,3R,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-3-fluoro-pyridine-2-carboxamide, 4-[[(2S,3S,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-3-fluoro-pyridine-2-carboxamide, 4-[[(2R,3S,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-3-fluoro-pyridine-2-carboxamide, 4-[[(2S,3R,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-3-fluoro-pyridine-2-carboxamide, 4-[[(2S,3S,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-3-fluoro-pyridine-2-carboxamide, 4-[[(2S,3S,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-3-fluoro-pyridine-2-carboxamide, 4-[[(2S,3S,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-3-fluoro-pyridine-2-carboxamide, 4-[[(2R,3R,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-6-fluoro-pyridine-2-carboxamide, 4-[[(2R,3R,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-6-fluoro-pyridine-2-carboxamide, 4-[[(2R,3R,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-6-fluoro-pyridine-2-carboxamide, 4-[[(2R,3S,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-6-fluoro-pyridine-2-carboxamide, 4-[[(2S,3R,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-6-fluoro-pyridine-2-carboxamide, 4-[[(2R,3R,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-6-fluoro-pyridine-2-carboxamide, 4-[[(2R,3S,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-6-fluoro-pyridine-2-carboxamide, 4-[[(2S,3R,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-6-fluoro-pyridine-2-carboxamide, 4-[[(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-6-fluoro-pyridine-2-carboxamide, 4-[[(2S,3R,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-6-fluoro-pyridine-2-carboxamide, 4-[[(2S,3S,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-6-fluoro-pyridine-2-carboxamide, 4-[[(2R,3S,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-6-fluoro-pyridine-2-carboxamide, 4-[[(2S,3R,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-6-fluoro-pyridine-2-carboxamide, 4-[[(2S,3S,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-6-fluoro-pyridine-2-carboxamide, 4-[[(2S,3S,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-6-fluoro-pyridine-2-carboxamide, 4-[[(2S,3S,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-6-fluoro-pyridine-2-carboxamide, 4-[[(2R,3R,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-6-methyl-pyridine-2-carboxamide, 4-[[(2R,3R,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-6-methyl-pyridine-2-carboxamide, 4-[[(2R,3R,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-6-methyl-pyridine-2-carboxamide, 4-[[(2R,3S,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-6-methyl-pyridine-2-carboxamide, 4-[[(2S,3R,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-6-methyl-pyridine-2-carboxamide, 4-[[(2R,3R,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-6-methyl-pyridine-2-carboxamide, 4-[[(2R,3S,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-6-methyl-pyridine-2-carboxamide, 4-[[(2S,3R,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-6-methyl-pyridine-2-carboxamide, 4-[[(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-6-methyl-pyridine-2-carboxamide, 4-[[(2S,3R,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-6-methyl-pyridine-2-carboxamide, 4-[[(2S,3S,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-6-methyl-pyridine-2-carboxamide, 4-[[(2R,3S,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-6-methyl-pyridine-2-carboxamide, 4-[[(2S,3R,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-6-methyl-pyridine-2-carboxamide, 4-[[(2S,3S,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-6-methyl-pyridine-2-carboxamide, 4-[[(2S,3S,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-6-methyl-pyridine-2-carboxamide, 4-[[(2S,3S,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-6-methyl-pyridine-2-carboxamide, 4-[[(2R,3R,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-3-methyl-pyridine-2-carboxamide, 4-[[(2R,3R,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-3-methyl-pyridine-2-carboxamide, 4-[[(2R,3R,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-3-methyl-pyridine-2-carboxamide, 4-[[(2R,3S,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-3-methyl-pyridine-2-carboxamide, 4-[[(2S,3R,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-3-methyl-pyridine-2-carboxamide, 4-[[(2R,3R,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-3-methyl-pyridine-2-carboxamide, 4-[[(2R,3S,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-3-methyl-pyridine-2-carboxamide, 4-[[(2S,3R,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-3-methyl-pyridine-2-carboxamide, 4-[[(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-3-methyl-pyridine-2-carboxamide, 4-[[(2S,3R,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-3-methyl-pyridine-2-carboxamide, 4-[[(2S,3S,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-3-methyl-pyridine-2-carboxamide, 4-[[(2R,3S,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-3-methyl-pyridine-2-carboxamide, 4-[[(2S,3R,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-3-methyl-pyridine-2-carboxamide, 4-[[(2S,3S,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-3-methyl-pyridine-2-carboxamide, 4-[[(2S,3S,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-3-methyl-pyridine-2-carboxamide, 4-[[(2S,3S,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-3-methyl-pyridine-2-carboxamide, 3-deuterium-4-[[(2R,3R,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 3-deuterium-4-[[(2R,3R,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 3-deuterium-4-[[(2R,3R,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 3-deuterium-4-[[(2R,3S,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 3-deuterium-4-[[(2S,3R,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 3-deuterium-4-[[(2R,3R,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 3-deuterium-4-[[(2R,3S,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 3-deuterium-4-[[(2S,3R,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 3-deuterium-4-[[(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 3-deuterium-4-[[(2S,3R,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 3-deuterium-4-[[(2S,3S,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 3-deuterium-4-[[(2R,3S,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 3-deuterium-4-[[(2S,3R,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 3-deuterium-4-[[(2S,3S,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 3-deuterium-4-[[(2S,3S,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 3-deuterium-4-[[(2S,3S,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 6-deuterium-4-[[(2R,3R,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 6-deuterium-4-[[(2R,3R,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 6-deuterium-4-[[(2R,3R,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 6-deuterium-4-[[(2R,3S,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 6-deuterium-4-[[(2S,3R,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 6-deuterium-4-[[(2R,3R,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 6-deuterium-4-[[(2R,3S,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 6-deuterium-4-[[(2S,3R,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 6-deuterium-4-[[(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 6-deuterium-4-[[(2S,3R,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 6-deuterium-4-[[(2S,3S,4R,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 6-deuterium-4-[[(2R,3S,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 6-deuterium-4-[[(2S,3R,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 6-deuterium-4-[[(2S,3S,4R,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 6-deuterium-4-[[(2S,3S,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 6-deuterium-4-[[(2S,3S,4S,5S)-3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4R,5R)-4-[[3-(3,4-difluoro-2-methyl-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4R,5S)-4-[[3-(3,4-difluoro-2-methyl-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4S,5R)-4-[[3-(3,4-difluoro-2-methyl-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4R,5R)-4-[[3-(3,4-difluoro-2-methyl-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4R,5R)-4-[[3-(3,4-difluoro-2-methyl-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4S,5S)-4-[[3-(3,4-difluoro-2-methyl-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4R,5S)-4-[[3-(3,4-difluoro-2-methyl-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4R,5S)-4-[[3-(3,4-difluoro-2-methyl-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4S,5R)-4-[[3-(3,4-difluoro-2-methyl-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4S,5R)-4-[[3-(3,4-difluoro-2-methyl-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4R,5R)-4-[[3-(3,4-difluoro-2-methyl-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4S,5S)-4-[[3-(3,4-difluoro-2-methyl-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4S,5S)-4-[[3-(3,4-difluoro-2-methyl-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4R,5S)-4-[[3-(3,4-difluoro-2-methyl-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4S,5R)-4-[[3-(3,4-difluoro-2-methyl-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4S,5S)-4-[[3-(3,4-difluoro-2-methyl-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4R,5R)-4-[[3-[4-(difluoromethyl)-3-fluoro-2-methoxy-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4R,5S)-4-[[3-[4-(difluoromethyl)-3-fluoro-2-methoxy-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4S,5R)-4-[[3-[4-(difluoromethyl)-3-fluoro-2-methoxy-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4R,5R)-4-[[3-[4-(difluoromethyl)-3-fluoro-2-methoxy-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4R,5R)-4-[[3-[4-(difluoromethyl)-3-fluoro-2-methoxy-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4S,5S)-4-[[3-[4-(difluoromethyl)-3-fluoro-2-methoxy-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4R,5S)-4-[[3-[4-(difluoromethyl)-3-fluoro-2-methoxy-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4R,5S)-4-[[3-[4-(difluoromethyl)-3-fluoro-2-methoxy-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4S,5R)-4-[[3-[4-(difluoromethyl)-3-fluoro-2-methoxy-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4S,5R)-4-[[3-[4-(difluoromethyl)-3-fluoro-2-methoxy-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4R,5R)-4-[[3-[4-(difluoromethyl)-3-fluoro-2-methoxy-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4S,5S)-4-[[3-[4-(difluoromethyl)-3-fluoro-2-methoxy-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4S,5S)-4-[[3-[4-(difluoromethyl)-3-fluoro-2-methoxy-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4R,5S)-4-[[3-[4-(difluoromethyl)-3-fluoro-2-methoxy-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4S,5R)-4-[[3-[4-(difluoromethyl)-3-fluoro-2-methoxy-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4S,5S)-4-[[3-[4-(difluoromethyl)-3-fluoro-2-methoxy-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4R,5R)-4-[[3-[2-methoxy-6-(trifluoromethyl)-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4R,5S)-4-[[3-[2-methoxy-6-(trifluoromethyl)-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4S,5R)-4-[[3-[2-methoxy-6-(trifluoromethyl)-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4R,5R)-4-[[3-[2-methoxy-6-(trifluoromethyl)-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4R,5R)-4-[[3-[2-methoxy-6-(trifluoromethyl)-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4S,5S)-4-[[3-[2-methoxy-6-(trifluoromethyl)-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4R,5S)-4-[[3-[2-methoxy-6-(trifluoromethyl)-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4R,5S)-4-[[3-[2-methoxy-6-(trifluoromethyl)-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4S,5R)-4-[[3-[2-methoxy-6-(trifluoromethyl)-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4S,5R)-4-[[3-[2-methoxy-6-(trifluoromethyl)-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4R,5R)-4-[[3-[2-methoxy-6-(trifluoromethyl)-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4S,5S)-4-[[3-[2-methoxy-6-(trifluoromethyl)-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4S,5S)-4-[[3-[2-methoxy-6-(trifluoromethyl)-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4R,5S)-4-[[3-[2-methoxy-6-(trifluoromethyl)-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4S,5R)-4-[[3-[2-methoxy-6-(trifluoromethyl)-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4S,5S)-4-[[3-[2-methoxy-6-(trifluoromethyl)-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4R,5R)-4-[[3-[4-methoxy-6-(trifluoromethyl)-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4R,5S)-4-[[3-[4-methoxy-6-(trifluoromethyl)-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4S,5R)-4-[[3-[4-methoxy-6-(trifluoromethyl)-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4R,5R)-4-[[3-[4-methoxy-6-(trifluoromethyl)-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4R,5R)-4-[[3-[4-methoxy-6-(trifluoromethyl)-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4S,5S)-4-[[3-[4-methoxy-6-(trifluoromethyl)-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4R,5S)-4-[[3-[4-methoxy-6-(trifluoromethyl)-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4R,5S)-4-[[3-[4-methoxy-6-(trifluoromethyl)-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4S,5R)-4-[[3-[4-methoxy-6-(trifluoromethyl)-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4S,5R)-4-[[3-[4-methoxy-6-(trifluoromethyl)-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4R,5R)-4-[[3-[4-methoxy-6-(trifluoromethyl)-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4S,5S)-4-[[3-[4-methoxy-6-(trifluoromethyl)-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4S,5S)-4-[[3-[4-methoxy-6-(trifluoromethyl)-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4R,5S)-4-[[3-[4-methoxy-6-(trifluoromethyl)-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4S,5R)-4-[[3-[4-methoxy-6-(trifluoromethyl)-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4S,5S)-4-[[3-[4-methoxy-6-(trifluoromethyl)-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4R,5R)-4-[[3-[6-(difluoromethyl)-2-methoxy-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4R,5S)-4-[[3-[6-(difluoromethyl)-2-methoxy-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4S,5R)-4-[[3-[6-(difluoromethyl)-2-methoxy-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4R,5R)-4-[[3-[6-(difluoromethyl)-2-methoxy-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4R,5R)-4-[[3-[6-(difluoromethyl)-2-methoxy-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4S,5S)-4-[[3-[6-(difluoromethyl)-2-methoxy-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4R,5S)-4-[[3-[6-(difluoromethyl)-2-methoxy-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4R,5S)-4-[[3-[6-(difluoromethyl)-2-methoxy-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4S,5R)-4-[[3-[6-(difluoromethyl)-2-methoxy-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4S,5R)-4-[[3-[6-(difluoromethyl)-2-methoxy-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4R,5R)-4-[[3-[6-(difluoromethyl)-2-methoxy-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4S,5S)-4-[[3-[6-(difluoromethyl)-2-methoxy-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4S,5S)-4-[[3-[6-(difluoromethyl)-2-methoxy-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4R,5S)-4-[[3-[6-(difluoromethyl)-2-methoxy-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4S,5R)-4-[[3-[6-(difluoromethyl)-2-methoxy-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4S,5S)-4-[[3-[6-(difluoromethyl)-2-methoxy-3-pyridyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4R,5R)-4-[[3-(3-methoxy-2-pyridyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4R,5S)-4-[[3-(3-methoxy-2-pyridyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4S,5R)-4-[[3-(3-methoxy-2-pyridyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4R,5R)-4-[[3-(3-methoxy-2-pyridyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4R,5R)-4-[[3-(3-methoxy-2-pyridyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4S,5S)-4-[[3-(3-methoxy-2-pyridyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4R,5S)-4-[[3-(3-methoxy-2-pyridyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4R,5S)-4-[[3-(3-methoxy-2-pyridyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4S,5R)-4-[[3-(3-methoxy-2-pyridyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4S,5R)-4-[[3-(3-methoxy-2-pyridyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4R,5R)-4-[[3-(3-methoxy-2-pyridyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4S,5S)-4-[[3-(3-methoxy-2-pyridyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4S,5S)-4-[[3-(3-methoxy-2-pyridyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4R,5S)-4-[[3-(3-methoxy-2-pyridyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4S,5R)-4-[[3-(3-methoxy-2-pyridyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4S,5S)-4-[[3-(3-methoxy-2-pyridyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4R,5R)-4-[[3-(3-methoxy-2-methyl-4-pyridyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4R,5S)-4-[[3-(3-methoxy-2-methyl-4-pyridyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4S,5R)-4-[[3-(3-methoxy-2-methyl-4-pyridyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4R,5R)-4-[[3-(3-methoxy-2-methyl-4-pyridyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4R,5R)-4-[[3-(3-methoxy-2-methyl-4-pyridyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4S,5S)-4-[[3-(3-methoxy-2-methyl-4-pyridyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4R,5S)-4-[[3-(3-methoxy-2-methyl-4-pyridyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4R,5S)-4-[[3-(3-methoxy-2-methyl-4-pyridyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4S,5R)-4-[[3-(3-methoxy-2-methyl-4-pyridyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4S,5R)-4-[[3-(3-methoxy-2-methyl-4-pyridyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4R,5R)-4-[[3-(3-methoxy-2-methyl-4-pyridyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3S,4S,5S)-4-[[3-(3-methoxy-2-methyl-4-pyridyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3R,4S,5S)-4-[[3-(3-methoxy-2-methyl-4-pyridyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4R,5S)-4-[[3-(3-methoxy-2-methyl-4-pyridyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4S,5R)-4-[[3-(3-methoxy-2-methyl-4-pyridyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2S,3S,4S,5S)-4-[[3-(3-methoxy-2-methyl-4-pyridyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3R,4R,5R)-3-[2-[(3,3-difluorocyclobutyl)methoxy]-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3R,4R,5S)-3-[2-[(3,3-difluorocyclobutyl)methoxy]-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3R,4S,5R)-3-[2-[(3,3-difluorocyclobutyl)methoxy]-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3S,4R,5R)-3-[2-[(3,3-difluorocyclobutyl)methoxy]-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3R,4R,5R)-3-[2-[(3,3-difluorocyclobutyl)methoxy]-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3R,4S,5S)-3-[2-[(3,3-difluorocyclobutyl)methoxy]-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3S,4R,5S)-3-[2-[(3,3-difluorocyclobutyl)methoxy]-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3R,4R,5S)-3-[2-[(3,3-difluorocyclobutyl)methoxy]-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3S,4S,5R)-3-[2-[(3,3-difluorocyclobutyl)methoxy]-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3R,4S,5R)-3-[2-[(3,3-difluorocyclobutyl)methoxy]-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3S,4R,5R)-3-[2-[(3,3-difluorocyclobutyl)methoxy]-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3S,4S,5S)-3-[2-[(3,3-difluorocyclobutyl)methoxy]-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3R,4S,5S)-3-[2-[(3,3-difluorocyclobutyl)methoxy]-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3S,4R,5S)-3-[2-[(3,3-difluorocyclobutyl)methoxy]-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3S,4S,5R)-3-[2-[(3,3-difluorocyclobutyl)methoxy]-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3S,4S,5S)-3-[2-[(3,3-difluorocyclobutyl)methoxy]-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3R,4R,5R)-3-[2-(cyclobutyloxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3R,4R,5S)-3-[2-(cyclobutyloxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3R,4S,5R)-3-[2-(cyclobutyloxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3S,4R,5R)-3-[2-(cyclobutyloxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3R,4R,5R)-3-[2-(cyclobutyloxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3R,4S,5S)-3-[2-(cyclobutyloxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3S,4R,5S)-3-[2-(cyclobutyloxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3R,4R,5S)-3-[2-(cyclobutyloxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3S,4S,5R)-3-[2-(cyclobutyloxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3R,4S,5R)-3-[2-(cyclobutyloxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3S,4R,5R)-3-[2-(cyclobutyloxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3S,4S,5S)-3-[2-(cyclobutyloxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3R,4S,5S)-3-[2-(cyclobutyloxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3S,4R,5S)-3-[2-(cyclobutyloxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3S,4S,5R)-3-[2-(cyclobutyloxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3S,4S,5S)-3-[2-(cyclobutyloxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3R,4R,5R)-3-(5-deuterium-3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3R,4R,5S)-3-(5-deuterium-3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3R,4S,5R)-3-(5-deuterium-3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3S,4R,5R)-3-(5-deuterium-3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3R,4R,5R)-3-(5-deuterium-3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3R,4S,5S)-3-(5-deuterium-3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3S,4R,5S)-3-(5-deuterium-3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3R,4R,5S)-3-(5-deuterium-3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3S,4S,5R)-3-(5-deuterium-3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3R,4S,5R)-3-(5-deuterium-3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3S,4R,5R)-3-(5-deuterium-3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3S,4S,5S)-3-(5-deuterium-3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3R,4S,5S)-3-(5-deuterium-3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3S,4R,5S)-3-(5-deuterium-3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3S,4S,5R)-3-(5-deuterium-3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3S,4S,5S)-3-(5-deuterium-3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3R,4R,5R)-3-(3,4-difluoro-2-vinyl-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3R,4R,5S)-3-(3,4-difluoro-2-vinyl-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3R,4S,5R)-3-(3,4-difluoro-2-vinyl-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3S,4R,5R)-3-(3,4-difluoro-2-vinyl-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3R,4R,5R)-3-(3,4-difluoro-2-vinyl-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3R,4S,5S)-3-(3,4-difluoro-2-vinyl-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3S,4R,5S)-3-(3,4-difluoro-2-vinyl-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3R,4R,5S)-3-(3,4-difluoro-2-vinyl-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3S,4S,5R)-3-(3,4-difluoro-2-vinyl-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3R,4S,5R)-3-(3,4-difluoro-2-vinyl-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3S,4R,5R)-3-(3,4-difluoro-2-vinyl-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3S,4S,5S)-3-(3,4-difluoro-2-vinyl-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3R,4S,5S)-3-(3,4-difluoro-2-vinyl-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3S,4R,5S)-3-(3,4-difluoro-2-vinyl-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3S,4S,5R)-3-(3,4-difluoro-2-vinyl-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3S,4S,5S)-3-(3,4-difluoro-2-vinyl-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, (2R,3R,4R,5R)-4-[[3-[2-(difluoromethoxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-methyl-pyridine-2-carboxamide, (2R,3R,4R,5S)-4-[[3-[2-(difluoromethoxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-methyl-pyridine-2-carboxamide, (2R,3R,4S,5R)-4-[[3-[2-(difluoromethoxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-methyl-pyridine-2-carboxamide, (2R,3S,4R,5R)-4-[[3-[2-(difluoromethoxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-methyl-pyridine-2-carboxamide, (2S,3R,4R,5R)-4-[[3-[2-(difluoromethoxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-methyl-pyridine-2-carboxamide, (2R,3R,4S,5S)-4-[[3-[2-(difluoromethoxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-methyl-pyridine-2-carboxamide, (2R,3S,4R,5S)-4-[[3-[2-(difluoromethoxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-methyl-pyridine-2-carboxamide, (2S,3R,4R,5S)-4-[[3-[2-(difluoromethoxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-methyl-pyridine-2-carboxamide, (2R,3S,4S,5R)-4-[[3-[2-(difluoromethoxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-methyl-pyridine-2-carboxamide, (2S,3R,4S,5R)-4-[[3-[2-(difluoromethoxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-methyl-pyridine-2-carboxamide, (2S,3S,4R,5R)-4-[[3-[2-(difluoromethoxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-methyl-pyridine-2-carboxamide, (2R,3S,4S,5S)-4-[[3-[2-(difluoromethoxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-methyl-pyridine-2-carboxamide, (2S,3R,4S,5S)-4-[[3-[2-(difluoromethoxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-methyl-pyridine-2-carboxamide, (2S,3S,4R,5S)-4-[[3-[2-(difluoromethoxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-methyl-pyridine-2-carboxamide, (2S,3S,4S,5R)-4-[[3-[2-(difluoromethoxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-methyl-pyridine-2-carboxamide, (2S,3S,4S,5S)-4-[[3-[2-(difluoromethoxy)-3,4-difluoro-phenyl]-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]-5-methyl-pyridine-2-carboxamide, 4-[[(2R,3R,4R,5R)-3-(5-chloro-3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3R,4R,5S)-3-(5-chloro-3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3R,4S,5R)-3-(5-chloro-3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3S,4R,5R)-3-(5-chloro-3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3R,4R,5R)-3-(5-chloro-3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3R,4S,5S)-3-(5-chloro-3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3S,4R,5S)-3-(5-chloro-3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3R,4R,5S)-3-(5-chloro-3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3S,4S,5R)-3-(5-chloro-3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3R,4S,5R)-3-(5-chloro-3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3S,4R,5R)-3-(5-chloro-3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3S,4S,5S)-3-(5-chloro-3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3R,4S,5S)-3-(5-chloro-3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3S,4R,5S)-3-(5-chloro-3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3S,4S,5R)-3-(5-chloro-3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3S,4S,5S)-3-(5-chloro-3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3R,4R,5R)-3-(2-ethyl-3,4-difluoro-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3R,4R,5S)-3-(2-ethyl-3,4-difluoro-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3R,4S,5R)-3-(2-ethyl-3,4-difluoro-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3S,4R,5R)-3-(2-ethyl-3,4-difluoro-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3R,4R,5R)-3-(2-ethyl-3,4-difluoro-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3R,4S,5S)-3-(2-ethyl-3,4-difluoro-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3S,4R,5S)-3-(2-ethyl-3,4-difluoro-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3R,4R,5S)-3-(2-ethyl-3,4-difluoro-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3S,4S,5R)-3-(2-ethyl-3,4-difluoro-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3R,4S,5R)-3-(2-ethyl-3,4-difluoro-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3S,4R,5R)-3-(2-ethyl-3,4-difluoro-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2R,3S,4S,5S)-3-(2-ethyl-3,4-difluoro-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3R,4S,5S)-3-(2-ethyl-3,4-difluoro-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3S,4R,5S)-3-(2-ethyl-3,4-difluoro-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, 4-[[(2S,3S,4S,5R)-3-(2-ethyl-3,4-difluoro-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide or 4-[[(2S,3S,4S,5S)-3-(2-ethyl-3,4-difluoro-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide.

40. The compound of any one of claims 1-39.

41. The compound of claim 40, wherein the compound has the formula 42. The compound of claim 41, wherein the compound is in crystalline solid Form A, and Form A is characterized by an XRPD pattern having diffraction at the following angles 2θ ± 0.2 degrees: 9.9, 13.9, 15.7 and 19.

0.

43. The compound of claim 42, wherein Form A is further characterized by a DSC thermogram having a melting onset at 186°C and a peak at 187°C.

44. The compound of claim 41, wherein the compound is in crystalline solid Form B, and Form B is characterized by an XRPD pattern having diffraction at the following angles 2θ ± 0.2 degrees: 12.8, 14.1, 15.2, 18.5, and 20.

3.

45. The compound of claim 44, wherein Form B is further characterized by solid phase having peaks at chemical shifts of 172.5, 172.1, 168.5, 168.3, 168.0, 151.5, 148.3, 147.8, 127.7, 122.7, 116.6, 115.1, 110.6, 86.5, 80.2, 63.2, 44.3, 23.0, and 13.1 ppm. 13 C NMR spectrum or solid state with peaks at chemical shifts of -137.1 and -152.8 ppm 19 F NMR spectrum.

46. ​​The compound of claim 44 or 45, wherein Form B is characterized by a DSC thermogram having a melting onset at 182°C and a peak at 183°C.

47. A compound as described in any of claims 44-46, wherein Form B is further characterized by -1 IR spectrum with peaks at.

48. The compound of any one of claims 44-47, wherein Form B is characterized by an orthorhombic crystal system as determined by single crystal X-ray analysis.

49. The compound of claim 48, wherein Form B is further characterized by P2 1 2 1 2 1 The space group was determined by single crystal X-ray analysis.

50. The compound of claim 48 or 49, wherein Form B is further characterized by a unit cell having the following dimensions as determined by single crystal X-ray analysis: α=90°; β=90°; and γ=90°.

51. The compound of any one of claims 44-50, wherein Form B is obtainable by dissolving the compound in ethyl acetate and then crystallizing the compound by adding n-heptane as an anti-solvent.

52. The compound of claim 40, wherein the compound has the formula 53. The compound of claim 52, wherein the compound is in crystalline solid Form A, and Form A is characterized by: Orthorhombic system, as determined by single crystal X-ray analysis; I222 space group, as determined by single crystal X-ray analysis; and The unit cell has the following dimensions, as determined by single crystal X-ray analysis: α=90°; β=90°; and γ=90°.

54. The compound of claim 40, wherein the compound has the formula 55. The compound of claim 54, wherein the compound is in crystalline solid Form A, and Form A is characterized by an XRPD pattern having diffraction at the following angles 2θ ± 0.2 degrees: 10.1, 13.7, 14.1, 16.3, and 20.

0.

56. The compound of claim 54, wherein the crystalline solid form is Form B, and Form B is characterized by an XRPD pattern having diffraction at the following angles 2θ ± 0.2 degrees: 6.8, 13.2, 16.1, 20.6, and 21.

3.

57. The compound of claim 55, wherein Form A is further characterized as monoclinic as determined by single crystal X-ray analysis.

58. The compound of claim 55 or 57, wherein Form A is further characterized by P2 1 The space group was determined by single crystal X-ray analysis.

59. The compound of any one of claims 55, 57 or 58, wherein Form A is further characterized by a unit cell having the following dimensions as determined by single crystal X-ray analysis: α=90°; β=90.0130(10)°; and γ=90°.

60. The compound of claim 40, wherein the compound has the formula 61. The compound of claim 60, wherein the compound is in crystalline solid Form A, and Form A is characterized by an XRPD pattern having diffraction at the following angles 2θ ± 0.2 degrees: 13.7, 15.2, and 18.

2.

62. The compound of claim 61, wherein Form A is further characterized by solid phase with peaks at chemical shifts of 171.4, 141.6, 118.0, 112.2, 23.0, and 11.6 ppm. 13 C NMR spectrum or solid state with peaks at chemical shifts of -74.6, -141.5 and -154.6 ppm 19 F NMR spectrum.

63. The compound of claim 61 or 62, wherein Form A is further characterized as monoclinic as determined by single crystal X-ray analysis.

64. A compound as described in any one of claims 61-63, wherein Form A is further characterized by P2 1 The space group was determined by single crystal X-ray analysis.

65. The compound of any one of claims 61-64, wherein Form A is further characterized by a unit cell having the following dimensions, as determined by single crystal X-ray analysis: α=90°; β=100.3980(1)°; and γ=90°.

66. The compound of claim 40, wherein the compound has the formula When using 25cm×21.2mm, When chiral SFC was used to separate a mixture of racemic diastereomers that were diastereoisomers at the 5-position, the compound had the absolute stereochemistry of the third eluting isomer.

67. The compound of claim 66, wherein the compound is in crystalline solid Form A, and Form A is characterized by an XRPD pattern having diffraction at the following angles 2θ ± 0.2 degrees: 9.2, 10.4 and 15.

7.

68. The compound of claim 67, wherein Form A is further characterized by solid phase with peaks at chemical shifts of 167.7, 126.0, 115.9, 43.5, and 20.3 ppm. 13 C NMR spectrum or solid state with peaks at chemical shifts of -82.2, -83.1, -111.7 and -114.4 ppm 19 F NMR spectrum.

69. The compound of claim 40, wherein the compound has the formula 70. The compound of claim 69, wherein the compound is in crystalline solid Form A, and Form A is characterized by an XRPD pattern having diffraction at the following angles 2θ ± 0.2 degrees: 17.2, 19.3, and 22.

3.

71. The compound of claim 70, wherein Form A is further characterized by solid phase with peaks at chemical shifts of 171.1, 149.3, 123.3, 41.6, and 20.0 ppm. 13 C NMR spectrum or solid state with peaks at chemical shifts of -78.2, -113.5 and -115.1 ppm 19 F NMR spectrum.

72. The compound of claim 70 or 71, wherein Form A is further characterized as monoclinic as determined by single crystal X-ray analysis.

73. A compound as described in any one of claims 70-72, wherein Form A is further characterized by P2 1 The space group was determined by single crystal X-ray analysis.

74. The compound of any one of claims 70-73, wherein Form A is further characterized by a unit cell having the following dimensions as determined by single crystal X-ray analysis: α=90°; β=98.487(2)°; and γ=90°.

75. The compound of claim 40, wherein the compound has the formula When using 25cm×10mm, When chiral SFC was used to separate a racemic mixture of enantiomers using an AS-H, 5 μm particle size column, the compound had the absolute stereochemistry of the second eluting isomer.

76. The compound of claim 75, wherein the compound is in crystalline solid Form A, and Form A is characterized by an XRPD pattern having diffraction at the following angles 2θ ± 0.2 degrees: 6.8, 7.9 and 13.

8.

77. A pharmaceutical composition comprising a therapeutically effective amount of a compound as described in any one of claims 1-39 or a pharmaceutically acceptable salt thereof or a compound as described in any one of claims 40-76 and one or more pharmaceutically acceptable carriers or vehicles.

78. A pharmaceutical composition comprising a compound as described in any one of claims 1-39 or a pharmaceutically acceptable salt thereof or a compound as described in any one of claims 40-76 and one or more pharmaceutically acceptable carriers or vehicles.

79. The use of a compound as described in any one of claims 1-39 or a pharmaceutically acceptable salt thereof, a compound as described in any one of claims 40-76 or a pharmaceutical composition as described in claim 77 or 78 in the preparation of a medicament for inhibiting voltage-gated sodium channels in a subject, wherein the voltage-gated sodium channels are Na V 1.

8.

80. Use of a compound as described in any one of claims 1 to 39 or a pharmaceutically acceptable salt thereof, a compound as described in any one of claims 40 to 76, or a pharmaceutical composition as described in claim 77 or 78 in the preparation of a medicament for treating or reducing the severity of chronic pain, intestinal pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, postoperative pain, multiple sclerosis, Chuck-Mare-Doucet syndrome, incontinence, pathological cough or arrhythmia in a subject.

81. The use of claim 80, wherein the medicament is for treating or reducing the severity of neuropathic pain in the subject.

82. The use of claim 81, wherein the neuropathic pain comprises post-herpetic neuralgia.

83. The use of claim 81, wherein the neuropathic pain comprises small fiber neuropathy.

84. The use of claim 81, wherein the neuropathic pain comprises idiopathic small fiber neuropathy.

85. The use of claim 81, wherein the neuropathic pain comprises diabetic neuropathy.

86. The method of claim 80, wherein the medicament is for treating or reducing the severity of musculoskeletal pain in the subject.

87. The use of claim 86, wherein the musculoskeletal pain comprises osteoarthritis pain.

88. The method of claim 80, wherein the medicament is for treating or alleviating the severity of acute pain in the subject.

89. The use of claim 88, wherein the acute pain comprises acute postoperative pain.

90. The use of claim 80, wherein the medicament is for treating or reducing the severity of postoperative pain in the subject.

91. The use of claim 90, wherein the postoperative pain comprises Capsulectomy pain.

92. The use of claim 90, wherein the post-operative pain comprises herniorrhaphy pain.

93. The use of claim 90, wherein the post-operative pain comprises abdominoplasty pain.

94. Use of a compound as described in any one of claims 1 to 39 or a pharmaceutically acceptable salt thereof, a compound as described in any one of claims 40 to 76, or a pharmaceutical composition as described in claim 77 or 78 in the preparation of a medicament for treating visceral pain in a subject or reducing its severity.

95. Use of a compound as described in any one of claims 1-39 or a pharmaceutically acceptable salt thereof, a compound as described in any one of claims 40-76, or a pharmaceutical composition as described in claim 77 or 78 in the preparation of a medicament for treating pain in a subject or alleviating its severity.

96. The use of any one of claims 79-95, wherein the medicament is administered simultaneously with, before, or after one or more other therapeutic agents.

Citation Information

Patent Citations

  • Plant for the centralised generation of thermal energy

    EP0000135A1

  • Pyridine Derivatives

    US20080312235A1

  • Pyridine derivatives

    US20090048306A1

  • Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels

    US20110306607A1

  • Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels

    US20120196869A1